0001171843-22-007281.txt : 20221109 0001171843-22-007281.hdr.sgml : 20221109 20221109143146 ACCESSION NUMBER: 0001171843-22-007281 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Anika Therapeutics, Inc. CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043145961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14027 FILM NUMBER: 221372027 BUSINESS ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 457-9000 MAIL ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA THERAPEUTICS INC DATE OF NAME CHANGE: 19970114 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 10-Q 1 anik20220930_10q.htm FORM 10-Q anik20220930_10q.htm
0000898437 Anika Therapeutics, Inc. false --12-31 Q3 2022 1,566 1,442 0.01 0.01 1,250 1,250 0 0 0 0 0.01 0.01 90,000 90,000 14,607 14,607 14,441 14,441 4.3 0 3 10 3 1.3 3.4 0.3 0.7 0.0 0.0 3 0 00008984372022-01-012022-09-30 xbrli:shares 00008984372022-10-31 iso4217:USD 00008984372022-09-30 00008984372021-12-31 iso4217:USDxbrli:shares 00008984372022-07-012022-09-30 00008984372021-07-012021-09-30 00008984372021-01-012021-09-30 0000898437us-gaap:CommonStockMember2021-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000898437us-gaap:RetainedEarningsMember2021-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000898437us-gaap:CommonStockMember2022-01-012022-03-31 0000898437us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-31 00008984372022-01-012022-03-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2022-01-012022-03-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-31 0000898437us-gaap:RetainedEarningsMember2022-01-012022-03-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-31 0000898437us-gaap:CommonStockMember2022-03-31 0000898437us-gaap:AdditionalPaidInCapitalMember2022-03-31 0000898437us-gaap:RetainedEarningsMember2022-03-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-31 00008984372022-03-31 0000898437us-gaap:CommonStockMember2022-04-012022-06-30 0000898437us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-30 00008984372022-04-012022-06-30 0000898437us-gaap:RetainedEarningsMember2022-04-012022-06-30 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-30 0000898437us-gaap:CommonStockMember2022-06-30 0000898437us-gaap:AdditionalPaidInCapitalMember2022-06-30 0000898437us-gaap:RetainedEarningsMember2022-06-30 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-30 00008984372022-06-30 0000898437us-gaap:CommonStockMember2022-07-012022-09-30 0000898437us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-30 0000898437us-gaap:RetainedEarningsMember2022-07-012022-09-30 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-30 0000898437us-gaap:CommonStockMember2022-09-30 0000898437us-gaap:AdditionalPaidInCapitalMember2022-09-30 0000898437us-gaap:RetainedEarningsMember2022-09-30 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-30 0000898437us-gaap:CommonStockMember2020-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000898437us-gaap:RetainedEarningsMember2020-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 00008984372020-12-31 0000898437us-gaap:CommonStockMember2021-01-012021-03-31 0000898437us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-31 0000898437us-gaap:RetainedEarningsMember2021-01-012021-03-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-31 00008984372021-01-012021-03-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2021-01-012021-03-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:RetainedEarningsMember2021-01-012021-03-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-31 0000898437us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-31 0000898437us-gaap:CommonStockMember2021-03-31 0000898437us-gaap:AdditionalPaidInCapitalMember2021-03-31 0000898437us-gaap:RetainedEarningsMember2021-03-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-31 00008984372021-03-31 0000898437us-gaap:CommonStockMember2021-04-012021-06-30 0000898437us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-30 0000898437us-gaap:RetainedEarningsMember2021-04-012021-06-30 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-30 00008984372021-04-012021-06-30 0000898437us-gaap:CommonStockMember2021-06-30 0000898437us-gaap:AdditionalPaidInCapitalMember2021-06-30 0000898437us-gaap:RetainedEarningsMember2021-06-30 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-30 00008984372021-06-30 0000898437us-gaap:CommonStockMember2021-07-012021-09-30 0000898437us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-30 0000898437us-gaap:RetainedEarningsMember2021-07-012021-09-30 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-30 0000898437us-gaap:CommonStockMember2021-09-30 0000898437us-gaap:AdditionalPaidInCapitalMember2021-09-30 0000898437us-gaap:RetainedEarningsMember2021-09-30 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-30 00008984372021-09-30 0000898437us-gaap:AccountingStandardsUpdate201602Member2022-01-012022-09-30 0000898437us-gaap:AccountingStandardsUpdate201602Member2021-01-012021-09-30 0000898437anik:ParcusMedicalMember2020-01-242020-01-24 0000898437anik:ParcusMedicalMember2021-12-31 0000898437anik:ParcusMedicalMember2022-07-012022-09-30 0000898437anik:ParcusMedicalMember2020-01-012020-03-31 0000898437anik:ParcusMedicalMember2020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:DevelopedTechnologyRightsMember2020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:TradeNamesMember2020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:CustomerRelationshipsMember2020-01-24 utr:Y 0000898437anik:ParcusMedicalMemberus-gaap:DevelopedTechnologyRightsMember2020-01-242020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:CustomerRelationshipsMember2020-01-242020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:TradeNamesMember2020-01-242020-01-24 0000898437anik:ArthrosurfaceMember2020-02-032020-02-03 0000898437anik:ArthrosurfaceMember2020-10-012020-10-31 0000898437anik:ArthrosurfaceMember2021-07-012021-07-31 0000898437anik:ArthrosurfaceMember2020-01-012020-03-31 0000898437anik:ArthrosurfaceMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:DevelopedTechnologyRightsMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:TradeNamesMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:CustomerRelationshipsMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:InProcessResearchAndDevelopmentMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:DevelopedTechnologyRightsMember2020-02-032020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:CustomerRelationshipsMember2020-02-032020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:TradeNamesMember2020-02-032020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:InProcessResearchAndDevelopmentMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-30 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-30 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-30 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-30 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-30 0000898437us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-30 0000898437us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-30 0000898437us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-30 0000898437us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-30 0000898437us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-30 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-31 0000898437us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-31 0000898437anik:ContingentConsiderationMember2021-12-31 0000898437anik:ContingentConsiderationMember2020-12-31 0000898437anik:ContingentConsiderationMember2022-01-012022-09-30 0000898437anik:ContingentConsiderationMember2021-01-012021-09-30 0000898437anik:ContingentConsiderationMember2022-09-30 0000898437anik:ContingentConsiderationMember2021-09-30 0000898437us-gaap:DevelopedTechnologyRightsMember2022-09-30 0000898437us-gaap:DevelopedTechnologyRightsMember2021-12-31 0000898437us-gaap:DevelopedTechnologyRightsMember2022-01-012022-09-30 0000898437us-gaap:InProcessResearchAndDevelopmentMember2022-09-30 0000898437us-gaap:InProcessResearchAndDevelopmentMember2021-12-31 0000898437us-gaap:CustomerRelationshipsMember2022-09-30 0000898437us-gaap:CustomerRelationshipsMember2021-12-31 0000898437us-gaap:CustomerRelationshipsMember2022-01-012022-09-30 0000898437us-gaap:DistributionRightsMember2022-09-30 0000898437us-gaap:DistributionRightsMember2021-12-31 0000898437us-gaap:DistributionRightsMember2022-01-012022-09-30 0000898437us-gaap:PatentsMember2022-09-30 0000898437us-gaap:PatentsMember2021-12-31 0000898437us-gaap:PatentsMember2022-01-012022-09-30 0000898437us-gaap:TradeNamesMember2022-09-30 0000898437us-gaap:TradeNamesMember2021-12-31 0000898437us-gaap:TradeNamesMember2022-01-012022-09-30 0000898437anik:LiabilitiesMember2022-09-30 0000898437anik:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-09-30 xbrli:pure 0000898437anik:AccruedExpensesAndOtherCurrentLiabilitiesMember2021-12-31 0000898437anik:OAPainManagementMember2022-07-012022-09-30 0000898437anik:OAPainManagementMember2021-07-012021-09-30 0000898437anik:OAPainManagementMember2022-01-012022-09-30 0000898437anik:OAPainManagementMember2021-01-012021-09-30 0000898437anik:JointPreservationAndRestorationMember2022-07-012022-09-30 0000898437anik:JointPreservationAndRestorationMember2021-07-012021-09-30 0000898437anik:JointPreservationAndRestorationMember2022-01-012022-09-30 0000898437anik:JointPreservationAndRestorationMember2021-01-012021-09-30 0000898437anik:NonorthopedicMember2022-07-012022-09-30 0000898437anik:NonorthopedicMember2021-07-012021-09-30 0000898437anik:NonorthopedicMember2022-01-012022-09-30 0000898437anik:NonorthopedicMember2021-01-012021-09-30 0000898437country:US2022-07-012022-09-30 0000898437country:US2021-04-012021-09-30 0000898437srt:EuropeMember2022-07-012022-09-30 0000898437srt:EuropeMember2021-04-012021-09-30 0000898437anik:OtherLocationMember2022-07-012022-09-30 0000898437anik:OtherLocationMember2021-04-012021-09-30 00008984372021-04-012021-09-30 0000898437country:US2022-01-012022-09-30 0000898437country:US2021-01-012021-09-30 0000898437srt:EuropeMember2022-01-012022-09-30 0000898437srt:EuropeMember2021-01-012021-09-30 0000898437anik:OtherLocationMember2022-01-012022-09-30 0000898437anik:OtherLocationMember2021-01-012021-09-30 0000898437anik:The2017PlanMember2022-06-082022-06-08 0000898437anik:The2017PlanMember2017-06-13 0000898437anik:The2017PlanMember2022-06-08 0000898437anik:The2017PlanMember2022-09-30 0000898437anik:The2021InducementPlanMember2021-11-04 0000898437anik:The2021InducementPlanMember2022-09-30 0000898437anik:The2021InducementPlanMember2022-01-012022-09-30 0000898437us-gaap:CostOfSalesMember2022-07-012022-09-30 0000898437us-gaap:CostOfSalesMember2021-07-012021-09-30 0000898437us-gaap:CostOfSalesMember2022-01-012022-09-30 0000898437us-gaap:CostOfSalesMember2021-01-012021-09-30 0000898437us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-30 0000898437us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-30 0000898437us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-30 0000898437us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-30 0000898437us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-30 0000898437us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-30 0000898437us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-30 0000898437us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-30 0000898437anik:PremiumPricedEmployeeStockOptionsMember2022-01-012022-09-30 0000898437us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-09-30 0000898437us-gaap:EmployeeStockOptionMember2022-01-012022-09-30 0000898437us-gaap:EmployeeStockOptionMember2022-09-30 0000898437anik:TotalShareholderReturnTsrsOptionsMember2022-01-012022-09-30 0000898437anik:TotalShareholderReturnTsrsOptionsMembersrt:MinimumMember2022-01-012022-09-30 0000898437anik:TotalShareholderReturnTsrsOptionsMembersrt:MaximumMember2022-01-012022-09-30 0000898437anik:TotalShareholderReturnTsrsOptionsMember2022-09-30 0000898437srt:MinimumMember2022-01-012022-09-30 0000898437srt:MaximumMember2022-01-012022-09-30 0000898437srt:MinimumMember2021-01-012021-09-30 0000898437srt:MaximumMember2021-01-012021-09-30 0000898437us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2022-01-012022-09-30 0000898437us-gaap:RestrictedStockUnitsRSUMember2021-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-30 0000898437us-gaap:RestrictedStockUnitsRSUMember2022-09-30 0000898437us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-30 0000898437us-gaap:PerformanceSharesMember2021-12-31 0000898437us-gaap:PerformanceSharesMember2022-01-012022-09-30 0000898437us-gaap:PerformanceSharesMember2022-09-30 0000898437us-gaap:PerformanceSharesMember2021-01-012021-09-30 0000898437us-gaap:ForeignCountryMemberus-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember2021-01-012021-12-31
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                  to                  

 

Commission File Number 001-14027

 

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

04-3145961

(State or Other Jurisdiction of

(I.R.S. Employer Identification No.)

Incorporation or Organization)

 

 

32 Wiggins Avenue, Bedford, Massachusetts 01730

(Address of Principal Executive Offices) (Zip Code)

 

(781) 457-9000

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

   

Common Stock, par value $0.01 per share

ANIK

NASDAQ Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ☐

Accelerated filer ☒

Non-accelerated filer ☐

Smaller reporting

company 

Emerging growth

company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes    No ☒

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

As of October 31, 2022, there were 14,609,669 outstanding shares of Common Stock, par value $0.01 per share.

 

 

 

 

 

ANIKA THERAPEUTICS, INC.

TABLE OF CONTENTS

 

   

Page

Part I

Financial Information

3

Item 1.

Condensed Consolidated Financial Statements (unaudited):

3
 

Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021

3
 

Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2022 and 2021

4
 

Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021

5
 

Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021

6
 

Notes to Consolidated Financial Statements

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

30

Item 4.

Controls and Procedures

30

Part II

Other Information

31

Item 1.

Legal Proceedings

31

Item 1A.

Risk Factors

31

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

32

Item 6.

Exhibits

32

Signatures

33

 

References in this Quarterly Report on Form 10-Q to “we,” “us,” “our” and “our company,” and other similar references refer to Anika Therapeutics, Inc. and its subsidiaries unless the context otherwise indicates.

 

Anika, Anika Therapeutics, Anikavisc, Arthrosurface, Cingal, Hyaff, Monovisc, Orthovisc, Parcus Medical, Tactoset and Hyvisc are our registered trademarks that appear in this Quarterly Report on Form 10-Q. For convenience, these trademarks appear in this Quarterly Report on Form 10-Q without ® and ™ symbols, but that practice does not mean that we will not assert, to the fullest extent under applicable law, our rights to the trademarks. This Quarterly Report on Form 10-Q also contains trademarks and trade names that are the property of other companies and licensed to us.

 

 

 

 

 

 

 

 

PART I:

FINANCIAL INFORMATION

 

ITEM 1.

FINANCIAL STATEMENTS

 

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except per share data)
(unaudited)

 

  

September 30,

  

December 31,

 

ASSETS

 

2022

  

2021

 

Current assets:

        

Cash and cash equivalents

 $87,777  $94,386 

Accounts receivable, less allowance for credit losses of $1,566 and $1,442 at September 30, 2022 and December 31, 2021, respectively

  34,168   29,843 

Inventories, net

  37,237   36,010 

Prepaid expenses and other current assets

  8,579   8,289 

Total current assets

  167,761   168,528 

Property and equipment, net

  47,390   47,602 

Right-of-use assets

  30,987   20,957 

Other long-term assets

  18,342   20,285 

Intangible assets, net

  76,545   82,382 

Goodwill

  6,721   7,781 

Total assets

 $347,746  $347,535 
         

LIABILITIES AND STOCKHOLDERS EQUITY

        

Current liabilities:

        

Accounts payable

 $8,353  $7,633 

Accrued expenses and other current liabilities

  17,999   17,847 

Contingent consideration

  -   4,315 

Total current liabilities

  26,352   29,795 

Other long-term liabilities

  474   1,258 

Deferred tax liability

  6,800   10,157 

Lease liabilities

  29,183   19,240 

Commitments and contingencies (Note 10)

          

Stockholders’ equity:

        

Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively

  -   - 

Common stock, $0.01 par value; 90,000 shares authorized, 14,607 and 14,441 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively

  146   144 

Additional paid-in-capital

  76,661   67,081 

Accumulated other comprehensive loss

  (7,497

)

  (5,718

)

Retained earnings

  215,627   225,578 

Total stockholders’ equity

  284,937   287,085 

Total liabilities and stockholders’ equity

 $347,746  $347,535 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

3

 

 

 

Anika Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Income

(in thousands, except per share data)

(unaudited) 

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Revenue

 $40,264  $39,536  $116,614  $111,973 

Cost of revenue

  17,485   16,513   47,169   47,164 

Gross Profit

  22,779   23,023   69,445   64,809 
                 

Operating expenses:

                

Research & development

  7,301   7,673   20,433   21,327 

Selling, general & administrative

  21,276   17,500   61,745   53,664 

Change in fair value of contingent consideration

  -   (3,450

)

  -   (21,920

)

Total operating expenses

  28,577   21,723   82,178   53,071 

(Loss) income from operations

  (5,798

)

  1,300   (12,733

)

  11,738 

Interest and other income (expense), net

  436   (48

)

  378   (141

)

(Loss) income before income taxes

  (5,362

)

  1,252   (12,355

)

  11,597 

(Benefit from) provision for income taxes

  (1,187

)

  694   (2,404

)

  1,670 

Net (loss) income

 $(4,175

)

 $558  $(9,951

)

 $9,927 
                 

Net (loss) income per share:

                

Basic

 $(0.29

)

 $0.04  $(0.68

)

 $0.69 

Diluted

 $(0.29

)

 $0.04  $(0.68

)

 $0.68 
                 

Weighted average common shares outstanding:

                

Basic

  14,603   14,429   14,542   14,389 

Diluted

  14,603   14,647   14,542   14,588 
                 

Net (loss) income

 $(4,175

)

 $558  $(9,951

)

 $9,927 

Foreign currency translation adjustment

  (851

)

  199   (1,779

)

  (777

)

Comprehensive (loss) income

 $(5,026

)

 $757  $(11,730

)

 $9,150 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 

4

 

 

Anika Therapeutics, Inc. and Subsidiaries

 

Consolidated Statements of Stockholders' Equity

 

(in thousands)

 
                         
  

Nine Months Ended September 30, 2022

 
                  

Accumulated

     
  

Common Stock

      

Other

  

Total

 
  

Number of

  

$.01 Par

  

Additional Paid

  

Retained

  

Comprehensive

  

Stockholders'

 
  

Shares

  

Value

  

in Capital

  

Earnings

  

Loss

  

Equity

 

Balance, January 1, 2022

  14,441  $144  $67,081  $225,578  $(5,718) $287,085 

Issuance of common stock for equity awards

  1   -   15   -   -   15 

Vesting of restricted stock units

  106   1   (1)  -   -   - 

Stock-based compensation expense

  -   -   2,545   -   -   2,545 

Retirement of common stock for minimum tax withholdings

  (30)  -   (844)  -   -   (844)

Net loss

  -   -   -   (2,933)  -   (2,933)

Other comprehensive income

  -   -   -   -   (81)  (81)

Balance, March 31, 2022

  14,518  $145  $68,796  $222,645  $(5,799) $285,787 

Vesting of restricted stock units

  61   1   (1)  -   -   - 

Issuance of ESPP shares

  20   -   -   -   -   - 

Stock-based compensation expense

  -   -   4,081   -   -   4,081 

Retirement of common stock for minimum tax withholdings

  (1)  -   (25)  -   -   (25)

Net loss

  -   -   -   (2,843)  -   (2,843)

Other comprehensive income

  -   -   -   -   (847)  (847)

Balance, June 30, 2022

  14,598  $146  $72,851  $219,802  $(6,646) $286,153 

Vesting of restricted stock units

  11   -   -   -   -   - 

Issuance of ESPP shares

  -   -   -   -   -   - 

Stock-based compensation expense

  -   -   3,876   -   -   3,876 

Retirement of common stock for minimum tax withholdings

  (2)  -   (66)  -   -   (66)

Net loss

  -   -   -   (4,175)  -   (4,175)

Other comprehensive income

  -   -   -   -   (851)  (851)

Balance, September 30, 2022

  14,607  $146  $76,661  $215,627  $(7,497) $284,937 

 

  

Nine Months Ended September 30, 2021

 
                  

Accumulated

     
  

Common Stock

      

Other

  

Total

 
  

Number of

  

$.01 Par

  

Additional Paid

  

Retained

  

Comprehensive

  

Stockholders'

 
  

Shares

  

Value

  

in Capital

  

Earnings

  

Loss

  

Equity

 

Balance, January 1, 2021

  14,329  $143  $55,355  $221,444  $(4,542

)

 $272,400 

Issuance of common stock for equity awards

  -   -   1   -   -   1 

Vesting of restricted stock units

  46   1   (1

)

  -   -   - 

Stock-based compensation expense

  -   -   2,259   -   -   2,259 

Retirement of common stock for minimum tax withholdings

  (9

)

  -   (333

)

  -   -   (333

)

Net income

  -   -   -   2,838   -   2,838 

Other comprehensive income

  -   -   -   -   (509

)

  (509

)

Balance, March 31, 2021

  14,366  $144  $57,281  $224,282  $(5,051

)

 $276,656 

Issuance of common stock for equity awards

  18   -   640   -   -   640 

Vesting of restricted stock units

  35   -   -   -   -   - 

Stock-based compensation expense

  -   -   2,797   -   -   2,797 

Retirement of common stock for minimum tax withholdings

  (1)  -   (19)  -   -   (19)

Net income

  -   -   -   6,531   -   6,531 

Other comprehensive income

  -   -   -   -   199   199 

Balance, June 30, 2021

  14,418  $144  $60,699  $230,813  $(4,852) $286,804 

Issuance of common stock for equity awards

  10   -   373   -   -   373 

Vesting of restricted stock units

  9   -   -   -   -   - 

Stock-based compensation expense

  -   -   2,863   -   -   2,863 

Retirement of common stock for minimum tax withholdings

  (1)  -   (71)  -   -   (71)

Net income

  -   -   -   558   -   558 

Other comprehensive income

  -   -   -   -   (467)  (467)

Balance, September 30, 2021

  14,436  $144  $63,864  $231,371  $(5,319) $290,060 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

Anika Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

   

Nine Months Ended

September 30

 
   

2022

   

2021

 

Cash flows from operating activities:

               

Net (loss) income

  $ (9,951

)

  $ 9,927  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation

    4,984       4,702  

Amortization of acquisition related intangible assets

    5,837       5,885  

Amortization of acquisition related inventory step-up

    -       6,244  

Non-cash operating lease cost

    1,322       1,312  

Change in fair value of contingent consideration

    -       (21,920 )

Loss on disposal of fixed assets

    -       831  

Stock-based compensation expense

    10,502       7,919  

Deferred income taxes

    (3,491

)

    1,018  

Provision (recovery) for doubtful accounts

    379       (60 )

Provision for inventory

    3,701       3,702  

Other

          (13 )

Changes in operating assets and liabilities:

               

Accounts receivable

    (4,983

)

    (8,321 )

Inventories

    (3,933

)

    (7,117 )

Prepaid expenses, other current and long-term assets

    (456

)

    1,864  

Accounts payable

    533       (702

)

Operating lease liabilities

    (1,054

)

    (1,247

)

Accrued expenses, other current and long-term liabilities

    115       3,104  

Contingent consideration

    -       (2,780 )

Income taxes

    423       (423

)

Net cash provided by operating activities

    3,928       3,925  
                 

Cash flows from investing activities:

               

Acquisition of Parcus Medical and Arthrosurface, net of cash acquired

    -       (363

)

Proceeds from maturities of investments

    -       2,501  

Purchases of property and equipment

    (4,957

)

    (4,016

)

Net cash used in investing activities

    (4,957

)

    (1,878

)

                 

Cash flows from financing activities:

               

Payments made on finance leases

    (284

)

    (210

)

Cash paid for tax withheld on vested restricted stock awards

    (935

)

    (423

)

Proceeds from exercises of equity awards

    15       1,014  

Contingent consideration payout

    (4,315 )     (7,220 )

Net cash used in financing activities

    (5,519

)

    (6,839 )
                 

Exchange rate impact on cash

    (61

)

    (49

)

                 

Decrease in cash and cash equivalents

    (6,609

)

    (4,841 )

Cash and cash equivalents at beginning of period

    94,386       95,817  

Cash and cash equivalents at end of period

  $ 87,777     $ 90,976  

Supplemental disclosure of cash flow information:

               

Non-cash investing activities:

               

Right-of-use assets obtained in exchange for operating lease liabilities

  $ 11,589     $ 195  

Purchases of property and equipment included in accounts payable and accrued expenses

  $ 108     $ 220  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

6

 

 

ANIKA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(amounts in thousands, except share and per share amounts or as otherwise noted)

(unaudited)

 

 

1.

Nature of Business

 

Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.

 

In early 2020, the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation solutions provider focused on sports medicine and soft tissue repair, and Arthrosurface, Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company’s product portfolio, developed over its 30 years of expertise in hyaluronic acid technology, into the broader joint preservation and restoration market with greater market potential, added high-growth revenue streams, increased the Company’s commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.

 

The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

 

There continue to be uncertainties regarding the pandemic of the ongoing coronavirus (“COVID-19”), and the Company is closely monitoring the impact of COVID-19 on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, business partners and a broader impact on elective surgeries. The Company is unable to predict the specific impact that COVID-19 may have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein may change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-19.

 

 

2.

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been or omitted pursuant to SEC rules and regulations relating to interim financial statements. The December 31, 2021 balances reported herein were derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.

 

The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the three-month and nine-month periods ended September 30, 2022, are not indicative of the results to be expected for the year ending December 31, 2022

 

Segment Information

 

Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer as of September 30, 2022. Based on the criteria established by Accounting Standards Codification 280, Segment Reporting, the Company has one operating and reportable segment.

 

7

 
 
 

3.

Business Combinations

 

Parcus Medical, LLC

 

On January 24, 2020, the Company completed the acquisition of Parcus Medical pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Parcus Medical Merger Agreement”). Parcus Medical is a sports medicine implant and instrumentation solutions provider focused on surgical repair and reconstruction of soft tissue.

 

Consideration Transferred

 

Pursuant to the Parcus Medical Merger Agreement, the Company acquired all outstanding equity of Parcus Medical for estimated total purchase consideration of $75.1 million, as of January 24, 2020, which consisted of:

 

Cash consideration

 $32,794 

Deferred consideration

  1,642 

Estimated fair value of contingent consideration

  40,700 

Estimated total purchase consideration

 $75,136 

 

Pursuant to the Parcus Medical Merger Agreement, contingent consideration represents additional payments that the Company may be required to make in the future which could total up to $60.0 million depending on the level of net sales of Parcus Medical products generated in 2020 through 2022.

 

The fair value of contingent consideration related to net sales as of January 24, 2020, and at each reporting date, was determined based on a Monte Carlo simulation model in an option pricing framework, whereby a range of possible scenarios were simulated. The liability for contingent consideration was included in current liabilities on the condensed consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. During the three months ended September 30, 2022, the Company paid the contingent consideration related to net sales in the amount of $4.3 million which was included in current liabilities as of December 31, 2021. The Company does not expect any further milestones to be achieved.

 

Acquisition-related costs were not included as a component of consideration transferred but were expensed in the periods in which the costs are incurred. The Company incurred approximately $1.9 million in transaction costs related to the Parcus Medical acquisition during the three-month period ending March 31, 2020. The transaction costs subsequent to March 31, 2020 were immaterial.

 

Fair Value of Net Assets Acquired

 

The estimate of fair value as of the acquisition date required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable, however, actual results may differ from these estimates.

 

The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of January 24, 2020, and was as follows:

 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $196 

Accounts receivable

  2,029 

Inventories

  10,968 

Prepaid expenses and other current assets

  364 

Property and equipment, net

  1,099 

Right-of-use assets

  944 

Intangible assets

  44,000 

Accounts payable, accrued expenses and other current liabilities

  (2,763

)

Other long-term liabilities

  (594

)

Lease liabilities

  (735

)

Net assets acquired

  55,508 

Goodwill

  19,628 

Estimated total purchase consideration

 $75,136 

 

8

 

The acquired intangible assets based on estimates of fair value as of January 24, 2020 were as follows:

 

Developed technology

 $41,100 

Trade name

  1,800 

Customer relationships

  1,100 

Total acquired intangible assets

 $44,000 

 

The fair value of developed technology will be amortized over a useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of the trade name over 5 years.

 

The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill was impaired in 2020 and there was no remaining goodwill as of December 31, 2020.

 

Arthrosurface, Inc.

 

On February 3, 2020, the Company completed the acquisition of Arthrosurface pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Arthrosurface Merger Agreement”). Arthrosurface is a joint preservation technology company specializing in less invasive, bone-preserving partial and total joint replacement solutions.

 

Consideration Transferred

 

Pursuant to the Arthrosurface Merger Agreement, the Company acquired all outstanding equity of Arthrosurface for estimated total purchase consideration of $90.3 million, as of February 3, 2020 which consisted of:

 

Cash consideration

 $61,909 

Estimated fair value of contingent consideration

  28,376 

Estimated total purchase consideration

 $90,285 

 

Pursuant to the Arthrosurface Merger Agreement, the Company could be required to make future payments of up to $40.0 million depending on the achievement of regulatory milestones and the level of net sales of Arthrosurface products from 2020 through 2021. The fair value of contingent consideration related to regulatory milestones as of February 3, 2020 was determined through a scenario-based discounted cash flow analysis using scenario probabilities and regulatory milestone dates. The fair value of contingent consideration related to net sales achievement as of February 3, 2020 was determined based upon a Monte Carlo simulation approach at acquisition date, whereby a range of possible scenarios were simulated. The Company paid $5.0 million in October 2020 and $10.0 million in July 2021 based upon the achievement of two distinct regulatory milestones. As of September 30, 2022, there were no milestones remaining.

 

Acquisition-related costs were not included as a component of consideration transferred but were expensed in the periods in which the costs are incurred. The Company incurred approximately $2.2 million in transaction costs related to the Arthrosurface acquisition during the three-month period ending March 31, 2020. The transaction costs subsequent to March 31, 2020 were immaterial.

 

Fair Value of Net Assets Acquired

 

The estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates.

 

9

 

The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of February 3, 2020, as follows:

 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $1,072 

Accounts receivable

  5,368 

Inventories

  15,652 

Prepaid expenses and other current assets

  535 

Property, plant and equipment

  3,394 

Other long-term assets

  7,548 

Intangible assets

  48,900 

Accounts payable, accrued expenses and other liabilities

  (3,929

)

Deferred tax liabilities

  (11,147

)

Net assets acquired

  67,393 

Goodwill

  22,892 

Estimated total purchase consideration

 $90,285 

Intangible assets acquired consist of:

    

Developed technology

 $37,000 

Trade name

  3,400 

Customer relationships

  7,900 

IPR&D

  600 

Total acquired intangible assets

 $48,900 

 

The fair value of developed technology will be amortized over an estimated useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of trade names over 5 years. A total of $0.6 million represents the fair value of IPR&D with an indefinite useful life which was impaired during the quarter ended December 31, 2021.

 

The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill was impaired in 2020 and there was no remaining goodwill as of December 31, 2020.

 

 

4.

Fair Value Measurements

 

The Company has certain cash equivalents in money market funds that are classified within Level 1 of the fair value hierarchy and are valued based on quoted prices in active markets. For cash, accounts receivables, accounts payable, and accrued interest, the carrying amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is not included in the table below. Contingent consideration related to the previously described business combinations are classified within Level 3 of the fair value hierarchy as the determination of fair value uses considerable judgement and represents the Company’s best estimate of an amount that could be realized in a market exchange for the asset or liability. There were no transfers between fair value levels during the nine-month periods ended September 30, 2022 or 2021. See Note 3, Business Combinations for additional discussion of contingent consideration as of September 30, 2022.

 

10

 
 
      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical

Assets

  

Observable

Inputs

  

Unobservable

Inputs

     
  

September 30, 2022

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,348  $67,348  $-  $-  $67,348 
                     

Other current liabilities:

                    

Contingent Consideration - Short Term

 $-  $-  $-  $-  $- 

 

      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical

Assets

  

Observable

Inputs

  

Unobservable

Inputs

     
  

December 31, 2021

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,046  $67,046  $-  $-  $67,046 
                     

Other current liabilities:

                    

Contingent Consideration - Short Term

 $4,315  $-  $-  $4,315  $- 

 

Contingent Consideration

 

The following table provides a rollforward of the contingent consideration related to business acquisitions discussed in Note 3, Business Combinations

 

  

Nine Months Ended

  

Nine Months Ended

 
  

September 30, 2022

  

September 30, 2021

 

Balance, beginning

 $4,315  $35,410 

Payments

  (4,315)  (10,000)

Change in fair value

  -   (21,920)

Balance, ending

 $-  $3,490 

 

 

11

 
 
 

5.

Inventories

 

Inventories consist of the following:

 

  

September 30,

  

December 31,

 
  

2022

  

2021

 

Raw materials

 $19,015  $16,881 

Work-in-process

  11,650   11,442 

Finished goods

  24,277   26,731 

Total

 $54,941  $55,054 
         

Inventories

 $37,237  $36,010 

Other long-term assets

  17,704   19,044 

Total

 $54,941  $55,054 

 

Inventories are stated net of inventory reserves of $10.0 million and $9.1 million as of September 30, 2022 and December 31, 2021, respectively.

 

 

6.

Intangible Assets

 

      

Nine Months Ended

September 30, 2022

  

December 31,

2021

     
  

Gross
Value

  

Less: Accumulated
Currency Translation
Adjustment

  

Less:
Accumulated
Amortization

  

Net Book
Value

  

Net Book
Value

  

Weighted
Average Useful
Life

 

Developed technology

 $89,580  $(1,607

)

 $(22,238

)

 $65,735  $70,081   15 

IPR&D

  2,656   (1,006

)

  -   1,650   1,650  

Indefinite

 

Customer relationships

  9,000   -   (2,402

)

  6,598   7,273   10 

Distributor relationships

  4,700   (415

)

  (4,285

)

  -   -   5 

Patents

  1,000   (189

)

  (668

)

  143   179   16 

Tradenames

  5,200   -   (2,781

)

  2,419   3,199   5 

Total

 $112,136  $(3,217

)

 $(32,374

)

 $76,545  $82,382   13 

 

The aggregate amortization expense related to intangible assets was $1.9 million and $2.0 million for the three-month periods ended September 30, 2022 and 2021, respectively, and $5.8 million and $5.9 million for each of the nine-month periods ended September 30, 2022 and 2021.

 

 

7.

Goodwill

 

The Company assesses goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there may be impairment.

 

Changes in the carrying value of goodwill for the nine months ended September 30, 2022 were as follows:

 

  

Nine Months Ended September 30, 2022

 

Balance, beginning

 $7,781 

Effect of foreign currency adjustments

  (1,060

)

Balance, ending

 $6,721 

 

12

 
 

8.

Leases

 

The Company leases its buildings and manufacturing facilities under operating leases. As of September 30, 2022, the Company had real estate leases in Bedford, Massachusetts, Franklin, Massachusetts, Sarasota, Florida, Warsaw, Indiana and Padova, Italy.

 

In June 2022, the Company finalized renewal options to extend the current term of its leases for its building and manufacturing facility in Bedford as well as its two facilities in Sarasota. With the extension of these renewal options, the Bedford lease term extends to 2027 with several lease renewal options into 2038 and the two leases in Sarasota extend to 2027 but may be extended by mutual agreement. The Sarasota leases also include a right to terminate in 2025 at the Company’s option. The current term of the Franklin lease extends to 2023 and the current term of the Padova lease extends to 2032, with a right to terminate at the Company’s option without penalty.

 

The following table summarizes the Company’s significant commitments under lease agreements as of September 30, 2022:

 

  

Operating Leases

 
     

2022 (Remainder of Year)

 $720 

2023

  3,081 

2024

  3,025 

2025

  3,066 

2026

  2,760 

Thereafter

  27,873 

Present value adjustment

  (9,421

)

Present value of lease payments

  31,105 

Less current portion included in accrued expenses and other current liabilities

  (1,922

)

Total lease liabilities

 $29,183 

 

During the three and nine months ended September 30, 2022, the Company incurred lease expense of $0.8 million and $2.1 million, respectively. During the three and nine months ended September 30, 2021, the Company incurred lease expense of $0.6 million and $1.9 million, respectively. As of September 30, 2022, the weighted average remaining operating lease term was 15.0 years and the weighted average incremental borrowing rate used to determine the operating lease liability was 3.6%.

 

 

9.

Accrued Expenses and Other Liabilities

 

Accrued expenses and other liabilities consist of the following:

 

  

September 30, 2022

  

December 31, 2021

 
         

Compensation and related expenses

 $11,166  $9,523 

Professional fees

  3,063   3,590 

Operating lease liability – current

  1,922   1,526 

Clinical trial costs

  1,352   1,961 

Financing lease liability – current

  -   188 

Other

  496   1,059 

Total

 $17,999  $17,847 

 

13

 
 
 

10.

Commitments and Contingencies

 

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties as of September 30, 2022 or December 31, 2021 and has no history of claims paid.

 

The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.

 

On October 21, 2021, the Company received notice that the former unitholders of Parcus Medical had filed a request for arbitration regarding the earnout provisions agreed to in the Parcus Medical Merger Agreement. The Company has engaged in the arbitration process and does not anticipate a resolution during 2022. The Company is unable to estimate the potential liability with respect to this matter at this time. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at this stage of the matter, including the significant number of legal and factual issues still to be resolved in the arbitration process. The Company intends to vigorously defend against the claims and believes it has strong defenses to the claims asserted.

 

 

11.

Revenue and Geographic Information

 

Revenue by product family was as follows: 

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 
                 

OA Pain Management

 $25,665  $26,153  $74,139  $69,790 

Joint Preservation and Restoration

  11,821   11,193   36,055   35,296 

Non-Orthopedics

  2,778   2,190   6,420   6,887 
  $40,264  $39,536  $116,614  $111,973 

 

Revenue from the Company’s sole significant customer, DePuy Synthes Mitek Sports Medicine (“Mitek”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 45% and 51% for the three months ended September 30, 2022 and 2021, respectively, and 43% and 46% for the nine months ended September 30, 2022 and 2021, respectively

 

The Company receives payments from our customers based on billing schedules established in each contract. Up-front payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Deferred revenue was $0.1 million and $1.0 million as of September 30, 2022 and December 31, 2021, respectively.

 

14

 
 

Total revenue by geographic location was as follows:

 

  

Three Months Ended September 30,

 
  

2022

  

2021

 
  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                

United States

 $31,093   77

%

 $30,910   78

%

Europe

  4,885   12

%

  4,238   11

%

Other

  4,286   11

%

  4,388   11

%

Total

 $40,264   100

%

 $39,536   100

%

 

  

Nine Months Ended September 30,

 
  

2022

  

2021

 
  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                

United States

 $87,552   75

%

 $85,984   77

%

Europe

  15,973   14

%

  14,808   13

%

Other

  13,089   11

%

  11,181   10

%

Total

 $116,614   100

%

 $111,973   100

%

 

 

12.

Equity Incentive Plan

 

Equity Incentive Plan

 

The Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”) was approved by the Company’s stockholders on June 13, 2017 and subsequently amended on June 18, 2019, June 16, 2020, June 16, 2021 and June 8, 2022. On June 8, 2022, the Company’s stockholders approved an amendment to the 2017 Plan increasing the number of shares by 250,000 shares from 4.6 million shares to 4.85 million shares. The 2017 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights (“SARs”), restricted stock awards, performance restricted stock units (“PSUs”), restricted stock units (“RSUs”), total shareholder return options (“TSRs”) and performance options that may be settled in cash, stock, or other property. In accordance with the 2017 Plan approved by the Company’s stockholders, including the amendments thereto, each share award other than stock options or SARs will reduce the number of total shares available for grant by two shares. Subject to adjustment for specified types of changes in the Company’s capitalization, no more than 4.85 million shares of common stock may be issued under the 2017 Plan. There were 1.2 million shares available for future grant at September 30, 2022 under the 2017 Plan.

 

The Anika Therapeutics, Inc. 2021 Inducement Plan (the “Inducement Plan”) was adopted by the Company’s board of directors on November 4, 2021. The Inducement Plan reserves 125,000 shares of common stock for issuance pursuant to equity-based awards granted under the Inducement Plan. Such awards may be granted only to an individual who was not previously the Company’s employee or director with the Company. The Inducement Plan provides for the grant of awards under terms substantially similar to the 2017 Plan (as amended). There were 4,883 shares available for future grant at September 30, 2022 under the Inducement Plan.

 

The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to or greater than the market price of the Company’s stock on the date of grant. Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over three years with a maximum contractual term of ten years.

 

15

 
 

The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows (in thousands):

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Cost of revenue

 $242  $142  $645  $485 

Research & development

  397   360   1,267   1,003 

Selling, general & administrative

  3,237   2,361   8,590   6,431 

Total stock-based compensation expense

 $3,876  $2,863  $10,502  $7,919 

 

Stock Options

 

Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of three years and expire 10 years after the date of grant. The grant-date fair value of options is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.

 

The following summarizes the activity under the Company’s stock option plans:

 

  

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average

Remaining

Contractual

Term (in years)

  

Aggregate Intrinsic

Value

(in thousands)

 

Outstanding as of December 31, 2021

  1,175,993  $39.56         

Granted

  486,901  $27.60         

Exercised

  (437

)

 $9.10      $10 

Forfeited and canceled

  (156,672

)

 $44.08         

Outstanding as of September 30, 2022

  1,505,785  $35.21   8.3  $78 

Vested, September 30, 2022

  499,617  $40.00   7.3  $8 

Vested or expected to vest, September 30, 2022

  1,505,785  $35.21   8.3  $78 

 

The aggregate intrinsic value of options exercised for the nine-month period ended September 30, 2022 was immaterial.

 

The Company granted 486,901 stock options during the nine-month ended September 30, 2022, of which 398,314 shares were premium-priced options.

 

As of September 30, 2022, there was $8.7 million of unrecognized compensation cost related to unvested stock options. This expense is expected to be recognized over a weighted average period of 1.8 years.

 

The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The Company estimates the fair value of TSRs using Monte-Carlo simulation model where the expected volatility assumption is evaluated over 6.3 years. The actual number of TSR options that may be earned ranges from 0% to 150% of the target number, depending on the total shareholder return of the Company relative to the peer group over the vesting period of 2.7 years. There were 104,638 TSRs as of September 30, 2022.

 

16

 
 

The assumptions used in the Black-Scholes pricing model for options granted during the nine months ended September 30, 2022 and 2021, along with the weighted-average grant-date fair values, were as follows:

 

 

Nine Months Ended September 30,

 

2022

2021

Risk free interest rate

 

1.3%

-

3.4%

 

0.3%

-

0.7%

Expected volatility

 

53.8%

-

55.5%

 

54.8%

-

56.1%

Expected life (years)

  

4.5

   

4.0

 

Expected dividend yield

  

0.0%

   

0.0%

 

Fair value per option

  

$11.26

   

$14.55

 

 

Restricted Stock Units

 

RSUs generally vest in equal annual installments over a three-year period. The grant-date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of RSUs based on the closing price of its common stock on the date of grant.

 

RSU activity for the nine-month period ended September 30, 2022 was as follows:

 

  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  412,658  $36.33 

Granted

  507,524  $25.14 

Vested

  (159,871

)

 $36.48 

Forfeited and cancelled

  (67,389

)

 $32.45 

Outstanding as of September 30, 2022

  692,922  $28.48 

 

The weighted-average grant-date fair value per share of RSUs granted was $25.14 for the nine-month period ended September 30, 2022. The total fair value of RSUs vested was $5.8 million and $3.9 million for the nine-month periods ended September 30, 2022 and 2021, respectively.

 

As of September 30, 2022, there was $14.8 million of unrecognized compensation cost related to time-based RSUs, which was expected to be recognized over a weighted-average period of 2.0 years.

 

Performance Stock Units

 

PSU activity for the nine-month ended September 30, 2022 was as follows:

 

  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  158,297  $37.44 

Performance factor adjustment

  2,125  $32.53 

Vested

  (19,125

)

 $32.53 

Forfeited and cancelled

  (23,400

)

 $41.86 

Outstanding as of September 30, 2022

  117,897  $34.98 

 

The total fair value of PSUs vested was $0.6 million and $0 for the nine-month period ended September 30, 2022 and 2021, respectively. As of September 30, 2022, none of the milestones related to the outstanding PSUs were expected to be achieved.

 

17

 
 
 

13.

Income Taxes

 

The Company recorded an income tax benefit of $1.2 million and $2.4 million for the three- and nine-month periods ended   September 30, 2022, resulting in effective tax rates of 22.1% and 19.5%, respectively. The Company recorded income tax expense of $0.7 million and $1.7 million for the three- and nine-month periods ended   September 30, 2021, based on effective tax rates of 55.4% and 14.4%, respectively.

 

The decrease in the effective tax rate for the three-month period ended  September 30, 2022, as compared to the same period in 2021, was primarily due to non-deductible stock-option activity during the three-month period ended  September 30, 2021. The increase in the effective tax rate for the nine-month period ended   September 30, 2022, as compared to the same period in 2021, was primarily due to the year-to-date net tax benefit in 2021 on the change in the fair value of contingent consideration, in the amount of $1.1 million, and a year-to-date discrete charge of $0.7 million in 2022 related to non-deductible stock compensation.

 

The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate, which varies by jurisdiction.

 

In connection with the preparation of the financial statements, the Company assessed whether it is more likely than not that it will be able to utilize, in future periods, the Company’s deferred income tax assets to offset future taxable income and tax liabilities. The Company concluded that it is more likely than not that its deferred tax assets will be realized, after evaluation and consideration of both the positive and negative evidence. On  December 31, 2021, the Company released a valuation allowance that had been previously recorded related to its net deferred tax assets in Italy in the amount of $0.9 million. The Company did not record a valuation allowance on its deferred tax balances as of  September 30, 2022.

 

 

14.

Earnings Per Share (EPS)

 

Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic EPS. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding share-based awards using the treasury stock method

 

The following table provides share information used in the calculation of the Company's basic and diluted earnings per share (in thousands):

 

  

Three Month Period Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Shares used in the calculation of basic earnings per share

  14,603   14,429   14,542   14,389 

Effect of dilutive securities:

                

Share-based payment awards

  -   218   -   199 

Diluted shares used in the calculation of earnings per share

  14,603   14,647   14,542   14,588 

 

The Company had a net loss during the three and nine-months ended September 30, 2022, and therefore all potential common shares would have been anti-dilutive and accordingly were excluded from the computation of diluted EPS. Stock options of 1.1 million shares were outstanding for the nine-month period ended September 30, 2021, respectively, and were not included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive.

 

18

 
 
 

ITEM 2.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion in conjunction with our financial statements and related notes appearing elsewhere in this report and our audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the year ended December 31, 2021, or our 2021 Form 10-K. In addition to historical information, this report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 concerning our business, consolidated financial condition, and results of operations. The Securities and Exchange Commission, or the SEC, encourages companies to disclose forward-looking statements so that investors can better understand a company’s prospects and make informed investment decisions. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as "will," "likely," "may," "believe," "expect," "anticipate," "intend," "seek," "designed," "develop," "would," "future," "can," "could," “estimate,” “potential,” and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. All statements other than statements of historical facts included in this report regarding our strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements regarding the effect of COVID-19 and related impacts on our business, operations, and financial results, expected future operating results, expectations regarding the timing and receipt of regulatory results, anticipated levels of capital expenditures, and expectations of the effect on our financial condition of claims, litigation, and governmental and regulatory proceedings.

 

Please also refer to those factors described in “Part I, Item 1A. Risk Factors” of our 2021 Form 10-K for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements. Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Management Overview

 

We are a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Based on our collaborations with clinicians to understand what they need most to treat their patients, we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis, or OA, pain management, regenerative solutions, sports medicine soft tissue repair and bone preserving joint technologies.

 

We have thirty years of global expertise developing, manufacturing and commercializing products based on and/or enhanced with our hyaluronic acid, or HA, technology platform. HA is a naturally occurring polymer found throughout the body that is vital for proper joint health and tissue function. Our proprietary technologies for modifying the HA molecule allow product properties to be tailored specifically to multiple uses, including enabling longer residence time to support OA pain management and creating a solid form of HA called Hyaff, which is a platform utilized in our regenerative solutions portfolio.

 

In early 2020, we expanded our overall technology platform, product portfolio, and significantly enhanced and accelerated our commercial infrastructure, especially in the United States, through our strategic acquisitions of Parcus Medical, a sports medicine and instrumentation solutions provider focused on soft tissue repair, and Arthrosurface, a company specializing in bone preserving partial and total joint replacement solutions. Through these acquisitions, we have transformed our company. We expanded our addressable market from the over $1 billion global OA pain management market to the over $8 billion global joint preservation market (which includes the faster growing sports medicine soft tissue repair and extremities segments), advanced our commercial capabilities, instituted systems and processes to support our transformation, and expanded our product pipeline and research and development expertise in our target markets.

 

As we look towards the future, our business is positioned to capture value within our target market of joint preservation. We believe our success will be driven by our:

 

 

Decades of experience in HA-based regenerative solutions and early intervention orthopedics combined under new seasoned leadership with a strong financial foundation for future investment in meaningful solutions for our customers and their patients;

 

19

 

 

 

Robust network of stakeholders in our target markets to identify evolving unmet patient treatment needs;

 

 

Prioritized investment in differentiated pipeline of regenerative solutions, bone preserving implants and sports medicine soft tissue repair products;

     
 

Leveraging our global commercial expertise and building out our capabilities to drive growth across the portfolio, with an intentional and increased focus on the ambulatory surgery centers site of care in the United States;

 

 

Opportunity to pursue strategic inorganic growth opportunities, including potential partnerships and smaller acquisitions, technology licensing, and leveraging our strong financial foundation and operational capabilities; and

 

 

Energized and experienced team focused on strong values, talent, and culture.

 

COVID-19 Pandemic and Resulting Supply Chain and Staffing Challenges

 

In March 2020, the World Health Organization declared the spread of the COVID-19 virus a pandemic. This pandemic has caused an economic downturn on a global scale, as well as significant volatility in the financial markets. There has been significant volatility in our results on a quarterly basis due to the worldwide cancellation or delay of elective procedures, staffing shortages and supply chain disruptions, as well as the impact on timelines associated with certain clinical studies. Resurgence of COVID-19 as a result of emerging variants or other factors could result in additional staffing shortages or supply chain disruptions that could impact our business and operations. We have had some disruption in our ability to supply products to our customers due to supply chain disruptions and staffing shortages which has caused back orders or delays in certain shipments to our customers. The companies that produce our products, product components or otherwise support our manufacturing processes, the distribution centers where we manage our inventory, or the operations of our logistics and other service providers, including third parties that sterilize and store our products, are or could be disrupted, temporarily close or experience worker shortages for a sustained period of time. To date, we believe we have taken adequate precaution to mitigate the impact of the current disruption of key materials, components and parts to the extent possible and reasonable. We expect, however, the current supply chain disruption with certain key suppliers to continue, which could have a material adverse effect on our operations. For additional information on the impact of supply chain disruption related to the COVID-19 pandemic on our manufacturing operations, please refer to the section captioned “Part II, Item 1A. Risk Factors.

 

Our commercial day-to-day operations have been impacted due to the worldwide cancellations and/or delays of elective procedures and restrictions on travel for both our employees and our clinician customers, and timelines associated with certain clinical studies and research and development programs have been delayed. While the impact has been limited to these items to date, we caution that there continues to be a possibility for potential future implementation of certain additional restrictions or other challenges associated with infections, staffing shortages, volatility in elective surgical procedures or supply chain disruptions due to COVID-19 and its current or new variants in certain jurisdictions. In particular, supply constraints that have continued into 2022 that we have partially been able to mitigate to date have impacted and could be expected to impact our ability to produce and supply our products. The impact of these challenges is currently unknown but could be significant.

 

Products

 

OA Pain Management

 

Our OA Pain Management product family consists of:

 

 

Monovisc and Orthovisc, our single- and multi-injection, HA-based viscosupplement product offerings indicated to provide pain relief from OA conditions solely for use in the knee. Our OA Pain Management products are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by DePuy Synthes Mitek Sports Medicine, or “Mitek”, part of the Johnson & Johnson Medical Companies. In December 2011, we entered into a fifteen-year licensing agreement with Mitek to exclusively market Monovisc in the United States through December 2026. In December 2003, we entered into a ten-year licensing agreement with Mitek to exclusively market Orthovisc in the United States. Mitek extended this agreement for additional five-year terms in 2007, 2012, 2017 and most recently in August 2022. The current agreement expires on December 20, 2028 unless extended at the option of Mitek. The Monovisc and Orthovisc products have been the market leaders, based on combined overall revenue in the viscosupplement market, since 2018. Internationally, we market our OA Pain Management products directly through a worldwide network of commercial distributors.

 

 

Cingal, our novel, third-generation, single-injection OA Pain Management product consisting of our proprietary cross-linked HA material combined with a fast-acting steroid. Cingal is designed to provide both short- and long-term pain relief. Cingal is CE Mark approved and for several years has been sold outside the United States directly in over 35 countries through our network of distributors. In the United States, Cingal is a pipeline product currently in clinical development and is not available for commercial sale.

 

 

Hyvisc, our high molecular weight injectable HA veterinary product approved for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA.

 

20

 

 

Joint Preservation and Restoration

 

Our Joint Preservation and Restoration product family consists of: 

 

 

Bone Preserving Joint Technologies. Our portfolio of more than 150 bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants, is designed to treat upper and lower extremity orthopedic conditions as well as knee and hip conditions caused by arthritic disease, acute trauma and injury. These products span multiple joints including the shoulder, foot/ankle, wrist, knee and hip and are generally intended to restore a patient’s natural anatomy and movement. These products are often used to treat patients with OA progression beyond where our OA Pain Management products can allow the patients to retain an active lifestyle when early surgical intervention becomes preferable.

 

 

Soft Tissue Repair. Our line of soft tissue repair solutions is used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, acute trauma and disease. These more traditional sports medicine solutions include screws, sutures, suture anchors, grafts and other surgical systems that facilitate surgical procedures on the shoulder, knee, hip, upper and lower extremities, and other soft tissues.

 

 

Regenerative Solutions. Our portfolio of orthopedic regenerative solutions leveraging our proprietary technologies based on HA and Hyaff, which is a solid form of HA. These products include Tactoset Injectable Bone Substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and for augmenting hardware fixation, such as suture anchors and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. Tactoset cleared and commercialized principally in the United States, whereas Hyalofast is CE Mark approved and currently available outside the United States in over 35 countries within Europe, South America, Asia, and certain other international markets. In the United States, Hyalofast is a product under clinical trial studies and is not available for commercial sale.

 

We currently commercialize Bone Preserving Joint Technologies, Soft Tissue Repair products, and Tactoset (from our Regenerative Solutions portfolio) in the United States by selling to hospitals and ambulatory surgery centers, through an independent network of sales representatives and distributors, and utilize our distributor network for sales in certain international markets.

 

Non-Orthopedic

 

Our Non-Orthopedic product family consists of legacy HA-based products that are marketed principally for non-orthopedic applications. These products include Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries, Hyalomatrix, used for the treatment of complex wounds such as burns and ulcers, as well as products used in connection with the treatment of ears, nose and throat disorders, and ophthalmic products, including injectable, high molecular weight HA products such as Anikavisc and Nuvisc, used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. These Non-Orthopedic products are sold through commercial sales and marketing partners around the world.

 

 

 

 

21

 

 

Results of Operations

 

Three and Nine Months Ended September 30, 2022 Compared to Three and Nine Months Ended September 30, 2021

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2022

   

2021

   

$ Inc/(Dec)

   

% Inc/(Dec)

   

2022

   

2021

   

$ Inc/(Dec)

   

% Inc/(Dec)

 
   

(in thousands, except percentages)

           

(in thousands, except percentages)

         

Revenue

  $ 40,264     $ 39,536     $ 728       2 %   $ 116,614     $ 111,973     $ 4,641       4 %

Cost of revenue

    17,485       16,513       972       6 %     47,169       47,164       5       0 %

Gross Profit

    22,779       23,023       (244 )     (1% )     69,445       64,809       4,636       7 %

Gross Margin

    57 %     58 %                     60 %     58 %                

Operating expenses:

                                                               

Research & development

    7,301       7,673       (372 )     (5% )     20,433       21,327       (894 )     (4% )

Selling, general & administrative

    21,276       17,500       3,776       22 %     61,745       53,664       8,081       15 %
                                                                 

Change in fair value of contingent consideration

    -       (3,450 )     3,450       (100% )     -       (21,920 )     21,920       (100% )

Total operating expenses

    28,577       21,723       6,854       32 %     82,178       53,071       29,107       55 %
(Loss) income  from operations     (5,797 )     1,300       (7,097 )     (546% )     (12,733 )     11,738       (24,471 )     (208% )

Interest and other income (expense), net

    436       (48 )     484       (1,008% )     378       (141 )     519       (368% )
(Loss) income before income taxes     (5,361 )     1,252       (6,613 )     (528% )     (12,355 )     11,597       (23,952 )     (207% )
(Benefit from) provision for income taxes     (1,187 )     694       (1,881 )     (271% )     (2,404 )     1,670       (4,074 )     (244% )
Net (loss) income   $ (4,175 )   $ 558     $ (4,733 )     (848% )   $ (9,951 )   $ 9,927     $ (19,878 )     (200% )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

22

 

Revenue

 

Revenue for the three-month period ended September 30, 2022 was $40.3 million, an increase of $0.8 million as compared to $39.5 million for the three-month period ended September 30, 2021. Revenue for the nine-month period ended September 30, 2022 was $116.6 million, an increase of $4.6 million as compared to $112.0 million for the nine-month period ended September 30, 2021.

 

The following tables present product revenue by product family:

 

   

Three Months Ended September 30,

 
   

2022

   

2021

   

$ Inc/(Dec)

   

% Inc/(Dec)

 
                                 

OA Pain Management

  $ 25,665     $ 26,153     $ (488 )     (2

%)

Joint Preservation and Restoration

    11,821       11,193       628       6

%

Non-Orthopedic

    2,778       2,190       588       27 %
    $ 40,264     $ 39,536     $ 728       2

%

 

 

   

Nine Months Ended September 30,

 
   

2022

   

2021

   

$ Inc/(Dec)

   

% Inc/(Dec)

 
                                 

OA Pain Management

  $ 74,139     $ 69,790     $ 4,349       6

%

Joint Preservation and Restoration

    36,055       35,296       759       2

%

Non-Orthopedic

    6,420       6,887       (467

)

    (7 )%
    $ 116,614     $ 111,973     $ 4,641       4

%

 

 

 

 

 

 

 

 

 

 

 

23

 

 

For the three-month period ended September 30, 2022, the increase in revenue was mainly due to growth in Joint Preservation and Restoration revenues as hospitals and ASCs recover from the COVID 19 pandemic and higher Non-Orthopedic revenues from the sales of certain legacy products related to end-of-life purchases. This revenue increase was offset by lower US OA Pain Management revenue primarily related to ordering patterns from Mitek in the prior year.

 

For the nine-month period ended September 30, 2022, the increase in revenue was mainly due an increase in OA Pain Management revenues from international viscosupplement distributors and Hyvisc equine product sales due to recovery from the COVID 19 pandemic as well as favorable ordering patterns, offset by lower US OA Pain Management sales to Mitek as a result of ordering patterns in the prior year. The increase in total revenue was also due to an increase in Joint Preservation and Restoration revenues as hospitals and ASCs performing more procedures as they recover from COVID 19 pandemic, which however remained limited due in part to constraints on staffing, offset by lower Non-Orthopedic revenue in part related to the timing of orders on legacy products.

 

Gross Profit and Margin

 

Gross profit for the three -and nine -month periods ended September 30, 2022 decreased by $0.2 million and increased by $4.6 million, to $22.8 million and $69.4 million, respectively. The decrease in gross profit for the three-month period ended September 30 2022 was related to a reserve of $2.6 million primarily associated with inventory for certain legacy Non-Orthopedic products that the Company no longer expects to sell. The increase in gross profit for the nine-month period ended September 30, 2022, as compared to the same period in 2021 was primarily due to increased revenue as well as the impact of inventory step-up charges associated with the acquisitions of Arthrosurface and Parcus Medical in 2021.

 

Gross margin for the three- and nine-month periods ended September 30, 2022 was 57% and 60%, respectively. Gross margin for the three- and nine-month periods ended September 30, 2021 was 58% for each period. The decrease in gross margin for the three-month period ended September 30, 2022 was due primarily to product rationalization charges in the third quarter of 2022. The increase in gross margin for the nine-month period ended September 30, 2022 was due primarily to the unfavorable impact of inventory step-up charges associated with the Arthrosurface and Parcus Medical in 2021.

 

Research and Development

 

Research and development expenses for the three- and nine-month periods ended September 30, 2022 were $7.3 million and $20.4 million, a decrease of $0.4 million and $0.9 million, respectively as compared to the same period in 2021. The decreases for the three-month and nine-month periods ended September 30, 2022 were primarily due to lower clinical trial spending, associated with the conclusion of our Cingal Phase III trial in 2022.

 

Selling, General and Administrative

 

Selling, general and administrative, or SG&A expenses for the three- and nine-month periods ended September 30, 2022 were $21.3 million and $61.7 million representing an increase of $3.8 million and $8.0 million, respectively as compared to the same period in 2021. This increase in SG&A expense for the three-month and nine-month periods ended September 30, 2022, was primarily due to expansion of our commercial capabilities in the United States and expanded marketing activities and other operational capabilities to support the growing business needs. Certain marketing and medical education activities also were more limited in 2021 due to the COVID-19 pandemic. The increase in SG&A expense was also due to higher stock-based compensation expense in 2022 driven by a change in headcount associated with the Company’s strategic transformation that accelerated in 2020 and 2021.

 

Contingent Consideration Fair Value Change

 

The fair value of contingent consideration as of September 30, 2022 did not change compared to December 31, 2021. During the three-month and six-month periods ended September 30, 2021, the change in the fair value of contingent consideration liabilities was $3.5 million and $21.9 million, respectively, resulting in a non-cash benefit to net income in those periods.

 

Income Taxes

 

The benefit from income taxes was $1.2 million and $2.4 million for the three- and six-month periods ended September 30, 2022, resulting in effective tax rates of 22.1% and 19.5%, respectively. The provision for income taxes was $0.7 million and $1.7 million for the three- and nine-month periods ended September 30, 2021, based on effective tax rates of 55.4% and 14.4%, respectively.

 

24

 

 

The decrease in the effective tax rate for the three-month period ended September 30, 2022, as compared to the same period in 2021, was primarily due to non-deductible stock-option activity during the three-month period ended September 30, 2021. The increase in the effective tax rate for the nine-month period ended  September 30, 2022, as compared to the same period in 2021, was primarily due to the net tax benefit in 2021 on the change in the fair value of contingent consideration and non-deductible stock compensation in 2022.

 

Net (Loss) Income

 

For the three and nine-month periods ended September, 2022, net loss was $4.2 million and $10.0 million, or $0.29 per diluted share and $0.68 per diluted share, respectively, compared to net income of $0.6 million and $9.9 million, or $0.04 per diluted share and $0.68 per diluted share, for the same periods in prior year. The decrease in net income and diluted earnings per share was primarily due to the change in fair value of contingent consideration of $21.9 million for the nine-months ended September 30, 2021, as well as increased spending to expand our commercial capability in the United States, partially offset by increased revenue.

 

Non-GAAP Financial Measures

 

We present certain information with respect to adjusted gross profit and adjusted gross margin, adjusted Earnings Before Interest, Tax, Depreciation and Amortization, or EBITDA, adjusted net income, adjusted diluted earnings per share or adjusted EPS, which are financial measures not based on any standardized methodology prescribed by accounting principles generally accepted in the United States, or GAAP, and is not necessarily comparable to similarly titled measures presented by other companies.

 

We have presented adjusted gross profit and adjusted gross margin, adjusted EBITDA, adjusted net income, adjusted EPS, because they are key measures used by our management and board of directors to understand and evaluate our operating performance and to develop operational goals for managing our business. We believe these financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude. In particular, we believe that the exclusion of these items in calculating these measures can provide a useful tool for period-to-period comparisons of our core operating performance. Accordingly, we believe that these measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects and allowing for greater transparency with respect to key financial metrics used by our management in their financial and operational decision-making.

 

Adjusted Gross Profit and Adjusted Gross Margin

 

We define adjusted gross profit as our gross profit excluding amortization of certain acquired intangible assets, the impact of inventory fair-value step up associated with our recent acquisitions and certain product rationalization charges. The amortized assets contribute to revenue generation, and the amortization of such assets will likely continue in future periods until such assets are fully amortized. These assets include the fair value of certain identified assets acquired in acquisitions, including developed technology and acquired tradenames. We define adjusted gross margin as adjusted gross profit divided by total revenue.

 

The following is a reconciliation of adjusted gross profit to gross profit for the three- and nine-month periods ended September 30, 2022 and 2021, respectively:

 

   

For the Three Months Ended

September 30,

   

For the Nine Months Ended

September 30,

 
   

2022

   

2021

   

2022

   

2021

 

Gross Profit

  $ 22,779     $ 23,023     $ 69,445     $ 64,809  

Product rationalization related charges

    2,636       -       2,636       2,063  

Acquisition related intangible asset amortization

    1,562       1,562       4,686       4,686  

Acquisition related inventory step up

    -       1,458       -       6,244  

Adjusted Gross Profit

  $ 26,977     $ 26,043     $ 76,767     $ 77,802  
                                 

Adjusted Gross Margin

    67

%

    66

%

    66

%

    69

%

 

25

 

 

Adjusted gross profit for the three- and nine-month periods ended September 30, 2022 increased by $1.0 million and decreased $1.0 million to $27.0 million and $76.8 million, respectively, representing adjusted gross margin of 67% and 66%. Adjusted gross profit for the three- and nine-month periods ended September 30, 2021 was $26.0 million and $77.8 million, respectively, representing gross margin of 66% and 69%, respectively. The decrease in adjusted gross margin for the nine-month period ended September 30, 2022, was primarily due to higher manufacturing costs and production inefficiencies caused in part by supply chain and staffing challenges.

 

Adjusted EBITDA 

 

We present information below with respect to adjusted EBITDA, which we define as our net income (loss) excluding interest and other income, net, income tax benefit (expense), depreciation and amortization, stock-based compensation, product rationalization, and acquisition related expenses. In light of the COVID-19 pandemic, we have also excluded the impacts of goodwill impairment charges and changes in the fair value of contingent consideration associated with our acquisition transactions in early 2020.

 

Adjusted EBITDA is not prepared in accordance with US GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with US GAAP. There are a number of limitations related to the use of adjusted EBITDA rather than net income (loss), which is the nearest US GAAP equivalent. Some of these limitations are:

 

 

adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;

 

 

we exclude stock-based compensation expense from adjusted EBITDA although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our employee compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses likely would be higher, which would affect our cash position;

 

 

we exclude acquisition related expenses, including transaction costs and other related expenses, amortization and depreciation of acquired assets in recent acquisitions, and the impact of inventory fair-value step up on cost of revenue;

 

 

we exclude certain impairment charges, including certain product rationalization charges as a result of managing our financial position in light of our recent acquisitions, the impact of COVID-19 and changing regulatory requirements;

 

 

we exclude goodwill impairment charges and changes in the fair value of contingent consideration;

 

 

the expenses and other items that we exclude in our calculation of adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report their operating results;

 

 

adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;

 

 

adjusted EBITDA does not reflect (benefit from) provision for income taxes or the cash requirements to pay taxes; and

 

 

adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments.

 

26

 

 

The following is a reconciliation of net income (loss) to adjusted EBITDA for the three- and nine-month periods ended September 30, 2022 and 2021, respectively:

 

   

For the Three Months Ended

September 30,

   

For the Nine Months Ended

September 30,

 
   

2022

   

2021

   

2022

   

2021

 

Net (loss) income

  $ (4,175

)

  $ 558     $ (9,951

)

  $ 9,927  

Interest and other expense, net

    (436

)

    48       (378 )     141  

(Benefit from) provision for income taxes

    (1,187

)

    694       (2,404

)

    1,670  

Depreciation and amortization

    1,549       1,789       4,980       5,226  

Share-based compensation

    3,876       2,863       10,502       7,919  

Product rationalization

    2,636       -       2,636       2,063  

Acquisition related intangible asset amortization

    1,787       1,787       5,361       5,361  

Acquisition related inventory step up

    -       1,458       -       6,244  

Change in fair value of contingent consideration

    -       (3,450

)

    -       (21,920

)

Adjusted EBITDA

  $ 4,050     $ 5,747     $ 10,746     $ 16,631  

 

Adjusted EBITDA for the three-month period ended September 30, 2022, decreased by $1.6 million as compared with the same period in 2021. The decrease in adjusted EBITDA for the period was primarily due to increased commercial spending to support future growth as certain marketing and medical education activities were more limited in 2021.

 

Adjusted EBITDA for the nine-month period ended September 30, 2022, decreased $5.9 million as compared with the same period in 2021. The decrease in adjusted EBITDA for the period was primarily due to lower adjusted gross profit, from higher manufacturing costs and production inefficiencies caused in part by supply chain and staffing challenges, as well as an increase in operating expenses primarily attributable to expansion of our commercial capability in the United States.

 

Adjusted Net Income (Loss) and Adjusted EPS

 

We present information below with respect to adjusted net income (loss) and adjusted EPS. We define adjusted net income (loss) as our net income (loss) excluding acquisition-related expenses, amortization and depreciation of acquired assets, the impact of inventory fair-value step up on cost of revenue and the impacts of goodwill impairment charges and changes in the fair value of contingent consideration, as well as certain impairment charges, including product rationalization charges, on a tax effected basis. Acquisition related expenses are those that we would not have incurred except as a direct result of acquisition transactions. Acquisition related expenses consist of investment banking, legal, accounting, and other professional and related expenses. The amortized assets contribute to revenue generation, and the amortization of such assets will recur in future periods until such assets are fully amortized. These assets include the estimated fair value of certain identified assets acquired in acquisitions, including in-process research and development, developed technology, customer relationships and acquired tradenames. We define adjusted EPS as US GAAP diluted earnings (loss) per share excluding the above adjustments to net income used in calculating adjusted net income, each on a per share and tax effected basis.

 

27

 

 

The following is a reconciliation of adjusted net income (loss) to net income (loss) for the three- and nine-month periods ended September 30, 2022 and 2021, respectively:

 

   

For the Three Months Ended

September 30,

   

For the Nine Months Ended

September 30,

 
   

2022

   

2021

   

2022

   

2021

 

Net (loss) income

  $ (4,175

)

  $ 558     $ (9,951

)

  $ 9,927  

Product rationalization, tax effected

    2,056       -       1,947       1,590  

Impairment on property and equipment; tax effected

    -       -       -       -  

Acquisition related intangible asset amortization; tax effected

    1,394       1,146       3,960       3,898  

Acquisition related inventory step up, tax effected

    -       935       -       4,626  

Change in fair value of contingent consideration, tax effected

    -       (1,865 )     -       (17,152 )

Adjusted net (loss) income

  $ (725

)

  $ 774     $ (4,044

)

  $ 2,889  

 

The following is a reconciliation of adjusted EPS to diluted earnings (loss) per share for the three- and nine-month periods ended September 30, 2022 and 2021:

 

   

For the Three Months Ended

September 30,

   

For the Nine Months Ended

September 30,

 
   

2022

   

2021

   

2022

   

2021

 

Diluted (loss) earnings per share (EPS)

  $ (0.29

)

  $ 0.04     $ (0.68

)

  $ 0.68  

Product rationalization, tax effected

    0.14       -       0.13       0.11  

Impairment on Property and Equipment

    -       -       -          

Acquisition related intangible asset amortization; tax effected

    0.10       0.08       0.27       0.27  

Acquisition related inventory step up, tax effected

    -       0.06       -       0.32  

Change in fair value of contingent consideration, tax effected

    -       (0.13

)

    -       (1.18

)

Adjusted diluted (loss) earnings per share (EPS)

  $ (0.05

)

  $ 0.05     $ (0.28

)

  $ 0.20  

 

Adjusted net (loss) income and adjusted diluted (loss) income per share in the three-month period ended September 30, 2022 decreased by $1.5 million or $0.10, respectively, as compared with the same period in 2021. The decrease for the period was primarily due to increased commercial spending to support future growth as certain marketing and medical education activities were more limited in 2021.

 

Adjusted net (loss) income in and adjusted diluted (loss) income per share the nine-month period ended September 30, 2022, decreased $6.9 million or $0.48, as compared with the same period in 2021. The decrease in adjusted net income for the period was primarily due to lower adjusted gross profit, from higher manufacturing costs and production inefficiencies caused in part by supply chain and staffing challenges due largely to the impact of the COVID-19 pandemic, as well as an increase in selling and marketing expenses primarily attributable to increased cost to support our commercial capability in the United States and an increase in stock-based compensation expense driven by incremental headcount associated with the Company’s strategic transformation that accelerated in 2020 and 2021.

 

Liquidity and Capital Resources

 

We require cash to fund our operating activities and to make capital expenditures and other investments in the business. We expect that our requirements for cash to fund these uses will increase as our operations expand. We continue to generate cash from operating activities and believe that our operating cash flows, cash currently on our condensed consolidated balance sheet and availability under our credit facility will be sufficient to allow us to continue to invest in our existing business, to manage our capital structure on a short and long-term basis, and to meet our anticipated operating cash needs. Cash, cash equivalents, and investments aggregated $87.8 million and $94.4 million, and working capital totaled $141.4 million and $138.7 million, at September 30, 2022 and December 31, 2021, respectively. We are closely monitoring our liquidity and capital resources for any potential impact that the COVID-19 pandemic may have on our operations.

 

28

 

 

On November 12, 2021, we entered into a Third Amendment to Credit Agreement with Bank of America N.A. as administrative agent, which amended our existing revolving line of credit agreement dated October 24, 2017 which provides up to $75.0 million in the form of a senior revolving line of credit. Subject to certain conditions, we may request up to an additional $75.0 million for a maximum aggregate commitment of $150.0 million. As of September 30, 2022, and December 31, 2021, there were no outstanding borrowings, and we are in compliance with the terms of the credit facility.

 

   

Nine Months Ended

September 30,

 
   

2022

   

2021

 

Cash provided by (used in)

               

Operating activities

  $ 3,928     $ 3,925  

Investing activities

    (4,957

)

    (1,878

)

Financing activities

    (5,519

)

    (6,839 )

Effect of exchange rate changes on cash

    (61

)

    (49

)

Net decrease in cash and cash equivalents

  $ (6,609

)

  $ (4,841 )

 

The following changes contributed to the net change in cash and cash equivalents in the nine-month period ended September 30, 2022 as compared to the same period in 2021.

 

Operating Activities

 

Cash provided by operating activities was $3.9 million for nine-month period ended September 30, 2022 was consistent with the same period in 2021, as the higher net loss was in part a result of higher non-cash stock compensation expense, and was offset by an improvement in working capital attributable to timing of collections and inventory purchases.

 

For the foreseeable future, we expect to continue to invest in research and development for new products and clinical studies as well as continued investment in our commercial infrastructure to support our growth strategy. These costs will be funded with a combination of cash on hand and cash expected to be generated from future operations. 

 

Investing Activities

 

Cash used in investing activities was $5.0 million for the nine-month period ended September 30, 2022, as compared to cash used in investing activities of $1.9 million for the same period in 2021. The change was primarily due to an increase in capital expenditures to support commercial growth of the business in the nine-month period ended September 30, 2022 and proceeds from maturities of investments that occurred in 2021.

 

Financing Activities

 

Cash used in financing activities was $5.5 million for the nine-month period ended September 30, 2022, as compared to cash used in financing activities of $6.8 million for the same period in 2021. The change was primarily attributable to lower contingent consideration payments in 2022 and lower stock option exercises in 2022.

 

29

 

 

Critical Accounting Policies and Estimates

 

The preparation of our consolidated financial statements in conformity with US GAAP requires management to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. We believe that our accounting policies for revenue recognition, accounts receivable and allowance for credit losses, goodwill, acquired in-process research and development, inventory and contingencies are based on, among other things, judgments and assumptions made by management that include inherent risks and uncertainties. There have been no significant changes to the above critical accounting policies or in the underlying accounting assumptions and estimates used in such policies from those disclosed in our annual consolidated financial statements and accompanying notes included in our 2021 Form 10-K for the year ended December 31, 2021 We monitor our estimates on an ongoing basis for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded in the period in which they become known. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates, if past experience or other assumptions do not turn out to be substantially accurate.

 

Recent Accounting Pronouncements

 

A discussion of Recent Accounting Pronouncements is included in our 2021 Form 10-K for the fiscal year ended December 31, 2021.

 

Contractual Obligations and Other Commercial Commitments

 

Our contractual obligations and other commercial commitments are summarized in the section captioned “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Contractual Obligations and Other Commercial Commitments” in our 2021 Form 10-K for the year ended December 31, 2021. There were no material changes to our contractual obligations reported in our 2021 Form 10-K during the nine months ended September 30, 2022 other than changes in operating leases reported in Note 8. For additional discussion, see Note 10 to the condensed consolidated financial statements included in this report.

 

To the extent that funds generated from our operations, together with our existing capital resources, are insufficient to meet future requirements, we will be required to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and others, or through other sources. No assurance can be given that any additional financing will be made available to us or will be available on acceptable terms should such a need arise.

 

Off-Balance Sheet Arrangements

 

We do not use special purpose entities or other off-balance sheet financing techniques that we believe have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, or capital resources.

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Our market risks and the ways we manage them are summarized in the section captioned “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in the first nine months of 2022 to our market risks or to our management of such risks.

 

ITEM 4.

CONTROLS AND PROCEDURES

 

 

(a)

Evaluation of disclosure controls and procedures.

 

As required by Rule 13a-15 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, we carried out an evaluation under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. On an on-going basis, we review and document our disclosure controls and procedures, and our internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.

 

 

(b)

Changes in internal controls over financial reporting.

 

There were no material changes in our internal control over financial reporting during the quarter ended September 30, 2022, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

 

30

 

 

PART II:

OTHER INFORMATION

 

ITEM 1.

LEGAL PROCEEDINGS

 

We are involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, we do not expect the resolution of these occasional legal proceedings to have a material adverse effect on our financial position, results of operations, or cash flow. There have been no material changes to the information provided in the section captioned “Part I, Item 3. Legal Proceedings” in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

ITEM 1A.

RISK FACTORS

 

Except as set forth below, there have been no material changes to the risk factors described in the section captioned “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended and supplemented by the information in “Part II, Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 and June 30, 2022. In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section captioned “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and in “Part II, Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, which could materially affect our business, financial condition, or future results. The risks described in our Annual Report on Form 10-K and such subsequently filed Quarterly Report on Form 10-Q, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may have a material adverse effect on our business, financial condition, and/or operating results.

 

Inflation could adversely affect our business, financial condition or results of operations.

 

Inflation has the potential to adversely affect our business, financial condition and results of operations by increasing our overall costs and increasing the risk that patients will curtail normal levels of elective orthopedic procedures due to pressure on the overall global economy. The existence of inflation in the economy has resulted in, and may continue to result in, higher shipping costs, supply shortages, increased costs of labor and other similar effects. As a result of inflation, we have experienced and may continue to experience, cost increases. Although we may take measures to mitigate the impact of inflation, if these measures are not effective our business, financial condition and results of operations could be adversely affected.

 

We rely on a small number of suppliers for certain key raw materials and a small number of suppliers for a number of other materials required for the manufacturing and delivery of our products, and disruption could materially adversely affect our business, financial condition, and results of operations.

 

Although we believe that alternative sources for many of these and other components and raw materials that we use in our manufacturing processes are available, we cannot be certain that the supply of key raw and other materials will continue to be available at current levels or will be sufficient to meet our future needs. The COVID-19 pandemic has impacted, and is expected to continue to impact, our supply chain as the companies that produce our products, product components or otherwise support our manufacturing processes, the distribution centers where we manage our inventory, or the operations of our logistics and other service providers, including third parties that sterilize and store our products, are, or may be, disrupted, temporarily closed or experience worker shortages for a sustained period of time. For example, for the manufacture of bone preserving joint technologies, we engage a single third-party organization as a contract manufacturer. Any supply interruption could harm our ability to manufacture our products until a new source of supply is identified and qualified. We may not be able to find sufficient alternative suppliers in a reasonable time-period, or on commercially reasonable terms, if at all, and our ability to produce and supply our products and our ability to generate revenue could be impaired.

 

Our global supply chain has been and is expected to continue to be materially adversely impacted due to the COVID-19 pandemic and faces new and ongoing challenges related to supply constraints.

 

We rely upon the facilities of our global suppliers to support our business. As a result of COVID-19 and the measures designed to contain its spread, certain of our suppliers have not had the materials, capacity, or capability to supply our needed materials and other supplies that we require to manufacture our products according to our schedule and specifications. It is uncertain to what extent these supply chain challenges will continue as the COVID-19 pandemic continues to evolve. In the past several months, variants of COVID-19 surged across the globe, causing further delays in the supply chain. Despite our attempts to mitigate the impact on our business, constrained supply conditions are expected to adversely impact the amount of revenue we realize. During the first nine months of 2022, we experienced disruptions in our supply chain and manufacturing capability that impacted our revenue for the period. If we are not able to mitigate the impact of these supply shortages, our ability to generate revenue will be significantly impacted. Further, logistics issues, including our ability and our supply chain’s ability to quickly ramp up production, and transportation demands may continue to cause delays. If our suppliers’ operations are curtailed, or if our suppliers are not able to deliver materials and supplies to us as scheduled, we may need to seek alternate sources of supply, which may be more expensive or require approval from regulatory agencies which could cause further delays. Alternative sources may not be available or may result in delays in shipments to us from our supply chain and subsequently to our customers, each of which would affect our results of operations. Even if alternative sources are identified, we may not be able to quickly establish additional or replacement sources for certain components or materials due, in part, to the FDA’s manufacturing requirements. If the duration of the production and supply chain disruptions continue for an extended period of time, the impact on our supply chain could have a material adverse effect on our results of operations and cash flows.

 

31

 

 

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Issuer Purchases of Equity Securities

 

On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program, which was completed in January 2020, and $20.0 million reserved for open market repurchases which represents the maximum value of shares that may yet be purchased. No open market repurchases were made during the nine-month period ended September 30, 2022.

 

ITEM 6.

EXHIBITS

 

Exhibit No.

   
     
3.1 Certificate of Incorporation of Anika Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 10-K (File No. 001-14027) filed by the Registrant on March 11, 2022)
     
3.2 Bylaws of Anika Therapeutics, Inc., effective as of June 6, 2018 (incorporated by reference to Exhibit 3.2 to the Current Report on Form 10-K (File No. 001-14027) filed by the Registrant on March 11, 2022)
     
†10.1 Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 8, 2022) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed (File No. 000-21326) by the Registrant on June 10, 2022)
   

(31)

Rule 13a-14(a)/15d-14(a) Certifications

     

*31.1

Certification of Dr. Cheryl R. Blanchard, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

*31.2

Certification of Michael Levitz, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

(32)

Section 1350 Certifications

     

**32.1

Certification of Dr. Cheryl R. Blanchard, and Michael Levitz, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     

(101)

XBRL

     

*101

The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 as filed with the SEC on November 9, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:

     
 

i.

Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021 (unaudited)

 

ii.

Consolidated Statements of Operations and Comprehensive Income for the Three and Nine Months Ended September 30, 2022 and September 30, 2021 (unaudited)

 

iii.

Consolidated Statements of Stockholders’ Equity for the Nine Months Ended September 30, 2022 and September 30, 20201(unaudited)

 

iv.

Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and September 30, 2021 (unaudited)

 

v.

Notes to Consolidated Financial Statements (unaudited)

   

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 

   

*

Filed herewith.

**

Furnished herewith.

Management contract or compensatory plan or arrangement.

 

 

32

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

ANIKA THERAPEUTICS, INC.

 
     

Date: November 9, 2022

By:

/s/ MICHAEL LEVITZ

 
   

Michael Levitz

 
   

Executive Vice President, Chief Financial Officer and Treasurer

   

(Authorized Officer and Principal Financial Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

33
EX-31.1 2 ex_440239.htm EXHIBIT 31.1

Exhibit 31.1

 

Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Cheryl Blanchard, certify that:

 

1. 

I have reviewed this report on Form 10-Q for the quarterly period ended September 30, 2022 of Anika Therapeutics, Inc.;

   

2. 

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

   

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

   

4. 

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d- 15(f)) for the registrant and have:

 

 

a. 

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

     
 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

     
 

c. 

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

     
 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a. 

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

     
 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 9, 2022

 

 

/s/ CHERYL BLANCHARD

 
 

Cheryl R. Blanchard, Ph.D.

 
 

President and Chief Executive Officer
(Principal Executive Officer)

 

 

 
EX-31.2 3 ex_440238.htm EXHIBIT 31.2

Exhibit 31.2

 

Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Michael Levitz, certify that:

 

1.

I have reviewed this report on Form 10-Q for the quarterly period ended September 30, 2022 of Anika Therapeutics, Inc.;

   

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

   

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

   

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d- 15(f)) for the registrant and have:

 

 

a. 

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

     
 

b. 

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

     
 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

     
 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a. 

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

     
 

b.  

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 9, 2022

 

 

/s/ MICHAEL LEVITZ

 
 

Michael Levitz

 
 

Executive Vice President, Chief Financial Officer and Treasurer

 
 

(Principal Financial Officer)

 

 

 
EX-32.1 4 ex_440237.htm EXHIBIT 32.1

Exhibit 32.1

 

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

The undersigned officers of Anika Therapeutics, Inc. (the “Company”) hereby certify to their knowledge and in their respective capacities that the Company’s quarterly report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 9, 2022

 

 

/s/ CHERYL BLANCHARD

 
 

Cheryl R. Blanchard, Ph.D.

 
 

President and Chief Executive Officer

 
 

(Principal Executive Officer)

 
     
 

/s/ MICHAEL LEVITZ

 
 

Michael Levitz

 
 

Executive Vice President, Chief Financial Officer and Treasurer

 
 

(Principal Financial Officer)

 

 

This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

 

 
EX-101.SCH 5 anik-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Business Combinations link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Inventories link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Goodwill link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Leases link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Revenue and Geographic Information link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Equity Incentive Plan link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Earnings Per Share ("EPS") link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 3 - Business Combinations (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 5 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 6 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 7 - Goodwill (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 11 - Revenue and Geographic Information (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 12 - Equity Incentive Plan (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 14 - Earnings Per Share ("EPS") (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 3 - Business Combinations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 5 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 6 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 6 - Intangible Assets - Summary of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 8 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 8 - Leases - Future Minimum Rental Payments for Leases (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 11 - Revenue and Geographic Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 11 - Revenue and Geographic Information - Revenues (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 12 - Equity Incentive Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 12 - Equity Incentive Plan - Stock Options (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 12 - Equity Incentive Plan - Performance Stock Units (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 13 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 14 - Earnings Per Share ("EPS") (Details Textual) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 anik-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 anik-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 anik-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Intangible assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Expected dividend yield Intangible assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Note To Financial Statement Details Textual Note 3 - Business Combinations Note 4 - Fair Value Measurements Note 5 - Inventories Risk free interest rate Note 6 - Intangible Assets Note 7 - Goodwill Note 8 - Leases Note 9 - Accrued Expenses and Other Liabilities Note 11 - Revenue and Geographic Information Prepaid expenses and other current assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Note 12 - Equity Incentive Plan Accounts receivable us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Income Tax Disclosure [Text Block] Note 14 - Earnings Per Share ("EPS") Note 3 - Business Combinations - Consideration Transferred (Details) Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) Cash and cash equivalents us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Contingent consideration Business Combination, Contingent Consideration, Liability, Current Note 3 - Business Combinations - Intangible Assets Acquired (Details) Inventories us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Expected volatility us-gaap_LiabilitiesCurrent Total current liabilities Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Note 4 - Fair Value Measurements - Contingent Consideration (Details) Note 5 - Inventories - Summary of Inventories (Details) Note 6 - Intangible Assets - Summary of Intangible Assets (Details) Expected life (years) (Year) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year) Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Note 8 - Leases - Future Minimum Rental Payments for Leases (Details) Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) Estimated total purchase consideration Business Combination, Consideration Transferred, Total Note 11 - Revenue and Geographic Information - Revenues (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 12 - Equity Incentive Plan - Stock Options (Details) Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Estimated fair value of contingent consideration Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) Note 12 - Equity Incentive Plan - Performance Stock Units (Details) Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Notes To Financial Statements Notes To Financial Statements [Abstract] Granted, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Foreign currency translation adjustment Vested, weighted average grant date fair value (in dollars per share) Proceeds from maturities of investments Forfeited and cancelled, weighted average grant date fair value (in dollars per share) Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding, weighted average grant date fair value (in dollars per share) Outstanding, weighted average grant date fair value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited and cancelled, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Outstanding, shares (in shares) Outstanding, shares (in shares) Granted (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, shares (in shares) Vested, shares (in shares) Vested and expected to vest, Weighted Average Remaining Contractual Term (Year) Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Vested and expected to vest, shares (in shares) Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) Other comprehensive income Vested and expected to vest, Aggregate Intrinsic Value Vested, Weighted Average Remaining Contractual Term (Year) Vested, Aggregate Intrinsic Value Exercised, Aggregate Intrinsic Value Outstanding, Weighted Average Remaining Contractual Term (Year) Outstanding, Aggregate Intrinsic Value Granted, Weighted Average Exercise Price (in dollars per share) Vested, Weighted Average Exercise Price (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding, Weighted Average Exercise Price (in dollars per share) Vested, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, Weighted Average Exercise (in dollars per share) Forfeited and canceled, Weighted Average Exercise Price (in dollars per share) Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Exercised, Weighted Average Exercise Price (in dollars per share) Compensation and related expenses us-gaap_EmployeeRelatedLiabilitiesCurrent Accounts payable Fair value per option Represents fair value per option related to share based compensation arrangement by share based payment award. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Outstanding, shares (in shares) Outstanding, shares (in shares) Provision (recovery) for doubtful accounts The amount of expense credit loss on accounts receivable, net of recoveries. Purchases of property and equipment included in accounts payable and accrued expenses Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Other us-gaap_OtherAccruedLiabilitiesCurrent us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Professional fees us-gaap_AccruedProfessionalFeesCurrent us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment OA Pain Management [member] Represents QA pain management. Non-Orthopedic [Member] Represents non-orthopedic. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Goodwill Disclosure [Text Block] Current liabilities: Developed Technology Rights [Member] us-gaap_Assets Total assets Supplemental disclosure of cash flow information: Patents [Member] Plan Name [Axis] Plan Name [Domain] In Process Research and Development [Member] us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Customer Relationships [Member] Distribution Rights [Member] Finite-Lived Intangible Assets by Major Class [Axis] Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Retirement of common stock for minimum tax withholdings Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Premium-Priced Employee Stock Options [Member] Information pertaining to premium priced employee stock options. Business Description and Basis of Presentation [Text Block] Award Type [Domain] Award Type [Axis] Net (loss) income Net (loss) income us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated Amortization anik_IncomeTaxExpenseBenefitChangeInFairValueOfContingentConsideration Income Tax Expense (Benefit), Change in Fair Value of Contingent Consideration Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to change in fair value of contingent consideration in continuing operations. Intangible assets, net Net book value Restricted Stock Units (RSUs) [Member] Performance Shares [Member] Performance factor adjustment (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that are related to performance factor adjustment during the reporting period. Share-Based Payment Arrangement, Option [Member] Performance factor adjustment (in dollars per share) The weighted average fair value at grant date related to performance factor adjustment. us-gaap_GoodwillForeignCurrencyTranslationGainLoss Effect of foreign currency adjustments Business Combination Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Property and equipment, net Goodwill Balance Balance anik_RevenuesFromAgreementsAsPercentOfTotalRevenue Revenues From Agreements as Percent of Total Revenue The percent of total revenue that revenue from agreements comprises. anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfTargetNumber Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number Represents percentage of target market for actual number of shares that may be earned for share-based compensation. Cash flows from investing activities: Earnings Per Share [Text Block] Income taxes Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block] Represents schedule of revenue and operating income, by geographical areas. Other Location [Member] Represents other location. Percentage of Revenue Represents the percentage of net revenue. Total Shareholder Return ("TSRs") Options [Member] Represents information related to total shareholder return ("TSRs") options. (Benefit from) provision for income taxes Income Tax Expense (Benefit), Total Accrued expenses, other current and long-term liabilities Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable The 2021 Inducement Plan [Member] Represents the 2021 Inducement Plan. Lessee, Operating Leases and Finance Leases [Text Block] The entire disclosure for operating leases and finance leases of lessee. Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of lessee's operating lease and finance lease liability. Cash and cash equivalents Stock-based compensation expense Stock-based compensation expense us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Change in fair value Amortization of acquisition related inventory step-up Amount of amortization expenses related to the acquisition inventory step-up. Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive (loss) income City Area Code anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice Share-based Compensation Arrangement by Share-based Payment Award, Premium Priced Options, Exercise Price as Percentage of Market Price The exercise price of premium priced options granted during the reporting period represented as percentage of market price. us-gaap_GainLossOnSaleOfPropertyPlantEquipment Loss on disposal of fixed assets Balance (in shares) Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Current Fiscal Year End Date Amortization of acquisition related intangible assets Amount of amortization expenses related to the acquisition related intangible assets. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses, other current and long-term assets us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent Cash equivalents anik_CashEquivalentsFairValueDisclosure Represents the fair value disclosure for cash equivalents as of the balance sheet date. Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Right-of-use assets obtained in exchange for operating lease liabilities us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Operating Lease, Weighted Average Remaining Lease Term (Year) Entity File Number Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Document Information [Line Items] anik_NumberOfSharesAvailableForGrantReducedByEachShareAwardIssuedOtherThanOptionsOrSARs Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs (in shares) Represents the number of shares by which shares available for grant is reduced for each share award issued after a specified date other than options or stock appreciation rights. Document Information [Table] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Payments Entity Filer Category Entity Current Reporting Status us-gaap_BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block] Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class. us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Tax Identification Number Entity Central Index Key Depreciation Entity Registrant Name Liability Class [Axis] Fair Value by Liability Class [Domain] Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] anik_AccumulatedCurrencyTranslationAdjustment Accumulated Currency Translation Adjustment Represents the amount of the accumulated currency translation adjustment. us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Common Stock, Shares Outstanding Clinical trial costs anik_AccruedClinicalTrialCostsCurrent Represents accrued clinical trial costs current. us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Nature of Operations [Text Block] Issuance of ESPP shares (in shares) Local Phone Number us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Exercised, shares (in shares) us-gaap_TableTextBlock Notes Tables Issuance of ESPP shares Vesting of restricted stock units (in shares) Vesting of restricted stock units Issuance of common stock for equity awards (in shares) Selling, general & administrative Issuance of common stock for equity awards Granted, shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited and canceled, shares (in shares) Raw materials us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Finished goods Work-in-process Reported Value Measurement [Member] UNITED STATES Retained earnings Research & development Accumulated other comprehensive loss Money Market Funds [Member] Changes in operating assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OtherNoncashIncomeExpense Other Inventory Disclosure [Text Block] Lease liabilities Total lease liabilities, operating leases Schedule of Inventory, Current [Table Text Block] Present value of lease payments, operating leases us-gaap_OperatingLeaseLiability Operating lease liability – current us-gaap_OperatingLeaseLiabilityCurrent Less current portion included in Accrued expenses and other current liabilities, operating leases Financing lease liability – current us-gaap_FinanceLeaseLiabilityCurrent Gross value Right-of-use assets us-gaap_FinanceLeasePrincipalPayments Payments made on finance leases us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Present value adjustment, operating leases Deferred income taxes us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2025, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2026, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2023, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2024, operating leases Other long-term assets us-gaap_ShareBasedCompensation Stock-based compensation expense us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear 2022 (Remainder of Year), operating leases Useful life (Year) Finite-Lived Intangible Asset, Useful Life (Year) Operating expenses: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Retirement of common stock for minimum tax withholdings (in shares) us-gaap_InventoryNoncurrent Other long-term assets us-gaap_AssetsCurrent Total current assets Change in fair value of contingent consideration anik_IncreaseDecreaseInContingentConsideration Contingent consideration Amount of increase (decrease) in the value of a contingent consideration liability. Interest and other income (expense), net Common stock, $0.01 par value; 90,000 shares authorized, 14,607 and 14,441 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively Adjustments to reconcile net income to net cash provided by operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively Preferred stock, shares issued (in shares) Geographical [Axis] Geographical [Domain] Preferred stock, shares authorized (in shares) Europe [Member] Inventories, net Inventories anik_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Thereafter, operating leases Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Portion at Fair Value Measurement [Member] [Default] Preferred stock, par value (in dollars per share) Estimate of Fair Value Measurement [Member] us-gaap_InventoryValuationReserves Inventory Valuation Reserves Measurement Basis [Axis] Fair Value, Inputs, Level 3 [Member] Revenue from External Customers by Products and Services [Table Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Cash flows from operating activities: Statement [Line Items] Accounts receivable, reserves Accounts receivable, less allowance for credit losses of $1,566 and $1,442 at September 30, 2022 and December 31, 2021, respectively Additional paid-in-capital AOCI Attributable to Parent [Member] Stockholders’ equity: Current assets: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Exchange rate impact on cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Decrease in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Commitments and contingencies (Note 10) us-gaap_OperatingIncomeLoss (Loss) income from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities us-gaap_GrossProfit Gross Profit Cost of revenue Deferred tax liability Provision for inventory anik_IncreaseDecreaseInLeaseLiabilities Operating lease liabilities The increase (decrease) during the reporting period in the lease liabilities. us-gaap_ContractWithCustomerLiability Contract with Customer, Liability, Total Accounting Standards Update 2016-02 [Member] us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Payment for Contingent Consideration Liability, Financing Activities Contingent consideration payout Accounting Standards Update [Domain] us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Cash paid for tax withheld on vested restricted stock awards Accounting Standards Update [Axis] us-gaap_ProductWarrantyAccrual Standard and Extended Product Warranty Accrual, Ending Balance Accrued Expenses and Other Current Liabilities [Member] Related to accrued expenses and other current liabilities. Liabilities [Member] Related to liabilities. us-gaap_CostsAndExpenses Total operating expenses Retained Earnings [Member] anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal Total The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of raw materials, work in process and finished goods. Proceeds from exercises of equity awards Revenue Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (Loss) income before income taxes Ministry of Economic Affairs and Finance, Italy [Member] Parcus Medical [Member] Related to Parcus Medical. The 2017 Plan [Member] Represents the Anika Therapeutics, Inc. Omnibus Incentive Plan (the “2017 Plan”). Income Tax Authority, Name [Axis] Right-of-use assets anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets Amount of operating lease, right of use assets acquired at the acquisition date. Income Tax Authority, Name [Domain] Income Tax Authority [Axis] Income Tax Authority [Domain] Arthrosurface [Member] Related to Arthrosurface. Foreign Tax Authority [Member] Revenue from Contract with Customer [Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Document Quarterly Report Entity Incorporation, State or Country Code Accounting Policies [Abstract] Document Transition Report Selling, General and Administrative Expenses [Member] Entity Interactive Data Current Security Exchange Name Title of 12(b) Security Cost of Sales [Member] Research and Development Expense [Member] Income Statement Location [Axis] Income Statement Location [Domain] Accrued expenses and other current liabilities Total Share-based payment awards (in shares) us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) Diluted shares used in the calculation of earnings per share (in shares) Joint Preservation and Restoration [Member] Represents Joint Preservation and Restoration. Asset Class [Axis] Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] us-gaap_EarningsPerShareDiluted Diluted (in dollars per share) Shares used in the calculation of basic earnings per share (in shares) Basic (in shares) Accounts Payable and Accrued Liabilities Disclosure [Text Block] us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent, Total Business Acquisition [Axis] us-gaap_EarningsPerShareBasic Basic (in dollars per share) Business Acquisition, Acquiree [Domain] Statement of Cash Flows [Abstract] us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Schedule of Accrued Liabilities [Table Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Deferred consideration Amount of deferred consideration by the acquirer as part of consideration transferred in a business combination. Cash flows from financing activities: Contingent Consideration [Member] Represents the information pertaining to the contingent consideration. anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseLiabilities Lease liabilities Amount of operating lease right-of-use liabilities assumed at the acquisition date. Other long-term liabilities anik_APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit Stock-based compensation expense Amount of increase (decrease) to additional paid-in capital (APIC) for recognition of cost (benefit) for award under share-based payment arrangement. Net assets acquired us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Estimated total purchase consideration us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Balance Total stockholders’ equity Balance Balance Non-cash operating lease cost us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther Other long-term liabilities us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Acquisition of Parcus Medical and Arthrosurface, net of cash acquired Class of Stock [Axis] us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Deferred tax liabilities Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cash consideration us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable Accounts payable, accrued expenses and other current liabilities Property and equipment, net us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Other long-term assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets EX-101.PRE 9 anik-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2022
Oct. 31, 2022
Document Information [Line Items]    
Entity Central Index Key 0000898437  
Entity Registrant Name Anika Therapeutics, Inc.  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2022  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-14027  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 04-3145961  
Entity Address, Address Line One 32 Wiggins Avenue  
Entity Address, City or Town Bedford  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 01730  
City Area Code 781  
Local Phone Number 457-9000  
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol ANIK  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   14,609,669
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 87,777 $ 94,386
Accounts receivable, less allowance for credit losses of $1,566 and $1,442 at September 30, 2022 and December 31, 2021, respectively 34,168 29,843
Inventories, net 37,237 36,010
Prepaid expenses and other current assets 8,579 8,289
Total current assets 167,761 168,528
Property and equipment, net 47,390 47,602
Right-of-use assets 30,987 20,957
Other long-term assets 18,342 20,285
Intangible assets, net 76,545 82,382
Goodwill 6,721 7,781
Total assets 347,746 347,535
Current liabilities:    
Accounts payable 8,353 7,633
Accrued expenses and other current liabilities 17,999 17,847
Contingent consideration 0 4,315
Total current liabilities 26,352 29,795
Other long-term liabilities 474 1,258
Deferred tax liability 6,800 10,157
Lease liabilities 29,183 19,240
Commitments and contingencies (Note 10)
Stockholders’ equity:    
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively 0 0
Common stock, $0.01 par value; 90,000 shares authorized, 14,607 and 14,441 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively 146 144
Additional paid-in-capital 76,661 67,081
Accumulated other comprehensive loss (7,497) (5,718)
Retained earnings 215,627 225,578
Total stockholders’ equity 284,937 287,085
Total liabilities and stockholders’ equity $ 347,746 $ 347,535
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
shares in Thousands, $ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Accounts receivable, reserves $ 1,566 $ 1,442
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,250 1,250
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 90,000 90,000
Common stock, shares issued (in shares) 14,607 14,441
Common stock, shares outstanding (in shares) 14,607 14,441
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue $ 40,264 $ 39,536 $ 116,614 $ 111,973
Cost of revenue 17,485 16,513 47,169 47,164
Gross Profit 22,779 23,023 69,445 64,809
Operating expenses:        
Research & development 7,301 7,673 20,433 21,327
Selling, general & administrative 21,276 17,500 61,745 53,664
Change in fair value of contingent consideration 0 (3,450) 0 (21,920)
Total operating expenses 28,577 21,723 82,178 53,071
(Loss) income from operations (5,798) 1,300 (12,733) 11,738
Interest and other income (expense), net 436 (48) 378 (141)
(Loss) income before income taxes (5,362) 1,252 (12,355) 11,597
(Benefit from) provision for income taxes (1,187) 694 (2,404) 1,670
Net (loss) income $ (4,175) $ 558 $ (9,951) $ 9,927
Basic (in dollars per share) $ (0.29) $ 0.04 $ (0.68) $ 0.69
Diluted (in dollars per share) $ (0.29) $ 0.04 $ (0.68) $ 0.68
Basic (in shares) 14,603 14,429 14,542 14,389
Diluted (in shares) 14,603 14,647 14,542 14,588
Net (loss) income $ (4,175) $ 558 $ (9,951) $ 9,927
Foreign currency translation adjustment (851) 199 (1,779) (777)
Comprehensive (loss) income $ (5,026) $ 757 $ (11,730) $ 9,150
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Restricted Stock Units (RSUs) [Member]
Common Stock [Member]
Restricted Stock Units (RSUs) [Member]
Additional Paid-in Capital [Member]
Restricted Stock Units (RSUs) [Member]
Retained Earnings [Member]
Restricted Stock Units (RSUs) [Member]
AOCI Attributable to Parent [Member]
Restricted Stock Units (RSUs) [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance (in shares)           14,329        
Balance           $ 143 $ 55,355 $ 221,444 $ (4,542) $ 272,400
Balance (in shares) at Dec. 31, 2020           14,329        
Balance at Dec. 31, 2020           $ 143 55,355 221,444 (4,542) 272,400
Issuance of common stock for equity awards           0 1 0 0 1
Vesting of restricted stock units (in shares) 46                  
Vesting of restricted stock units $ 1 $ (1) $ 0 $ 0 $ 0          
Stock-based compensation expense           $ 0 2,259 0 0 2,259
Retirement of common stock for minimum tax withholdings (in shares)           (9)        
Retirement of common stock for minimum tax withholdings           $ 0 (333) 0 0 (333)
Net (loss) income           0 0 2,838 0 2,838
Other comprehensive income           $ 0 0 0 (509) (509)
Balance (in shares) at Mar. 31, 2021           14,366        
Balance at Mar. 31, 2021           $ 144 57,281 224,282 (5,051) 276,656
Balance (in shares) at Dec. 31, 2020           14,329        
Balance at Dec. 31, 2020           $ 143 55,355 221,444 (4,542) 272,400
Net (loss) income                   9,927
Balance (in shares) at Sep. 30, 2021           14,436        
Balance at Sep. 30, 2021           $ 144 63,864 231,371 (5,319) 290,060
Balance (in shares)           14,366        
Balance           $ 144 57,281 224,282 (5,051) 276,656
Balance (in shares) at Mar. 31, 2021           14,366        
Balance at Mar. 31, 2021           $ 144 57,281 224,282 (5,051) 276,656
Issuance of common stock for equity awards (in shares)           18        
Issuance of common stock for equity awards           $ 0 640 0 0 640
Vesting of restricted stock units (in shares)           35        
Vesting of restricted stock units           $ 0 0 0 0 0
Stock-based compensation expense           $ 0 2,797 0 0 2,797
Retirement of common stock for minimum tax withholdings (in shares)           (1)        
Retirement of common stock for minimum tax withholdings           $ 0 (19) 0 0 (19)
Net (loss) income           0 0 6,531 0 6,531
Other comprehensive income           $ 0 0 0 199 199
Balance (in shares) at Jun. 30, 2021           14,418        
Balance at Jun. 30, 2021           $ 144 60,699 230,813 (4,852) 286,804
Balance (in shares)           14,418        
Balance           $ 144 60,699 230,813 (4,852) 286,804
Issuance of common stock for equity awards (in shares)           10        
Issuance of common stock for equity awards           $ 0 373 0 0 373
Vesting of restricted stock units (in shares)           9        
Vesting of restricted stock units           $ 0 0 0 0 0
Stock-based compensation expense           $ 0 2,863 0 0 2,863
Retirement of common stock for minimum tax withholdings (in shares)           (1)        
Retirement of common stock for minimum tax withholdings           $ 0 (71) 0 0 (71)
Net (loss) income           0 0 558 0 558
Other comprehensive income           $ 0 0 0 (467) (467)
Balance (in shares) at Sep. 30, 2021           14,436        
Balance at Sep. 30, 2021           $ 144 63,864 231,371 (5,319) 290,060
Balance (in shares)           14,436        
Balance           $ 144 63,864 231,371 (5,319) 290,060
Balance (in shares)           14,441        
Balance           $ 144 67,081 225,578 (5,718) 287,085
Balance (in shares) at Dec. 31, 2021           14,441        
Balance at Dec. 31, 2021           $ 144 67,081 225,578 (5,718) 287,085
Issuance of common stock for equity awards (in shares)           1        
Issuance of common stock for equity awards           $ 0 15     15
Vesting of restricted stock units (in shares) 106                  
Vesting of restricted stock units $ 1 $ (1)                
Stock-based compensation expense             2,545     2,545
Retirement of common stock for minimum tax withholdings (in shares)           (30)        
Retirement of common stock for minimum tax withholdings           $ 0 (844)     (844)
Net (loss) income               (2,933)   (2,933)
Other comprehensive income                 (81) (81)
Balance (in shares) at Mar. 31, 2022           14,518        
Balance at Mar. 31, 2022           $ 145 68,796 222,645 (5,799) 285,787
Balance (in shares) at Dec. 31, 2021           14,441        
Balance at Dec. 31, 2021           $ 144 67,081 225,578 (5,718) 287,085
Net (loss) income                   (9,951)
Balance (in shares) at Sep. 30, 2022           14,607        
Balance at Sep. 30, 2022           $ 146 76,661 215,627 (7,497) 284,937
Balance (in shares)           14,518        
Balance           $ 145 68,796 222,645 (5,799) 285,787
Balance (in shares) at Mar. 31, 2022           14,518        
Balance at Mar. 31, 2022           $ 145 68,796 222,645 (5,799) 285,787
Vesting of restricted stock units (in shares)           61        
Vesting of restricted stock units           $ 1 (1)     0
Stock-based compensation expense             4,081     4,081
Retirement of common stock for minimum tax withholdings (in shares)           (1)        
Retirement of common stock for minimum tax withholdings           $ 0 (25)     (25)
Net (loss) income               (2,843)   (2,843)
Other comprehensive income                 (847) (847)
Issuance of ESPP shares (in shares)           20        
Issuance of ESPP shares           $ 0 0     0
Balance (in shares) at Jun. 30, 2022           14,598        
Balance at Jun. 30, 2022           $ 146 72,851 219,802 (6,646) 286,153
Balance (in shares)           14,598        
Balance           $ 146 72,851 219,802 (6,646) 286,153
Vesting of restricted stock units (in shares)           11        
Vesting of restricted stock units           $ 0 0     0
Stock-based compensation expense             3,876     3,876
Retirement of common stock for minimum tax withholdings (in shares)           (2)        
Retirement of common stock for minimum tax withholdings           $ 0 (66)     (66)
Net (loss) income               (4,175)   (4,175)
Other comprehensive income                 (851) (851)
Issuance of ESPP shares           $ 0 0     0
Balance (in shares) at Sep. 30, 2022           14,607        
Balance at Sep. 30, 2022           $ 146 76,661 215,627 (7,497) 284,937
Balance (in shares)           14,607        
Balance           $ 146 $ 76,661 $ 215,627 $ (7,497) $ 284,937
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net (loss) income $ (9,951) $ 9,927
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 4,984 4,702
Amortization of acquisition related intangible assets 5,837 5,885
Amortization of acquisition related inventory step-up 0 6,244
Non-cash operating lease cost 1,322 1,312
Change in fair value of contingent consideration 0 (21,920)
Loss on disposal of fixed assets 0 831
Stock-based compensation expense 10,502 7,919
Deferred income taxes (3,491) 1,018
Provision (recovery) for doubtful accounts 379 (60)
Provision for inventory 3,701 3,702
Other (13)
Changes in operating assets and liabilities:    
Accounts receivable (4,983) (8,321)
Inventories (3,933) (7,117)
Prepaid expenses, other current and long-term assets (456) 1,864
Accounts payable 533 (702)
Operating lease liabilities (1,054) (1,247)
Accrued expenses, other current and long-term liabilities 115 3,104
Contingent consideration 0 (2,780)
Income taxes 423 (423)
Net cash provided by operating activities 3,928 3,925
Cash flows from investing activities:    
Acquisition of Parcus Medical and Arthrosurface, net of cash acquired 0 (363)
Proceeds from maturities of investments 0 2,501
Purchases of property and equipment (4,957) (4,016)
Net cash used in investing activities (4,957) (1,878)
Cash flows from financing activities:    
Payments made on finance leases (284) (210)
Cash paid for tax withheld on vested restricted stock awards (935) (423)
Proceeds from exercises of equity awards 15 1,014
Contingent consideration payout (4,315) (7,220)
Net cash used in financing activities (5,519) (6,839)
Exchange rate impact on cash (61) (49)
Decrease in cash and cash equivalents (6,609) (4,841)
Cash and cash equivalents at beginning of period 94,386 95,817
Cash and cash equivalents at end of period 87,777 90,976
Supplemental disclosure of cash flow information:    
Purchases of property and equipment included in accounts payable and accrued expenses 108 220
Accounting Standards Update 2016-02 [Member]    
Supplemental disclosure of cash flow information:    
Right-of-use assets obtained in exchange for operating lease liabilities $ 11,589 $ 195
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 1 - Nature of Business
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Nature of Operations [Text Block]

1.

Nature of Business

 

Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.

 

In early 2020, the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation solutions provider focused on sports medicine and soft tissue repair, and Arthrosurface, Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company’s product portfolio, developed over its 30 years of expertise in hyaluronic acid technology, into the broader joint preservation and restoration market with greater market potential, added high-growth revenue streams, increased the Company’s commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.

 

The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

 

There continue to be uncertainties regarding the pandemic of the ongoing coronavirus (“COVID-19”), and the Company is closely monitoring the impact of COVID-19 on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, business partners and a broader impact on elective surgeries. The Company is unable to predict the specific impact that COVID-19 may have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein may change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-19.

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 2 - Basis of Presentation
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]

2.

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been or omitted pursuant to SEC rules and regulations relating to interim financial statements. The December 31, 2021 balances reported herein were derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.

 

The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2021. The results of operations for the three-month and nine-month periods ended September 30, 2022, are not indicative of the results to be expected for the year ending December 31, 2022

 

Segment Information

 

Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer as of September 30, 2022. Based on the criteria established by Accounting Standards Codification 280, Segment Reporting, the Company has one operating and reportable segment.

 

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 3 - Business Combinations
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

3.

Business Combinations

 

Parcus Medical, LLC

 

On January 24, 2020, the Company completed the acquisition of Parcus Medical pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Parcus Medical Merger Agreement”). Parcus Medical is a sports medicine implant and instrumentation solutions provider focused on surgical repair and reconstruction of soft tissue.

 

Consideration Transferred

 

Pursuant to the Parcus Medical Merger Agreement, the Company acquired all outstanding equity of Parcus Medical for estimated total purchase consideration of $75.1 million, as of January 24, 2020, which consisted of:

 

Cash consideration

 $32,794 

Deferred consideration

  1,642 

Estimated fair value of contingent consideration

  40,700 

Estimated total purchase consideration

 $75,136 

 

Pursuant to the Parcus Medical Merger Agreement, contingent consideration represents additional payments that the Company may be required to make in the future which could total up to $60.0 million depending on the level of net sales of Parcus Medical products generated in 2020 through 2022.

 

The fair value of contingent consideration related to net sales as of January 24, 2020, and at each reporting date, was determined based on a Monte Carlo simulation model in an option pricing framework, whereby a range of possible scenarios were simulated. The liability for contingent consideration was included in current liabilities on the condensed consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. During the three months ended September 30, 2022, the Company paid the contingent consideration related to net sales in the amount of $4.3 million which was included in current liabilities as of December 31, 2021. The Company does not expect any further milestones to be achieved.

 

Acquisition-related costs were not included as a component of consideration transferred but were expensed in the periods in which the costs are incurred. The Company incurred approximately $1.9 million in transaction costs related to the Parcus Medical acquisition during the three-month period ending March 31, 2020. The transaction costs subsequent to March 31, 2020 were immaterial.

 

Fair Value of Net Assets Acquired

 

The estimate of fair value as of the acquisition date required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable, however, actual results may differ from these estimates.

 

The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of January 24, 2020, and was as follows:

 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $196 

Accounts receivable

  2,029 

Inventories

  10,968 

Prepaid expenses and other current assets

  364 

Property and equipment, net

  1,099 

Right-of-use assets

  944 

Intangible assets

  44,000 

Accounts payable, accrued expenses and other current liabilities

  (2,763

)

Other long-term liabilities

  (594

)

Lease liabilities

  (735

)

Net assets acquired

  55,508 

Goodwill

  19,628 

Estimated total purchase consideration

 $75,136 

 

The acquired intangible assets based on estimates of fair value as of January 24, 2020 were as follows:

 

Developed technology

 $41,100 

Trade name

  1,800 

Customer relationships

  1,100 

Total acquired intangible assets

 $44,000 

 

The fair value of developed technology will be amortized over a useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of the trade name over 5 years.

 

The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill was impaired in 2020 and there was no remaining goodwill as of December 31, 2020.

 

Arthrosurface, Inc.

 

On February 3, 2020, the Company completed the acquisition of Arthrosurface pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Arthrosurface Merger Agreement”). Arthrosurface is a joint preservation technology company specializing in less invasive, bone-preserving partial and total joint replacement solutions.

 

Consideration Transferred

 

Pursuant to the Arthrosurface Merger Agreement, the Company acquired all outstanding equity of Arthrosurface for estimated total purchase consideration of $90.3 million, as of February 3, 2020 which consisted of:

 

Cash consideration

 $61,909 

Estimated fair value of contingent consideration

  28,376 

Estimated total purchase consideration

 $90,285 

 

Pursuant to the Arthrosurface Merger Agreement, the Company could be required to make future payments of up to $40.0 million depending on the achievement of regulatory milestones and the level of net sales of Arthrosurface products from 2020 through 2021. The fair value of contingent consideration related to regulatory milestones as of February 3, 2020 was determined through a scenario-based discounted cash flow analysis using scenario probabilities and regulatory milestone dates. The fair value of contingent consideration related to net sales achievement as of February 3, 2020 was determined based upon a Monte Carlo simulation approach at acquisition date, whereby a range of possible scenarios were simulated. The Company paid $5.0 million in October 2020 and $10.0 million in July 2021 based upon the achievement of two distinct regulatory milestones. As of September 30, 2022, there were no milestones remaining.

 

Acquisition-related costs were not included as a component of consideration transferred but were expensed in the periods in which the costs are incurred. The Company incurred approximately $2.2 million in transaction costs related to the Arthrosurface acquisition during the three-month period ending March 31, 2020. The transaction costs subsequent to March 31, 2020 were immaterial.

 

Fair Value of Net Assets Acquired

 

The estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates.

 

The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of February 3, 2020, as follows:

 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $1,072 

Accounts receivable

  5,368 

Inventories

  15,652 

Prepaid expenses and other current assets

  535 

Property, plant and equipment

  3,394 

Other long-term assets

  7,548 

Intangible assets

  48,900 

Accounts payable, accrued expenses and other liabilities

  (3,929

)

Deferred tax liabilities

  (11,147

)

Net assets acquired

  67,393 

Goodwill

  22,892 

Estimated total purchase consideration

 $90,285 

Intangible assets acquired consist of:

    

Developed technology

 $37,000 

Trade name

  3,400 

Customer relationships

  7,900 

IPR&D

  600 

Total acquired intangible assets

 $48,900 

 

The fair value of developed technology will be amortized over an estimated useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of trade names over 5 years. A total of $0.6 million represents the fair value of IPR&D with an indefinite useful life which was impaired during the quarter ended December 31, 2021.

 

The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill was impaired in 2020 and there was no remaining goodwill as of December 31, 2020.

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 4 - Fair Value Measurements
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

4.

Fair Value Measurements

 

The Company has certain cash equivalents in money market funds that are classified within Level 1 of the fair value hierarchy and are valued based on quoted prices in active markets. For cash, accounts receivables, accounts payable, and accrued interest, the carrying amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is not included in the table below. Contingent consideration related to the previously described business combinations are classified within Level 3 of the fair value hierarchy as the determination of fair value uses considerable judgement and represents the Company’s best estimate of an amount that could be realized in a market exchange for the asset or liability. There were no transfers between fair value levels during the nine-month periods ended September 30, 2022 or 2021. See Note 3, Business Combinations for additional discussion of contingent consideration as of September 30, 2022.

 

      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical

Assets

  

Observable

Inputs

  

Unobservable

Inputs

     
  

September 30, 2022

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,348  $67,348  $-  $-  $67,348 
                     

Other current liabilities:

                    

Contingent Consideration - Short Term

 $-  $-  $-  $-  $- 

 

      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical

Assets

  

Observable

Inputs

  

Unobservable

Inputs

     
  

December 31, 2021

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,046  $67,046  $-  $-  $67,046 
                     

Other current liabilities:

                    

Contingent Consideration - Short Term

 $4,315  $-  $-  $4,315  $- 

 

Contingent Consideration

 

The following table provides a rollforward of the contingent consideration related to business acquisitions discussed in Note 3, Business Combinations

 

  

Nine Months Ended

  

Nine Months Ended

 
  

September 30, 2022

  

September 30, 2021

 

Balance, beginning

 $4,315  $35,410 

Payments

  (4,315)  (10,000)

Change in fair value

  -   (21,920)

Balance, ending

 $-  $3,490 

 

 

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 5 - Inventories
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Inventory Disclosure [Text Block]

5.

Inventories

 

Inventories consist of the following:

 

  

September 30,

  

December 31,

 
  

2022

  

2021

 

Raw materials

 $19,015  $16,881 

Work-in-process

  11,650   11,442 

Finished goods

  24,277   26,731 

Total

 $54,941  $55,054 
         

Inventories

 $37,237  $36,010 

Other long-term assets

  17,704   19,044 

Total

 $54,941  $55,054 

 

Inventories are stated net of inventory reserves of $10.0 million and $9.1 million as of September 30, 2022 and December 31, 2021, respectively.

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 6 - Intangible Assets
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

6.

Intangible Assets

 

      

Nine Months Ended

September 30, 2022

  

December 31,

2021

     
  

Gross
Value

  

Less: Accumulated
Currency Translation
Adjustment

  

Less:
Accumulated
Amortization

  

Net Book
Value

  

Net Book
Value

  

Weighted
Average Useful
Life

 

Developed technology

 $89,580  $(1,607

)

 $(22,238

)

 $65,735  $70,081   15 

IPR&D

  2,656   (1,006

)

  -   1,650   1,650  

Indefinite

 

Customer relationships

  9,000   -   (2,402

)

  6,598   7,273   10 

Distributor relationships

  4,700   (415

)

  (4,285

)

  -   -   5 

Patents

  1,000   (189

)

  (668

)

  143   179   16 

Tradenames

  5,200   -   (2,781

)

  2,419   3,199   5 

Total

 $112,136  $(3,217

)

 $(32,374

)

 $76,545  $82,382   13 

 

The aggregate amortization expense related to intangible assets was $1.9 million and $2.0 million for the three-month periods ended September 30, 2022 and 2021, respectively, and $5.8 million and $5.9 million for each of the nine-month periods ended September 30, 2022 and 2021.

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 7 - Goodwill
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Goodwill Disclosure [Text Block]

7.

Goodwill

 

The Company assesses goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there may be impairment.

 

Changes in the carrying value of goodwill for the nine months ended September 30, 2022 were as follows:

 

  

Nine Months Ended September 30, 2022

 

Balance, beginning

 $7,781 

Effect of foreign currency adjustments

  (1,060

)

Balance, ending

 $6,721 

 

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 8 - Leases
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Lessee, Operating Leases and Finance Leases [Text Block]

8.

Leases

 

The Company leases its buildings and manufacturing facilities under operating leases. As of September 30, 2022, the Company had real estate leases in Bedford, Massachusetts, Franklin, Massachusetts, Sarasota, Florida, Warsaw, Indiana and Padova, Italy.

 

In June 2022, the Company finalized renewal options to extend the current term of its leases for its building and manufacturing facility in Bedford as well as its two facilities in Sarasota. With the extension of these renewal options, the Bedford lease term extends to 2027 with several lease renewal options into 2038 and the two leases in Sarasota extend to 2027 but may be extended by mutual agreement. The Sarasota leases also include a right to terminate in 2025 at the Company’s option. The current term of the Franklin lease extends to 2023 and the current term of the Padova lease extends to 2032, with a right to terminate at the Company’s option without penalty.

 

The following table summarizes the Company’s significant commitments under lease agreements as of September 30, 2022:

 

  

Operating Leases

 
     

2022 (Remainder of Year)

 $720 

2023

  3,081 

2024

  3,025 

2025

  3,066 

2026

  2,760 

Thereafter

  27,873 

Present value adjustment

  (9,421

)

Present value of lease payments

  31,105 

Less current portion included in accrued expenses and other current liabilities

  (1,922

)

Total lease liabilities

 $29,183 

 

During the three and nine months ended September 30, 2022, the Company incurred lease expense of $0.8 million and $2.1 million, respectively. During the three and nine months ended September 30, 2021, the Company incurred lease expense of $0.6 million and $1.9 million, respectively. As of September 30, 2022, the weighted average remaining operating lease term was 15.0 years and the weighted average incremental borrowing rate used to determine the operating lease liability was 3.6%.

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 9 - Accrued Expenses and Other Liabilities
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

9.

Accrued Expenses and Other Liabilities

 

Accrued expenses and other liabilities consist of the following:

 

  

September 30, 2022

  

December 31, 2021

 
         

Compensation and related expenses

 $11,166  $9,523 

Professional fees

  3,063   3,590 

Operating lease liability – current

  1,922   1,526 

Clinical trial costs

  1,352   1,961 

Financing lease liability – current

  -   188 

Other

  496   1,059 

Total

 $17,999  $17,847 

 

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 10 - Commitments and Contingencies
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

10.

Commitments and Contingencies

 

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties as of September 30, 2022 or December 31, 2021 and has no history of claims paid.

 

The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.

 

On October 21, 2021, the Company received notice that the former unitholders of Parcus Medical had filed a request for arbitration regarding the earnout provisions agreed to in the Parcus Medical Merger Agreement. The Company has engaged in the arbitration process and does not anticipate a resolution during 2022. The Company is unable to estimate the potential liability with respect to this matter at this time. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at this stage of the matter, including the significant number of legal and factual issues still to be resolved in the arbitration process. The Company intends to vigorously defend against the claims and believes it has strong defenses to the claims asserted.

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 11 - Revenue and Geographic Information
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

11.

Revenue and Geographic Information

 

Revenue by product family was as follows: 

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 
                 

OA Pain Management

 $25,665  $26,153  $74,139  $69,790 

Joint Preservation and Restoration

  11,821   11,193   36,055   35,296 

Non-Orthopedics

  2,778   2,190   6,420   6,887 
  $40,264  $39,536  $116,614  $111,973 

 

Revenue from the Company’s sole significant customer, DePuy Synthes Mitek Sports Medicine (“Mitek”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 45% and 51% for the three months ended September 30, 2022 and 2021, respectively, and 43% and 46% for the nine months ended September 30, 2022 and 2021, respectively

 

The Company receives payments from our customers based on billing schedules established in each contract. Up-front payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Deferred revenue was $0.1 million and $1.0 million as of September 30, 2022 and December 31, 2021, respectively.

 

Total revenue by geographic location was as follows:

 

  

Three Months Ended September 30,

 
  

2022

  

2021

 
  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                

United States

 $31,093   77

%

 $30,910   78

%

Europe

  4,885   12

%

  4,238   11

%

Other

  4,286   11

%

  4,388   11

%

Total

 $40,264   100

%

 $39,536   100

%

 

  

Nine Months Ended September 30,

 
  

2022

  

2021

 
  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                

United States

 $87,552   75

%

 $85,984   77

%

Europe

  15,973   14

%

  14,808   13

%

Other

  13,089   11

%

  11,181   10

%

Total

 $116,614   100

%

 $111,973   100

%

 

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Equity Incentive Plan
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

12.

Equity Incentive Plan

 

Equity Incentive Plan

 

The Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”) was approved by the Company’s stockholders on June 13, 2017 and subsequently amended on June 18, 2019, June 16, 2020, June 16, 2021 and June 8, 2022. On June 8, 2022, the Company’s stockholders approved an amendment to the 2017 Plan increasing the number of shares by 250,000 shares from 4.6 million shares to 4.85 million shares. The 2017 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights (“SARs”), restricted stock awards, performance restricted stock units (“PSUs”), restricted stock units (“RSUs”), total shareholder return options (“TSRs”) and performance options that may be settled in cash, stock, or other property. In accordance with the 2017 Plan approved by the Company’s stockholders, including the amendments thereto, each share award other than stock options or SARs will reduce the number of total shares available for grant by two shares. Subject to adjustment for specified types of changes in the Company’s capitalization, no more than 4.85 million shares of common stock may be issued under the 2017 Plan. There were 1.2 million shares available for future grant at September 30, 2022 under the 2017 Plan.

 

The Anika Therapeutics, Inc. 2021 Inducement Plan (the “Inducement Plan”) was adopted by the Company’s board of directors on November 4, 2021. The Inducement Plan reserves 125,000 shares of common stock for issuance pursuant to equity-based awards granted under the Inducement Plan. Such awards may be granted only to an individual who was not previously the Company’s employee or director with the Company. The Inducement Plan provides for the grant of awards under terms substantially similar to the 2017 Plan (as amended). There were 4,883 shares available for future grant at September 30, 2022 under the Inducement Plan.

 

The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to or greater than the market price of the Company’s stock on the date of grant. Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over three years with a maximum contractual term of ten years.

 

The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows (in thousands):

 

  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Cost of revenue

 $242  $142  $645  $485 

Research & development

  397   360   1,267   1,003 

Selling, general & administrative

  3,237   2,361   8,590   6,431 

Total stock-based compensation expense

 $3,876  $2,863  $10,502  $7,919 

 

Stock Options

 

Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of three years and expire 10 years after the date of grant. The grant-date fair value of options is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.

 

The following summarizes the activity under the Company’s stock option plans:

 

  

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average

Remaining

Contractual

Term (in years)

  

Aggregate Intrinsic

Value

(in thousands)

 

Outstanding as of December 31, 2021

  1,175,993  $39.56         

Granted

  486,901  $27.60         

Exercised

  (437

)

 $9.10      $10 

Forfeited and canceled

  (156,672

)

 $44.08         

Outstanding as of September 30, 2022

  1,505,785  $35.21   8.3  $78 

Vested, September 30, 2022

  499,617  $40.00   7.3  $8 

Vested or expected to vest, September 30, 2022

  1,505,785  $35.21   8.3  $78 

 

The aggregate intrinsic value of options exercised for the nine-month period ended September 30, 2022 was immaterial.

 

The Company granted 486,901 stock options during the nine-month ended September 30, 2022, of which 398,314 shares were premium-priced options.

 

As of September 30, 2022, there was $8.7 million of unrecognized compensation cost related to unvested stock options. This expense is expected to be recognized over a weighted average period of 1.8 years.

 

The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The Company estimates the fair value of TSRs using Monte-Carlo simulation model where the expected volatility assumption is evaluated over 6.3 years. The actual number of TSR options that may be earned ranges from 0% to 150% of the target number, depending on the total shareholder return of the Company relative to the peer group over the vesting period of 2.7 years. There were 104,638 TSRs as of September 30, 2022.

 

The assumptions used in the Black-Scholes pricing model for options granted during the nine months ended September 30, 2022 and 2021, along with the weighted-average grant-date fair values, were as follows:

 

 

Nine Months Ended September 30,

 

2022

2021

Risk free interest rate

 

1.3%

-

3.4%

 

0.3%

-

0.7%

Expected volatility

 

53.8%

-

55.5%

 

54.8%

-

56.1%

Expected life (years)

  

4.5

   

4.0

 

Expected dividend yield

  

0.0%

   

0.0%

 

Fair value per option

  

$11.26

   

$14.55

 

 

Restricted Stock Units

 

RSUs generally vest in equal annual installments over a three-year period. The grant-date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of RSUs based on the closing price of its common stock on the date of grant.

 

RSU activity for the nine-month period ended September 30, 2022 was as follows:

 

  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  412,658  $36.33 

Granted

  507,524  $25.14 

Vested

  (159,871

)

 $36.48 

Forfeited and cancelled

  (67,389

)

 $32.45 

Outstanding as of September 30, 2022

  692,922  $28.48 

 

The weighted-average grant-date fair value per share of RSUs granted was $25.14 for the nine-month period ended September 30, 2022. The total fair value of RSUs vested was $5.8 million and $3.9 million for the nine-month periods ended September 30, 2022 and 2021, respectively.

 

As of September 30, 2022, there was $14.8 million of unrecognized compensation cost related to time-based RSUs, which was expected to be recognized over a weighted-average period of 2.0 years.

 

Performance Stock Units

 

PSU activity for the nine-month ended September 30, 2022 was as follows:

 

  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  158,297  $37.44 

Performance factor adjustment

  2,125  $32.53 

Vested

  (19,125

)

 $32.53 

Forfeited and cancelled

  (23,400

)

 $41.86 

Outstanding as of September 30, 2022

  117,897  $34.98 

 

The total fair value of PSUs vested was $0.6 million and $0 for the nine-month period ended September 30, 2022 and 2021, respectively. As of September 30, 2022, none of the milestones related to the outstanding PSUs were expected to be achieved.

 

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 13 - Income Taxes
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

13.

Income Taxes

 

The Company recorded an income tax benefit of $1.2 million and $2.4 million for the three- and nine-month periods ended   September 30, 2022, resulting in effective tax rates of 22.1% and 19.5%, respectively. The Company recorded income tax expense of $0.7 million and $1.7 million for the three- and nine-month periods ended   September 30, 2021, based on effective tax rates of 55.4% and 14.4%, respectively.

 

The decrease in the effective tax rate for the three-month period ended  September 30, 2022, as compared to the same period in 2021, was primarily due to non-deductible stock-option activity during the three-month period ended  September 30, 2021. The increase in the effective tax rate for the nine-month period ended   September 30, 2022, as compared to the same period in 2021, was primarily due to the year-to-date net tax benefit in 2021 on the change in the fair value of contingent consideration, in the amount of $1.1 million, and a year-to-date discrete charge of $0.7 million in 2022 related to non-deductible stock compensation.

 

The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate, which varies by jurisdiction.

 

In connection with the preparation of the financial statements, the Company assessed whether it is more likely than not that it will be able to utilize, in future periods, the Company’s deferred income tax assets to offset future taxable income and tax liabilities. The Company concluded that it is more likely than not that its deferred tax assets will be realized, after evaluation and consideration of both the positive and negative evidence. On  December 31, 2021, the Company released a valuation allowance that had been previously recorded related to its net deferred tax assets in Italy in the amount of $0.9 million. The Company did not record a valuation allowance on its deferred tax balances as of  September 30, 2022.

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 14 - Earnings Per Share ("EPS")
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

14.

Earnings Per Share (EPS)

 

Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic EPS. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding share-based awards using the treasury stock method

 

The following table provides share information used in the calculation of the Company's basic and diluted earnings per share (in thousands):

 

  

Three Month Period Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Shares used in the calculation of basic earnings per share

  14,603   14,429   14,542   14,389 

Effect of dilutive securities:

                

Share-based payment awards

  -   218   -   199 

Diluted shares used in the calculation of earnings per share

  14,603   14,647   14,542   14,588 

 

The Company had a net loss during the three and nine-months ended September 30, 2022, and therefore all potential common shares would have been anti-dilutive and accordingly were excluded from the computation of diluted EPS. Stock options of 1.1 million shares were outstanding for the nine-month period ended September 30, 2021, respectively, and were not included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive.

 

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 3 - Business Combinations (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]

Cash consideration

 $32,794 

Deferred consideration

  1,642 

Estimated fair value of contingent consideration

  40,700 

Estimated total purchase consideration

 $75,136 

Cash consideration

 $61,909 

Estimated fair value of contingent consideration

  28,376 

Estimated total purchase consideration

 $90,285 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $196 

Accounts receivable

  2,029 

Inventories

  10,968 

Prepaid expenses and other current assets

  364 

Property and equipment, net

  1,099 

Right-of-use assets

  944 

Intangible assets

  44,000 

Accounts payable, accrued expenses and other current liabilities

  (2,763

)

Other long-term liabilities

  (594

)

Lease liabilities

  (735

)

Net assets acquired

  55,508 

Goodwill

  19,628 

Estimated total purchase consideration

 $75,136 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $1,072 

Accounts receivable

  5,368 

Inventories

  15,652 

Prepaid expenses and other current assets

  535 

Property, plant and equipment

  3,394 

Other long-term assets

  7,548 

Intangible assets

  48,900 

Accounts payable, accrued expenses and other liabilities

  (3,929

)

Deferred tax liabilities

  (11,147

)

Net assets acquired

  67,393 

Goodwill

  22,892 

Estimated total purchase consideration

 $90,285 

Intangible assets acquired consist of:

    

Developed technology

 $37,000 

Trade name

  3,400 

Customer relationships

  7,900 

IPR&D

  600 

Total acquired intangible assets

 $48,900 
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

Developed technology

 $41,100 

Trade name

  1,800 

Customer relationships

  1,100 

Total acquired intangible assets

 $44,000 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 4 - Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical

Assets

  

Observable

Inputs

  

Unobservable

Inputs

     
  

September 30, 2022

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,348  $67,348  $-  $-  $67,348 
                     

Other current liabilities:

                    

Contingent Consideration - Short Term

 $-  $-  $-  $-  $- 
      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical

Assets

  

Observable

Inputs

  

Unobservable

Inputs

     
  

December 31, 2021

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,046  $67,046  $-  $-  $67,046 
                     

Other current liabilities:

                    

Contingent Consideration - Short Term

 $4,315  $-  $-  $4,315  $- 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
  

Nine Months Ended

  

Nine Months Ended

 
  

September 30, 2022

  

September 30, 2021

 

Balance, beginning

 $4,315  $35,410 

Payments

  (4,315)  (10,000)

Change in fair value

  -   (21,920)

Balance, ending

 $-  $3,490 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 5 - Inventories (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
  

September 30,

  

December 31,

 
  

2022

  

2021

 

Raw materials

 $19,015  $16,881 

Work-in-process

  11,650   11,442 

Finished goods

  24,277   26,731 

Total

 $54,941  $55,054 
         

Inventories

 $37,237  $36,010 

Other long-term assets

  17,704   19,044 

Total

 $54,941  $55,054 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 6 - Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]
      

Nine Months Ended

September 30, 2022

  

December 31,

2021

     
  

Gross
Value

  

Less: Accumulated
Currency Translation
Adjustment

  

Less:
Accumulated
Amortization

  

Net Book
Value

  

Net Book
Value

  

Weighted
Average Useful
Life

 

Developed technology

 $89,580  $(1,607

)

 $(22,238

)

 $65,735  $70,081   15 

IPR&D

  2,656   (1,006

)

  -   1,650   1,650  

Indefinite

 

Customer relationships

  9,000   -   (2,402

)

  6,598   7,273   10 

Distributor relationships

  4,700   (415

)

  (4,285

)

  -   -   5 

Patents

  1,000   (189

)

  (668

)

  143   179   16 

Tradenames

  5,200   -   (2,781

)

  2,419   3,199   5 

Total

 $112,136  $(3,217

)

 $(32,374

)

 $76,545  $82,382   13 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 7 - Goodwill (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of Goodwill [Table Text Block]
  

Nine Months Ended September 30, 2022

 

Balance, beginning

 $7,781 

Effect of foreign currency adjustments

  (1,060

)

Balance, ending

 $6,721 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 8 - Leases (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]
  

Operating Leases

 
     

2022 (Remainder of Year)

 $720 

2023

  3,081 

2024

  3,025 

2025

  3,066 

2026

  2,760 

Thereafter

  27,873 

Present value adjustment

  (9,421

)

Present value of lease payments

  31,105 

Less current portion included in accrued expenses and other current liabilities

  (1,922

)

Total lease liabilities

 $29,183 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 9 - Accrued Expenses and Other Liabilities (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
  

September 30, 2022

  

December 31, 2021

 
         

Compensation and related expenses

 $11,166  $9,523 

Professional fees

  3,063   3,590 

Operating lease liability – current

  1,922   1,526 

Clinical trial costs

  1,352   1,961 

Financing lease liability – current

  -   188 

Other

  496   1,059 

Total

 $17,999  $17,847 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 11 - Revenue and Geographic Information (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Revenue from External Customers by Products and Services [Table Text Block]
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 
                 

OA Pain Management

 $25,665  $26,153  $74,139  $69,790 

Joint Preservation and Restoration

  11,821   11,193   36,055   35,296 

Non-Orthopedics

  2,778   2,190   6,420   6,887 
  $40,264  $39,536  $116,614  $111,973 
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]
  

Three Months Ended September 30,

 
  

2022

  

2021

 
  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                

United States

 $31,093   77

%

 $30,910   78

%

Europe

  4,885   12

%

  4,238   11

%

Other

  4,286   11

%

  4,388   11

%

Total

 $40,264   100

%

 $39,536   100

%

  

Nine Months Ended September 30,

 
  

2022

  

2021

 
  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                

United States

 $87,552   75

%

 $85,984   77

%

Europe

  15,973   14

%

  14,808   13

%

Other

  13,089   11

%

  11,181   10

%

Total

 $116,614   100

%

 $111,973   100

%

XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Equity Incentive Plan (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Cost of revenue

 $242  $142  $645  $485 

Research & development

  397   360   1,267   1,003 

Selling, general & administrative

  3,237   2,361   8,590   6,431 

Total stock-based compensation expense

 $3,876  $2,863  $10,502  $7,919 
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average

Remaining

Contractual

Term (in years)

  

Aggregate Intrinsic

Value

(in thousands)

 

Outstanding as of December 31, 2021

  1,175,993  $39.56         

Granted

  486,901  $27.60         

Exercised

  (437

)

 $9.10      $10 

Forfeited and canceled

  (156,672

)

 $44.08         

Outstanding as of September 30, 2022

  1,505,785  $35.21   8.3  $78 

Vested, September 30, 2022

  499,617  $40.00   7.3  $8 

Vested or expected to vest, September 30, 2022

  1,505,785  $35.21   8.3  $78 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
 

Nine Months Ended September 30,

 

2022

2021

Risk free interest rate

 

1.3%

-

3.4%

 

0.3%

-

0.7%

Expected volatility

 

53.8%

-

55.5%

 

54.8%

-

56.1%

Expected life (years)

  

4.5

   

4.0

 

Expected dividend yield

  

0.0%

   

0.0%

 

Fair value per option

  

$11.26

   

$14.55

 
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  412,658  $36.33 

Granted

  507,524  $25.14 

Vested

  (159,871

)

 $36.48 

Forfeited and cancelled

  (67,389

)

 $32.45 

Outstanding as of September 30, 2022

  692,922  $28.48 
Schedule of Nonvested Performance-Based Units Activity [Table Text Block]
  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  158,297  $37.44 

Performance factor adjustment

  2,125  $32.53 

Vested

  (19,125

)

 $32.53 

Forfeited and cancelled

  (23,400

)

 $41.86 

Outstanding as of September 30, 2022

  117,897  $34.98 
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 14 - Earnings Per Share ("EPS") (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Three Month Period Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Shares used in the calculation of basic earnings per share

  14,603   14,429   14,542   14,389 

Effect of dilutive securities:

                

Share-based payment awards

  -   218   -   199 

Diluted shares used in the calculation of earnings per share

  14,603   14,647   14,542   14,588 
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 3 - Business Combinations (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 03, 2020
Jan. 24, 2020
Jul. 31, 2021
Oct. 31, 2020
Sep. 30, 2022
Mar. 31, 2020
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Business Combination, Contingent Consideration, Liability, Current         $ 0   $ 0   $ 4,315
Finite-Lived Intangible Asset, Useful Life (Year)             13 years    
Payment for Contingent Consideration Liability, Financing Activities             $ 4,315 $ 7,220  
Developed Technology Rights [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year)             15 years    
Customer Relationships [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year)             10 years    
Trade Names [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year)             5 years    
Parcus Medical [Member]                  
Business Combination, Consideration Transferred, Total   $ 75,136              
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High   60,000              
Business Combination, Contingent Consideration, Liability, Current                 4,300
Business Combination, Acquisition Related Costs           $ 1,900      
Payment for Contingent Consideration Liability, Financing Activities         $ 4,300        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   $ 44,000              
Parcus Medical [Member] | Developed Technology Rights [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year)   15 years              
Parcus Medical [Member] | Customer Relationships [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year)   10 years              
Parcus Medical [Member] | Trade Names [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year)   5 years              
Arthrosurface [Member]                  
Business Combination, Consideration Transferred, Total $ 90,285                
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High 40,000                
Business Combination, Acquisition Related Costs           $ 2,200      
Payment for Contingent Consideration Liability, Financing Activities     $ 10,000 $ 5,000          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles $ 48,900                
Arthrosurface [Member] | Developed Technology Rights [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year) 15 years                
Arthrosurface [Member] | Customer Relationships [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year) 10 years                
Arthrosurface [Member] | Trade Names [Member]                  
Finite-Lived Intangible Asset, Useful Life (Year) 5 years                
Arthrosurface [Member] | In Process Research and Development [Member]                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                 $ 600
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 3 - Business Combinations - Consideration Transferred (Details) - USD ($)
$ in Thousands
Feb. 03, 2020
Jan. 24, 2020
Parcus Medical [Member]    
Cash consideration   $ 32,794
Deferred consideration   1,642
Estimated fair value of contingent consideration   40,700
Estimated total purchase consideration   $ 75,136
Arthrosurface [Member]    
Cash consideration $ 61,909  
Estimated fair value of contingent consideration 28,376  
Estimated total purchase consideration $ 90,285  
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Feb. 03, 2020
Jan. 24, 2020
Goodwill $ 6,721 $ 7,781    
Parcus Medical [Member]        
Cash and cash equivalents       $ 196
Accounts receivable       2,029
Inventories       10,968
Prepaid expenses and other current assets       364
Property and equipment, net       1,099
Right-of-use assets       944
Intangible assets       44,000
Accounts payable, accrued expenses and other current liabilities       (2,763)
Other long-term liabilities       (594)
Lease liabilities       (735)
Net assets acquired       55,508
Goodwill       19,628
Estimated total purchase consideration       75,136
Intangible assets       44,000
Parcus Medical [Member] | Developed Technology Rights [Member]        
Intangible assets       41,100
Parcus Medical [Member] | Trade Names [Member]        
Intangible assets       1,800
Parcus Medical [Member] | Customer Relationships [Member]        
Intangible assets       $ 1,100
Arthrosurface [Member]        
Cash and cash equivalents     $ 1,072  
Accounts receivable     5,368  
Inventories     15,652  
Prepaid expenses and other current assets     535  
Property and equipment, net     3,394  
Intangible assets     48,900  
Accounts payable, accrued expenses and other current liabilities     (3,929)  
Net assets acquired     67,393  
Goodwill     22,892  
Estimated total purchase consideration     90,285  
Other long-term assets     7,548  
Deferred tax liabilities     (11,147)  
Intangible assets     48,900  
Arthrosurface [Member] | Developed Technology Rights [Member]        
Intangible assets     37,000  
Arthrosurface [Member] | Trade Names [Member]        
Intangible assets     3,400  
Arthrosurface [Member] | Customer Relationships [Member]        
Intangible assets     7,900  
Arthrosurface [Member] | In Process Research and Development [Member]        
Intangible assets   $ 600    
Intangible assets     $ 600  
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 3 - Business Combinations - Intangible Assets Acquired (Details) - Parcus Medical [Member]
$ in Millions
Jan. 24, 2020
USD ($)
Intangible assets $ 44.0
Developed Technology Rights [Member]  
Intangible assets 41.1
Trade Names [Member]  
Intangible assets 1.8
Customer Relationships [Member]  
Intangible assets $ 1.1
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Business Combination, Contingent Consideration, Liability, Current $ 0 $ 4,315
Estimate of Fair Value Measurement [Member]    
Business Combination, Contingent Consideration, Liability, Current 0 4,315
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Business Combination, Contingent Consideration, Liability, Current 0 0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Business Combination, Contingent Consideration, Liability, Current 0 0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Business Combination, Contingent Consideration, Liability, Current 0 4,315
Reported Value Measurement [Member]    
Business Combination, Contingent Consideration, Liability, Current 0 0
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]    
Cash equivalents 67,348 67,046
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash equivalents 67,348 67,046
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash equivalents 0 0
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash equivalents 0 0
Money Market Funds [Member] | Reported Value Measurement [Member]    
Cash equivalents $ 67,348 $ 67,046
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 4 - Fair Value Measurements - Contingent Consideration (Details) - Contingent Consideration [Member] - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Balance $ 4,315 $ 35,410
Payments (4,315) (10,000)
Change in fair value 0 (21,920)
Balance $ 0 $ 3,490
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 5 - Inventories (Details Textual) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Inventory Valuation Reserves $ 10.0 $ 9.1
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 5 - Inventories - Summary of Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Raw materials $ 19,015 $ 16,881
Work-in-process 11,650 11,442
Finished goods 24,277 26,731
Total 54,941 55,054
Inventories 37,237 36,010
Other long-term assets $ 17,704 $ 19,044
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 6 - Intangible Assets (Details Textual) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Amortization of Intangible Assets $ 1.9 $ 2.0 $ 5.8 $ 5.9
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 6 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Gross value $ 112,136  
Accumulated Currency Translation Adjustment (3,217)  
Accumulated Amortization (32,374)  
Net book value $ 76,545 $ 82,382
Useful life (Year) 13 years  
Developed Technology Rights [Member]    
Gross value $ 89,580  
Accumulated Currency Translation Adjustment (1,607)  
Accumulated Amortization (22,238)  
Net book value $ 65,735 70,081
Useful life (Year) 15 years  
In Process Research and Development [Member]    
Gross value $ 2,656  
Accumulated Currency Translation Adjustment (1,006)  
Accumulated Amortization 0  
Net book value 1,650 1,650
Customer Relationships [Member]    
Gross value 9,000  
Accumulated Currency Translation Adjustment 0  
Accumulated Amortization (2,402)  
Net book value $ 6,598 7,273
Useful life (Year) 10 years  
Distribution Rights [Member]    
Gross value $ 4,700  
Accumulated Currency Translation Adjustment (415)  
Accumulated Amortization (4,285)  
Net book value $ 0 0
Useful life (Year) 5 years  
Patents [Member]    
Gross value $ 1,000  
Accumulated Currency Translation Adjustment (189)  
Accumulated Amortization (668)  
Net book value $ 143 179
Useful life (Year) 16 years  
Trade Names [Member]    
Gross value $ 5,200  
Accumulated Currency Translation Adjustment 0  
Accumulated Amortization (2,781)  
Net book value $ 2,419 $ 3,199
Useful life (Year) 5 years  
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2022
USD ($)
Balance $ 7,781
Effect of foreign currency adjustments (1,060)
Balance $ 6,721
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 8 - Leases (Details Textual) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating Lease, Expense $ 0.8 $ 2.1 $ 0.6 $ 1.9
Operating Lease, Weighted Average Remaining Lease Term (Year) 15 years   15 years  
Operating Lease, Weighted Average Discount Rate, Percent 3.60%   3.60%  
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 8 - Leases - Future Minimum Rental Payments for Leases (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
2022 (Remainder of Year), operating leases $ 720  
2023, operating leases 3,081  
2024, operating leases 3,025  
2025, operating leases 3,066  
2026, operating leases 2,760  
Thereafter, operating leases 27,873  
Present value adjustment, operating leases (9,421)  
Total lease liabilities, operating leases 29,183 $ 19,240
Liabilities [Member]    
Present value of lease payments, operating leases 31,105  
Accrued Expenses and Other Current Liabilities [Member]    
Less current portion included in Accrued expenses and other current liabilities, operating leases $ (1,922) $ (1,526)
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Compensation and related expenses $ 11,166 $ 9,523
Professional fees 3,063 3,590
Clinical trial costs 1,352 1,961
Other 496 1,059
Total 17,999 17,847
Accrued Expenses and Other Current Liabilities [Member]    
Operating lease liability – current 1,922 1,526
Financing lease liability – current $ 0 $ 188
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 10 - Commitments and Contingencies (Details Textual) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Standard and Extended Product Warranty Accrual, Ending Balance $ 0 $ 0
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 11 - Revenue and Geographic Information (Details Textual) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Revenues From Agreements as Percent of Total Revenue 45.00% 51.00% 43.00% 46.00%  
Contract with Customer, Liability, Total $ 0.1   $ 0.1   $ 1.0
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 11 - Revenue and Geographic Information - Revenues (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue $ 40,264 $ 39,536 $ 39,536 $ 116,614 $ 111,973
OA Pain Management [member]          
Revenue 25,665 26,153   74,139 69,790
Joint Preservation and Restoration [Member]          
Revenue 11,821 11,193   36,055 35,296
Non-Orthopedic [Member]          
Revenue $ 2,778 $ 2,190   $ 6,420 $ 6,887
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue $ 40,264 $ 39,536 $ 39,536 $ 116,614 $ 111,973
Percentage of Revenue 100.00%   100.00% 100.00% 100.00%
UNITED STATES          
Revenue $ 31,093   $ 30,910 $ 87,552 $ 85,984
Percentage of Revenue 77.00%   78.00% 75.00% 77.00%
Europe [Member]          
Revenue $ 4,885   $ 4,238 $ 15,973 $ 14,808
Percentage of Revenue 12.00%   11.00% 14.00% 13.00%
Other Location [Member]          
Revenue $ 4,286   $ 4,388 $ 13,089 $ 11,181
Percentage of Revenue 11.00%   11.00% 11.00% 10.00%
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Equity Incentive Plan (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Jun. 08, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Nov. 04, 2021
Jun. 13, 2017
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)   486,901        
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)   4 years 6 months 4 years      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)   1,505,785   1,175,993    
Premium-Priced Employee Stock Options [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Premium Priced Options, Exercise Price as Percentage of Market Price   110.00%        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)   398,314        
Share-Based Payment Arrangement, Option [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)   10 years        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   $ 8,700        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)   1 year 9 months 18 days        
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)   3 years        
Total Shareholder Return ("TSRs") Options [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)   2 years 8 months 12 days        
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)   6 years 3 months 18 days        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)   104,638        
Total Shareholder Return ("TSRs") Options [Member] | Minimum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number   0.00%        
Total Shareholder Return ("TSRs") Options [Member] | Maximum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number   150.00%        
Restricted Stock Units (RSUs) [Member]            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   $ 14,800        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)   2 years        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)   $ 25.14        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value   $ 5,800 $ 3,900      
Restricted Stock Units (RSUs) [Member] | Minimum [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)   3 years        
Performance Shares [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value   $ 600 $ 0      
The 2017 Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 250,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 4,850,000         4,600,000
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs (in shares)           2
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)   1,200,000        
The 2021 Inducement Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)   4,883        
Common Stock, Capital Shares Reserved for Future Issuance (in shares)         125,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)   3 years        
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)   10 years        
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Stock-based compensation expense $ 3,876 $ 2,863 $ 10,502 $ 7,919
Stock-based compensation expense 3,876 2,863 10,502 7,919
Cost of Sales [Member]        
Stock-based compensation expense 242 142 645 485
Stock-based compensation expense 242 142 645 485
Research and Development Expense [Member]        
Stock-based compensation expense 397 360 1,267 1,003
Stock-based compensation expense 397 360 1,267 1,003
Selling, General and Administrative Expenses [Member]        
Stock-based compensation expense 3,237 2,361 8,590 6,431
Stock-based compensation expense $ 3,237 $ 2,361 $ 8,590 $ 6,431
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Equity Incentive Plan - Stock Options (Details)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Outstanding, shares (in shares) | shares 1,175,993
Outstanding, Weighted Average Exercise (in dollars per share) | $ / shares $ 39.56
Granted, shares (in shares) | shares 486,901
Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 27.60
Exercised, shares (in shares) | shares (437)
Exercised, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 9.10
Exercised, Aggregate Intrinsic Value | $ $ 10
Forfeited and canceled, shares (in shares) | shares (156,672)
Forfeited and canceled, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 44.08
Outstanding, shares (in shares) | shares 1,505,785
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 35.21
Outstanding, Weighted Average Remaining Contractual Term (Year) 8 years 3 months 18 days
Outstanding, Aggregate Intrinsic Value | $ $ 78
Vested, shares (in shares) | shares 499,617
Vested, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 40.00
Vested, Weighted Average Remaining Contractual Term (Year) 7 years 3 months 18 days
Vested, Aggregate Intrinsic Value | $ $ 8
Vested and expected to vest, shares (in shares) | shares 1,505,785
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 35.21
Vested and expected to vest, Weighted Average Remaining Contractual Term (Year) 8 years 3 months 18 days
Vested and expected to vest, Aggregate Intrinsic Value | $ $ 78
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Expected life (years) (Year) 4 years 6 months 4 years
Expected dividend yield 0.00% 0.00%
Fair value per option 0.1126 0.1455
Minimum [Member]    
Risk free interest rate 1.30% 0.30%
Expected volatility 53.80% 54.80%
Maximum [Member]    
Risk free interest rate 3.40% 0.70%
Expected volatility 55.50% 56.10%
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member]
9 Months Ended
Sep. 30, 2022
$ / shares
shares
Outstanding, shares (in shares) | shares 412,658
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares $ 36.33
Granted (in shares) | shares 507,524
Granted, weighted average grant date fair value (in dollars per share) | $ / shares $ 25.14
Vested, shares (in shares) | shares (159,871)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares $ 36.48
Forfeited and cancelled, shares (in shares) | shares (67,389)
Forfeited and cancelled, weighted average grant date fair value (in dollars per share) | $ / shares $ 32.45
Outstanding, shares (in shares) | shares 692,922
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares $ 28.48
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Equity Incentive Plan - Performance Stock Units (Details) - Performance Shares [Member]
9 Months Ended
Sep. 30, 2022
$ / shares
shares
Outstanding, shares (in shares) | shares 158,297
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares $ 37.44
Performance factor adjustment (in shares) | shares 2,125
Performance factor adjustment (in dollars per share) | $ / shares $ 32.53
Vested, shares (in shares) | shares (19,125)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares $ 32.53
Forfeited and cancelled, shares (in shares) | shares (23,400)
Forfeited and cancelled, weighted average grant date fair value (in dollars per share) | $ / shares $ 41.86
Outstanding, shares (in shares) | shares 117,897
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares $ 34.98
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 13 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Income Tax Expense (Benefit), Total $ (1,187) $ 694 $ (2,404) $ 1,670  
Effective Income Tax Rate Reconciliation, Percent, Total 22.10% 55.40% 19.50% 14.40%  
Income Tax Expense (Benefit), Change in Fair Value of Contingent Consideration       $ 1,100  
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount     $ 700    
Deferred Tax Assets, Valuation Allowance $ 0   $ 0    
Foreign Tax Authority [Member] | Ministry of Economic Affairs and Finance, Italy [Member]          
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount         $ (900)
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 14 - Earnings Per Share ("EPS") (Details Textual)
shares in Millions
9 Months Ended
Sep. 30, 2021
shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 1.1
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Shares used in the calculation of basic earnings per share (in shares) 14,603 14,429 14,542 14,389
Share-based payment awards (in shares) 0 218 0 199
Diluted shares used in the calculation of earnings per share (in shares) 14,603 14,647 14,542 14,588
XML 67 anik20220930_10q_htm.xml IDEA: XBRL DOCUMENT 0000898437 2022-01-01 2022-09-30 0000898437 2022-10-31 0000898437 2022-09-30 0000898437 2021-12-31 0000898437 2022-07-01 2022-09-30 0000898437 2021-07-01 2021-09-30 0000898437 2021-01-01 2021-09-30 0000898437 us-gaap:CommonStockMember 2021-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000898437 us-gaap:RetainedEarningsMember 2021-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000898437 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000898437 2022-01-01 2022-03-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000898437 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000898437 us-gaap:CommonStockMember 2022-03-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000898437 us-gaap:RetainedEarningsMember 2022-03-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000898437 2022-03-31 0000898437 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000898437 2022-04-01 2022-06-30 0000898437 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000898437 us-gaap:CommonStockMember 2022-06-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000898437 us-gaap:RetainedEarningsMember 2022-06-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000898437 2022-06-30 0000898437 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000898437 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000898437 us-gaap:CommonStockMember 2022-09-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000898437 us-gaap:RetainedEarningsMember 2022-09-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000898437 us-gaap:CommonStockMember 2020-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000898437 us-gaap:RetainedEarningsMember 2020-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000898437 2020-12-31 0000898437 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000898437 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000898437 2021-01-01 2021-03-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0000898437 us-gaap:CommonStockMember 2021-03-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000898437 us-gaap:RetainedEarningsMember 2021-03-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000898437 2021-03-31 0000898437 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000898437 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000898437 2021-04-01 2021-06-30 0000898437 us-gaap:CommonStockMember 2021-06-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000898437 us-gaap:RetainedEarningsMember 2021-06-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000898437 2021-06-30 0000898437 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000898437 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000898437 us-gaap:CommonStockMember 2021-09-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000898437 us-gaap:RetainedEarningsMember 2021-09-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000898437 2021-09-30 0000898437 us-gaap:AccountingStandardsUpdate201602Member 2022-01-01 2022-09-30 0000898437 us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 2021-09-30 0000898437 anik:ParcusMedicalMember 2020-01-24 2020-01-24 0000898437 anik:ParcusMedicalMember 2021-12-31 0000898437 anik:ParcusMedicalMember 2022-07-01 2022-09-30 0000898437 anik:ParcusMedicalMember 2020-01-01 2020-03-31 0000898437 anik:ParcusMedicalMember 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:DevelopedTechnologyRightsMember 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:TradeNamesMember 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:CustomerRelationshipsMember 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:DevelopedTechnologyRightsMember 2020-01-24 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:CustomerRelationshipsMember 2020-01-24 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:TradeNamesMember 2020-01-24 2020-01-24 0000898437 anik:ArthrosurfaceMember 2020-02-03 2020-02-03 0000898437 anik:ArthrosurfaceMember 2020-10-01 2020-10-31 0000898437 anik:ArthrosurfaceMember 2021-07-01 2021-07-31 0000898437 anik:ArthrosurfaceMember 2020-01-01 2020-03-31 0000898437 anik:ArthrosurfaceMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:DevelopedTechnologyRightsMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:TradeNamesMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:CustomerRelationshipsMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:InProcessResearchAndDevelopmentMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:DevelopedTechnologyRightsMember 2020-02-03 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:CustomerRelationshipsMember 2020-02-03 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:TradeNamesMember 2020-02-03 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-09-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000898437 anik:ContingentConsiderationMember 2021-12-31 0000898437 anik:ContingentConsiderationMember 2020-12-31 0000898437 anik:ContingentConsiderationMember 2022-01-01 2022-09-30 0000898437 anik:ContingentConsiderationMember 2021-01-01 2021-09-30 0000898437 anik:ContingentConsiderationMember 2022-09-30 0000898437 anik:ContingentConsiderationMember 2021-09-30 0000898437 us-gaap:DevelopedTechnologyRightsMember 2022-09-30 0000898437 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000898437 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-09-30 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2022-09-30 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000898437 us-gaap:CustomerRelationshipsMember 2022-09-30 0000898437 us-gaap:CustomerRelationshipsMember 2021-12-31 0000898437 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0000898437 us-gaap:DistributionRightsMember 2022-09-30 0000898437 us-gaap:DistributionRightsMember 2021-12-31 0000898437 us-gaap:DistributionRightsMember 2022-01-01 2022-09-30 0000898437 us-gaap:PatentsMember 2022-09-30 0000898437 us-gaap:PatentsMember 2021-12-31 0000898437 us-gaap:PatentsMember 2022-01-01 2022-09-30 0000898437 us-gaap:TradeNamesMember 2022-09-30 0000898437 us-gaap:TradeNamesMember 2021-12-31 0000898437 us-gaap:TradeNamesMember 2022-01-01 2022-09-30 0000898437 anik:LiabilitiesMember 2022-09-30 0000898437 anik:AccruedExpensesAndOtherCurrentLiabilitiesMember 2022-09-30 0000898437 anik:AccruedExpensesAndOtherCurrentLiabilitiesMember 2021-12-31 0000898437 anik:OAPainManagementMember 2022-07-01 2022-09-30 0000898437 anik:OAPainManagementMember 2021-07-01 2021-09-30 0000898437 anik:OAPainManagementMember 2022-01-01 2022-09-30 0000898437 anik:OAPainManagementMember 2021-01-01 2021-09-30 0000898437 anik:JointPreservationAndRestorationMember 2022-07-01 2022-09-30 0000898437 anik:JointPreservationAndRestorationMember 2021-07-01 2021-09-30 0000898437 anik:JointPreservationAndRestorationMember 2022-01-01 2022-09-30 0000898437 anik:JointPreservationAndRestorationMember 2021-01-01 2021-09-30 0000898437 anik:NonorthopedicMember 2022-07-01 2022-09-30 0000898437 anik:NonorthopedicMember 2021-07-01 2021-09-30 0000898437 anik:NonorthopedicMember 2022-01-01 2022-09-30 0000898437 anik:NonorthopedicMember 2021-01-01 2021-09-30 0000898437 country:US 2022-07-01 2022-09-30 0000898437 country:US 2021-04-01 2021-09-30 0000898437 srt:EuropeMember 2022-07-01 2022-09-30 0000898437 srt:EuropeMember 2021-04-01 2021-09-30 0000898437 anik:OtherLocationMember 2022-07-01 2022-09-30 0000898437 anik:OtherLocationMember 2021-04-01 2021-09-30 0000898437 2021-04-01 2021-09-30 0000898437 country:US 2022-01-01 2022-09-30 0000898437 country:US 2021-01-01 2021-09-30 0000898437 srt:EuropeMember 2022-01-01 2022-09-30 0000898437 srt:EuropeMember 2021-01-01 2021-09-30 0000898437 anik:OtherLocationMember 2022-01-01 2022-09-30 0000898437 anik:OtherLocationMember 2021-01-01 2021-09-30 0000898437 anik:The2017PlanMember 2022-06-08 2022-06-08 0000898437 anik:The2017PlanMember 2017-06-13 0000898437 anik:The2017PlanMember 2022-06-08 0000898437 anik:The2017PlanMember 2022-09-30 0000898437 anik:The2021InducementPlanMember 2021-11-04 0000898437 anik:The2021InducementPlanMember 2022-09-30 0000898437 anik:The2021InducementPlanMember 2022-01-01 2022-09-30 0000898437 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000898437 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000898437 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000898437 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000898437 anik:PremiumPricedEmployeeStockOptionsMember 2022-01-01 2022-09-30 0000898437 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000898437 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000898437 us-gaap:EmployeeStockOptionMember 2022-09-30 0000898437 anik:TotalShareholderReturnTsrsOptionsMember 2022-01-01 2022-09-30 0000898437 srt:MinimumMember anik:TotalShareholderReturnTsrsOptionsMember 2022-01-01 2022-09-30 0000898437 srt:MaximumMember anik:TotalShareholderReturnTsrsOptionsMember 2022-01-01 2022-09-30 0000898437 anik:TotalShareholderReturnTsrsOptionsMember 2022-09-30 0000898437 srt:MinimumMember 2022-01-01 2022-09-30 0000898437 srt:MaximumMember 2022-01-01 2022-09-30 0000898437 srt:MinimumMember 2021-01-01 2021-09-30 0000898437 srt:MaximumMember 2021-01-01 2021-09-30 0000898437 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000898437 us-gaap:PerformanceSharesMember 2021-12-31 0000898437 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0000898437 us-gaap:PerformanceSharesMember 2022-09-30 0000898437 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0000898437 us-gaap:ForeignCountryMember us-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember 2021-01-01 2021-12-31 shares iso4217:USD iso4217:USD shares utr:Y pure 0000898437 Anika Therapeutics, Inc. false --12-31 Q3 2022 1566000 1442000 0.01 0.01 1250000 1250000 0 0 0 0 0.01 0.01 90000000 90000000 14607000 14607000 14441000 14441000 4300000 0 P3Y P10Y P3Y 0.013 0.034 0.003 0.007 0.000 0.000 P3Y 0 10-Q true 2022-09-30 false 001-14027 DE 04-3145961 32 Wiggins Avenue Bedford MA 01730 781 457-9000 Common Stock, par value $0.01 per share ANIK NASDAQ Yes Yes Accelerated Filer false false false 14609669 87777000 94386000 34168000 29843000 37237000 36010000 8579000 8289000 167761000 168528000 47390000 47602000 30987000 20957000 18342000 20285000 76545000 82382000 6721000 7781000 347746000 347535000 8353000 7633000 17999000 17847000 0 4315000 26352000 29795000 474000 1258000 6800000 10157000 29183000 19240000 0 0 146000 144000 76661000 67081000 -7497000 -5718000 215627000 225578000 284937000 287085000 347746000 347535000 40264000 39536000 116614000 111973000 17485000 16513000 47169000 47164000 22779000 23023000 69445000 64809000 7301000 7673000 20433000 21327000 21276000 17500000 61745000 53664000 0 -3450000 0 -21920000 28577000 21723000 82178000 53071000 -5798000 1300000 -12733000 11738000 436000 -48000 378000 -141000 -5362000 1252000 -12355000 11597000 -1187000 694000 -2404000 1670000 -4175000 558000 -9951000 9927000 -0.29 0.04 -0.68 0.69 -0.29 0.04 -0.68 0.68 14603000 14429000 14542000 14389000 14603000 14647000 14542000 14588000 -4175000 558000 -9951000 9927000 -851000 199000 -1779000 -777000 -5026000 757000 -11730000 9150000 14441000 144000 67081000 225578000 -5718000 287085000 1000 0 15000 15000 106000 1000 -1000 2545000 2545000 30000 -0 844000 844000 -2933000 -2933000 -81000 -81000 14518000 145000 68796000 222645000 -5799000 285787000 61000 1000 -1000 0 20000 0 0 0 4081000 4081000 1000 -0 25000 25000 -2843000 -2843000 -847000 -847000 14598000 146000 72851000 219802000 -6646000 286153000 11000 0 0 0 0 0 0 3876000 3876000 2000 -0 66000 66000 -4175000 -4175000 -851000 -851000 14607000 146000 76661000 215627000 -7497000 284937000 14329000 143000 55355000 221444000 -4542000 272400000 0 1000 0 0 1000 46000 1000 -1000 0 0 0 0 2259000 0 0 2259000 9000 -0 333000 -0 -0 333000 0 0 2838000 0 2838000 0 0 0 -509000 -509000 14366000 144000 57281000 224282000 -5051000 276656000 18000 0 640000 0 0 640000 35000 0 0 0 0 0 0 2797000 0 0 2797000 1000 -0 19000 -0 -0 19000 0 0 6531000 0 6531000 0 0 0 199000 199000 14418000 144000 60699000 230813000 -4852000 286804000 10000 0 373000 0 0 373000 9000 0 0 0 0 0 0 2863000 0 0 2863000 1000 -0 71000 -0 -0 71000 0 0 558000 0 558000 0 0 0 -467000 -467000 14436000 144000 63864000 231371000 -5319000 290060000 -9951000 9927000 4984000 4702000 5837000 5885000 0 6244000 1322000 1312000 0 -21920000 -0 -831000 10502000 7919000 -3491000 1018000 379000 -60000 3701000 3702000 13000 4983000 8321000 3933000 7117000 456000 -1864000 533000 -702000 -1054000 -1247000 115000 3104000 0 -2780000 423000 -423000 3928000 3925000 -0 363000 0 2501000 4957000 4016000 -4957000 -1878000 284000 210000 935000 423000 15000 1014000 4315000 7220000 -5519000 -6839000 -61000 -49000 -6609000 -4841000 94386000 95817000 87777000 90976000 11589000 195000 108000 220000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="vertical-align:top;width:183.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Nature of Business</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In early <em style="font: inherit;">2020,</em> the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation solutions provider focused on sports medicine and soft tissue repair, and Arthrosurface, Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company’s product portfolio, developed over its <em style="font: inherit;">30</em> years of expertise in hyaluronic acid technology, into the broader joint preservation and restoration market with greater market potential, added high-growth revenue streams, increased the Company’s commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is subject to risks common to companies in the life sciences industry including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There continue to be uncertainties regarding the pandemic of the ongoing coronavirus (“COVID-<em style="font: inherit;">19”</em>), and the Company is closely monitoring the impact of COVID-<em style="font: inherit;">19</em> on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, business partners and a broader impact on elective surgeries. The Company is unable to predict the specific impact that COVID-<em style="font: inherit;">19</em> <em style="font: inherit;"> may </em>have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein <em style="font: inherit;"> may </em>change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-<em style="font: inherit;">19.</em></p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="vertical-align:top;width:183.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Basis of Presentation</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been or omitted pursuant to SEC rules and regulations relating to interim financial statements. The <em style="font: inherit;"> December 31, 2021 </em>balances reported herein were derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2021. </em>The results of operations for the <em style="font: inherit;">three</em>-month and <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2022, </em>are <em style="font: inherit;">not</em> indicative of the results to be expected for the year ending <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Segment Information</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer as of <em style="font: inherit;"> September 30, 2022. </em>Based on the criteria established by Accounting Standards Codification <em style="font: inherit;">280,</em> <i>Segment Reportin</i>g, the Company has <em style="font: inherit;">one</em> operating and reportable segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em></b></p> </td><td style="vertical-align:top;width:183.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Business Combinations</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Parcus Medical, LLC</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> January 24, 2020, </em>the Company completed the acquisition of Parcus Medical pursuant to the terms of the Agreement and Plan of Merger, dated as of <em style="font: inherit;"> January 4, 2020 (</em>the “Parcus Medical Merger Agreement”). Parcus Medical is a sports medicine implant and instrumentation solutions provider focused on surgical repair and reconstruction of soft tissue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Consideration Transferred</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the Parcus Medical Merger Agreement, the Company acquired all outstanding equity of Parcus Medical for estimated total purchase consideration of $75.1 million, as of <em style="font: inherit;"> January 24, 2020, </em>which consisted of:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,794</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,642</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Estimated fair value of contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,136</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the Parcus Medical Merger Agreement, contingent consideration represents additional payments that the Company <em style="font: inherit;"> may </em>be required to make in the future which could total up to $60.0 million depending on the level of net sales of Parcus Medical products generated in <em style="font: inherit;">2020</em> through <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The fair value of contingent consideration related to net sales as of <em style="font: inherit;"> January 24, 2020, </em>and at each reporting date, was determined based on a Monte Carlo simulation model in an option pricing framework, whereby a range of possible scenarios were simulated. The liability for contingent consideration was included in current liabilities on the condensed consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2022, </em>the Company paid the contingent consideration related to net sales in the amount of $4.3 million which was included in current liabilities as of <em style="font: inherit;"> December 31, 2021. </em>The Company does <em style="font: inherit;">not</em> expect any further milestones to be achieved.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Acquisition-related costs were <em style="font: inherit;">not</em> included as a component of consideration transferred but were expensed in the periods in which the costs are incurred. The Company incurred approximately $1.9 million in transaction costs related to the Parcus Medical acquisition during the <em style="font: inherit;">three</em>-month period ending <em style="font: inherit;"> March 31, 2020. </em>The transaction costs subsequent to <em style="font: inherit;"> March 31, 2020 </em>were immaterial.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Net Assets Acquired</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The estimate of fair value as of the acquisition date required the use of significant assumptions and estimates. Critical estimates included, but were <em style="font: inherit;">not</em> limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable, however, actual results <em style="font: inherit;"> may </em>differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of <em style="font: inherit;"> January 24, 2020, </em>and was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognized identifiable assets acquired and liabilities assumed:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">196</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,968</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">364</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">944</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Accounts payable, accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,763</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Other long-term liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(594</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">55,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,136</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The acquired intangible assets based on estimates of fair value as of <em style="font: inherit;"> January 24, 2020 </em>were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Trade name</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total acquired intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The fair value of developed technology will be amortized over a useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of the trade name over 5 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill was impaired in <em style="font: inherit;">2020</em> and there was <em style="font: inherit;">no</em> remaining goodwill as of <em style="font: inherit;"> December 31, 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Arthrosurface, Inc.</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> February 3, 2020, </em>the Company completed the acquisition of Arthrosurface pursuant to the terms of the Agreement and Plan of Merger, dated as of <em style="font: inherit;"> January 4, 2020 (</em>the “Arthrosurface Merger Agreement”). Arthrosurface is a joint preservation technology company specializing in less invasive, bone-preserving partial and total joint replacement solutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Consideration Transferred</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the Arthrosurface Merger Agreement, the Company acquired all outstanding equity of Arthrosurface for estimated total purchase consideration of $90.3 million, as of <em style="font: inherit;"> February 3, 2020 </em>which consisted of:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">61,909</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Estimated fair value of contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,285</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Pursuant to the Arthrosurface Merger Agreement, the Company could be required to make future payments of up to $40.0 million depending on the achievement of regulatory milestones and the level of net sales of Arthrosurface products from <em style="font: inherit;">2020</em> through <em style="font: inherit;">2021.</em> The fair value of contingent consideration related to regulatory milestones as of <em style="font: inherit;"> February 3, 2020 </em>was determined through a scenario-based discounted cash flow analysis using scenario probabilities and regulatory milestone dates. The fair value of contingent consideration related to net sales achievement as of <em style="font: inherit;"> February 3, 2020 </em>was determined based upon a Monte Carlo simulation approach at acquisition date, whereby a range of possible scenarios were simulated. The Company paid $5.0 million in <em style="font: inherit;"> October 2020 </em>and $10.0 million in <em style="font: inherit;"> July 2021 </em>based upon the achievement of <em style="font: inherit;">two</em> distinct regulatory milestones. As of <em style="font: inherit;"> September 30, 2022, </em>there were <em style="font: inherit;">no</em> milestones remaining.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Acquisition-related costs were <em style="font: inherit;">not</em> included as a component of consideration transferred but were expensed in the periods in which the costs are incurred. The Company incurred approximately $2.2 million in transaction costs related to the Arthrosurface acquisition during the <em style="font: inherit;">three</em>-month period ending <em style="font: inherit;"> March 31, 2020. </em>The transaction costs subsequent to <em style="font: inherit;"> March 31, 2020 </em>were immaterial.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Net Assets Acquired</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were <em style="font: inherit;">not</em> limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results <em style="font: inherit;"> may </em>differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of <em style="font: inherit;"> February 3, 2020, </em>as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognized identifiable assets acquired and liabilities assumed:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,368</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,652</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Property, plant and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,394</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,548</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Accounts payable, accrued expenses and other liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,929</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,147</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">67,393</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,285</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Intangible assets acquired consist of:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Trade name</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total acquired intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The fair value of developed technology will be amortized over an estimated useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of trade names over 5 years. A total of $0.6 million represents the fair value of IPR&amp;D with an indefinite useful life which was impaired during the quarter ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill was impaired in <em style="font: inherit;">2020</em> and there was <em style="font: inherit;">no</em> remaining goodwill as of <em style="font: inherit;"> December 31, 2020.</em></p> 75100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,794</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,642</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Estimated fair value of contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,136</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">61,909</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Estimated fair value of contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,285</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 32794000 1642000 40700000 75136000 60000000.0 4300000 1900000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognized identifiable assets acquired and liabilities assumed:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">196</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,968</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">364</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">944</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Accounts payable, accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,763</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Other long-term liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(594</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">55,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,136</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognized identifiable assets acquired and liabilities assumed:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,368</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,652</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Property, plant and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,394</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,548</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Accounts payable, accrued expenses and other liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,929</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,147</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">67,393</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,285</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Intangible assets acquired consist of:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Trade name</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total acquired intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 196000 2029000 10968000 364000 1099000 944000 44000000 2763000 594000 735000 55508000 19628000 75136000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Trade name</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total acquired intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 41100000 1800000 1100000 44000000 P15Y P10Y P5Y 90300000 61909000 28376000 90285000 40000000.0 5000000.0 10000000.0 2200000 1072000 5368000 15652000 535000 3394000 7548000 48900000 3929000 11147000 67393000 22892000 90285000 37000000 3400000 7900000 600000 48900000 P15Y P10Y P5Y 600000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em></b></p> </td><td style="vertical-align:top;width:183.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Fair Value Measurements</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has certain cash equivalents in money market funds that are classified within Level <em style="font: inherit;">1</em> of the fair value hierarchy and are valued based on quoted prices in active markets. For cash, accounts receivables, accounts payable, and accrued interest, the carrying amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is <em style="font: inherit;">not</em> included in the table below. Contingent consideration related to the previously described business combinations are classified within Level <em style="font: inherit;">3</em> of the fair value hierarchy as the determination of fair value uses considerable judgement and represents the Company’s best estimate of an amount that could be realized in a market exchange for the asset or liability. There were <em style="font: inherit;">no</em> transfers between fair value levels during the <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2022 </em>or <em style="font: inherit;">2021.</em> See Note <em style="font: inherit;">3,</em> <i>Business Combinations</i> for additional discussion of contingent consideration as of <em style="font: inherit;"> September 30, 2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Active Markets</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant Other</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; padding-left: 0px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>for Identical </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Assets </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Observable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Unobservable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>September 30, 2022</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 1)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 2)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 3)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amortized Cost</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash equivalents:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Contingent Consideration - Short Term</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Active Markets</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant Other</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>for Identical </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Assets </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Observable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Unobservable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31, 2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 1)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 2)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 3)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amortized Cost</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash equivalents:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Contingent Consideration - Short Term</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contingent Consideration</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table provides a rollforward of the contingent consideration related to business acquisitions discussed in Note <em style="font: inherit;">3,</em> <i>Business Combinations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, 2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">35,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(21,920</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, ending</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Active Markets</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant Other</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; padding-left: 0px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>for Identical </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Assets </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Observable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Unobservable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>September 30, 2022</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 1)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 2)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 3)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; padding: 0px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amortized Cost</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash equivalents:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,348</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Contingent Consideration - Short Term</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Active Markets</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant Other</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>for Identical </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Assets </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Observable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Unobservable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31, 2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 1)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 2)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 3)</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Amortized Cost</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash equivalents:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Contingent Consideration - Short Term</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 67348000 67348000 0 0 67348000 0 0 0 0 0 67046000 67046000 0 0 67046000 4315000 0 0 4315000 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, 2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">35,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(21,920</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, ending</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 4315000 35410000 4315000 10000000 -0 21920000 0 3490000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b></p> </td><td style="vertical-align:top;width:183.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Inventories</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,881</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Work-in-process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,442</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,731</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">54,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,010</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,044</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">54,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories are stated net of inventory reserves of $10.0 million and $9.1 million as of <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,881</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Work-in-process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,442</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,731</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">54,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,010</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,044</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">54,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 19015000 16881000 11650000 11442000 24277000 26731000 54941000 55054000 37237000 36010000 17704000 19044000 54941000 55054000 10000000.0 9100000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em></b></p> </td><td style="vertical-align: top; width: 94%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Intangible Assets</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross </b><br/> <b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Less: Accumulated </b><br/> <b>Currency Translation </b><br/> <b>Adjustment</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Less: </b><br/> <b>Accumulated </b><br/> <b>Amortization</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net Book </b><br/> <b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net Book </b><br/> <b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted </b><br/> <b>Average Useful </b><br/> <b>Life</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 28%; padding: 0px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">89,580</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(22,238</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">65,735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,656</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Indefinite</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,598</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,273</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Distributor relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(415</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,285</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">179</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tradenames</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,136</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(32,374</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,382</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The aggregate amortization expense related to intangible assets was $1.9 million and $2.0 million for the <em style="font: inherit;">three</em>-month periods ended <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;">2021,</em> respectively, and $5.8 million and $5.9 million for each of the <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;">2021.</em></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross </b><br/> <b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Less: Accumulated </b><br/> <b>Currency Translation </b><br/> <b>Adjustment</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Less: </b><br/> <b>Accumulated </b><br/> <b>Amortization</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net Book </b><br/> <b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net Book </b><br/> <b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted </b><br/> <b>Average Useful </b><br/> <b>Life</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 28%; padding: 0px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">89,580</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(22,238</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">65,735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,656</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Indefinite</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,402</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,598</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,273</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Distributor relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(415</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,285</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">179</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tradenames</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,136</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(32,374</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,382</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 89580000 1607000 22238000 65735000 70081000 P15Y 2656000 1006000 -0 1650000 1650000 9000000 -0 2402000 6598000 7273000 P10Y 4700000 415000 4285000 0 0 P5Y 1000000 189000 668000 143000 179000 P16Y 5200000 -0 2781000 2419000 3199000 P5Y 112136000 3217000 32374000 76545000 82382000 P13Y 1900000 2000000.0 5800000 5900000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b></p> </td><td style="vertical-align:top;width:183.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Goodwill</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company assesses goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there <em style="font: inherit;"> may </em>be impairment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Changes in the carrying value of goodwill for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022 </em>were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>Nine Months Ended September 30, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance, beginning</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Effect of foreign currency adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance, ending</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>Nine Months Ended September 30, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance, beginning</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Effect of foreign currency adjustments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance, ending</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 7781000 -1060000 6721000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b></p> </td><td style="vertical-align:top;width:183.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Leases</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company leases its buildings and manufacturing facilities under operating leases. As of <em style="font: inherit;"> September 30, 2022, </em>the Company had real estate leases in Bedford, Massachusetts, Franklin, Massachusetts, Sarasota, Florida, Warsaw, Indiana and Padova, Italy.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In <em style="font: inherit;"> June 2022, </em>the Company finalized renewal options to extend the current term of its leases for its building and manufacturing facility in Bedford as well as its <em style="font: inherit;">two</em> facilities in Sarasota. With the extension of these renewal options, the Bedford lease term extends to <em style="font: inherit;">2027</em> with several lease renewal options into <em style="font: inherit;">2038</em> and the <em style="font: inherit;">two</em> leases in Sarasota extend to <em style="font: inherit;">2027</em> but <em style="font: inherit;"> may </em>be extended by mutual agreement. The Sarasota leases also include a right to terminate in <em style="font: inherit;">2025</em> at the Company’s option. The current term of the Franklin lease extends to <em style="font: inherit;">2023</em> and the current term of the Padova lease extends to <em style="font: inherit;">2032,</em> with a right to terminate at the Company’s option without penalty.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes the Company’s significant commitments under lease agreements as of <em style="font: inherit;"> September 30, 2022:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Operating Leases</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2022 (Remainder of Year)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">720</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,760</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,873</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Present value adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,421</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Present value of lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Less current portion included in accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,922</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,183</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022, </em>the Company incurred lease expense of $0.8 million and $2.1 million, respectively. During the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>the Company incurred lease expense of $0.6 million and $1.9 million, respectively. As of <em style="font: inherit;"> September 30, 2022, </em>the weighted average remaining operating lease term was 15.0 years and the weighted average incremental borrowing rate used to determine the operating lease liability was 3.6%.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Operating Leases</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2022 (Remainder of Year)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">720</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,760</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,873</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Present value adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,421</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Present value of lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Less current portion included in accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,922</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,183</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 720000 3081000 3025000 3066000 2760000 27873000 9421000 31105000 1922000 29183000 800000 2100000 600000 1900000 P15Y 0.036 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em></b></p> </td><td style="vertical-align:top;width:183.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Accrued Expenses and Other Liabilities</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accrued expenses and other liabilities consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b> <b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b> <b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compensation and related expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,523</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professional fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,063</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,590</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating lease liability – current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,922</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical trial costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,352</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,961</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financing lease liability – current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">188</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,059</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,847</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b> <b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b> <b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compensation and related expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,523</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professional fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,063</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,590</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating lease liability – current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,922</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical trial costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,352</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,961</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financing lease liability – current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">188</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,059</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,847</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 11166000 9523000 3063000 3590000 1922000 1526000 1352000 1961000 0 188000 496000 1059000 17999000 17847000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b></p> </td><td style="vertical-align:top;width:183.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Commitments and Contingencies</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company <em style="font: inherit;"> may </em>also warrant that the products it manufactures do <em style="font: inherit;">not</em> infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any <em style="font: inherit;">third</em> party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties as of <em style="font: inherit;"> September 30, 2022 </em>or <em style="font: inherit;"> December 31, 2021 </em>and has <em style="font: inherit;">no</em> history of claims paid.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does <em style="font: inherit;">not</em> expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> October 21, 2021, </em>the Company received notice that the former unitholders of Parcus Medical had filed a request for arbitration regarding the earnout provisions agreed to in the Parcus Medical Merger Agreement. The Company has engaged in the arbitration process and does <em style="font: inherit;">not</em> anticipate a resolution during <em style="font: inherit;">2022.</em> The Company is unable to estimate the potential liability with respect to this matter at this time. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at this stage of the matter, including the significant number of legal and factual issues still to be resolved in the arbitration process. The Company intends to vigorously defend against the claims and believes it has strong defenses to the claims asserted.</p> 0 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b></p> </td><td style="vertical-align:top;width:183.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Revenue and Geographic Information</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Revenue by product family was as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">OA Pain Management</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26,153</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">69,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Joint Preservation and Restoration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,821</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,193</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,055</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-Orthopedics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,190</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,264</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,614</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">111,973</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Revenue from the Company’s sole significant customer, DePuy Synthes Mitek Sports Medicine (“Mitek”), part of the Johnson &amp; Johnson Medical Companies, as a percentage of the Company’s total revenue was 45% and 51% for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;">2021,</em> respectively, and 43% and 46% for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;">2021,</em> respectively</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company receives payments from our customers based on billing schedules established in each contract. Up-front payments are recorded as deferred revenue upon receipt or when due and <em style="font: inherit;"> may </em>require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Deferred revenue was $0.1 million and $1.0 million as of <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Total revenue by geographic location was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Geographic Location:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,093</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,910</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Europe</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,238</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,286</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,388</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,264</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Geographic Location:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">87,552</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">85,984</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Europe</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,973</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,089</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,614</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">111,973</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">OA Pain Management</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26,153</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">69,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Joint Preservation and Restoration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,821</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,193</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,055</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-Orthopedics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,190</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,887</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,264</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,614</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">111,973</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 25665000 26153000 74139000 69790000 11821000 11193000 36055000 35296000 2778000 2190000 6420000 6887000 40264000 39536000 116614000 111973000 0.45 0.51 0.43 0.46 100000 1000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Geographic Location:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,093</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,910</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Europe</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,885</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,238</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,286</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,388</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,264</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Geographic Location:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">87,552</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">85,984</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Europe</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,973</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,089</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,614</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">111,973</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> 31093000 0.77 30910000 0.78 4885000 0.12 4238000 0.11 4286000 0.11 4388000 0.11 40264000 1 39536000 1 87552000 0.75 85984000 0.77 15973000 0.14 14808000 0.13 13089000 0.11 11181000 0.10 116614000 1 111973000 1 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b></p> </td><td style="vertical-align:top;width:183.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Equity Incentive Plan</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Equity Incentive Plan</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Anika Therapeutics, Inc. <em style="font: inherit;">2017</em> Omnibus Incentive Plan (the <em style="font: inherit;">“2017</em> Plan”) was approved by the Company’s stockholders on <em style="font: inherit;"> June 13, 2017 </em>and subsequently amended on <em style="font: inherit;"> June 18, 2019, </em><em style="font: inherit;"> June 16, 2020, </em><em style="font: inherit;"> June 16, 2021 </em>and <em style="font: inherit;"> June 8, 2022. </em>On <em style="font: inherit;"> June 8, 2022, </em>the Company’s stockholders approved an amendment to the <em style="font: inherit;">2017</em> Plan increasing the number of shares by 250,000 shares from 4.6 million shares to 4.85 million shares. The <em style="font: inherit;">2017</em> Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights (“SARs”), restricted stock awards, performance restricted stock units (“PSUs”), restricted stock units (“RSUs”), total shareholder return options (“TSRs”) and performance options that <em style="font: inherit;"> may </em>be settled in cash, stock, or other property. In accordance with the <em style="font: inherit;">2017</em> Plan approved by the Company’s stockholders, including the amendments thereto, each share award other than stock options or SARs will reduce the number of total shares available for grant by two shares. Subject to adjustment for specified types of changes in the Company’s capitalization, <em style="font: inherit;">no</em> more than <em style="font: inherit;">4.85</em> million shares of common stock <em style="font: inherit;"> may </em>be issued under the <em style="font: inherit;">2017</em> Plan. There were 1.2 million shares available for future grant at <em style="font: inherit;"> September 30, 2022 </em>under the <em style="font: inherit;">2017</em> Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Anika Therapeutics, Inc. <em style="font: inherit;">2021</em> Inducement Plan (the “Inducement Plan”) was adopted by the Company’s board of directors on <em style="font: inherit;"> November 4, 2021. </em>The Inducement Plan reserves 125,000 shares of common stock for issuance pursuant to equity-based awards granted under the Inducement Plan. Such awards <em style="font: inherit;"> may </em>be granted only to an individual who was <em style="font: inherit;">not</em> previously the Company’s employee or director with the Company. The Inducement Plan provides for the grant of awards under terms substantially similar to the <em style="font: inherit;">2017</em> Plan (as amended). There were 4,883 shares available for future grant at <em style="font: inherit;"> September 30, 2022 </em>under the Inducement Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company <em style="font: inherit;"> may </em>satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to or greater than the market price of the Company’s stock on the date of grant. Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over <span style="-sec-ix-hidden:c90893160">three</span> years with a maximum contractual term of <span style="-sec-ix-hidden:c90893161">ten</span> years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cost of revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">645</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">485</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research &amp; development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,267</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,003</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Selling, general &amp; administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,361</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,590</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,431</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,876</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,863</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,502</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Options</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of <span style="-sec-ix-hidden:c90893164">three</span> years and expire 10 years after the date of grant. The grant-date fair value of options is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following summarizes the activity under the Company’s stock option plans:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 18pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;text-indent:-9pt;"><b><b>Number of Options</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 18pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;text-indent:-5pt;"><b><b>Weighted Average Exercise Price</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;text-indent:-6pt;"><b><b>Weighted Average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;text-indent:-6pt;"><b><b>Remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;text-indent:-6pt;"><b><b>Contractual</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;text-indent:-6pt;"><b><b>Term (in years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 27pt;text-indent:-5pt;"><b><b>Aggregate Intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;text-indent:-14pt;"><b><b>Value</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 27pt;text-indent:-14pt;"><b><b>(in thousands)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,175,993</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39.56</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">486,901</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(437</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forfeited and canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(156,672</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,505,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vested, September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499,617</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vested or expected to vest, September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,505,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The aggregate intrinsic value of options exercised for the <em style="font: inherit;">nine</em>-month period ended <em style="font: inherit;"> September 30, 2022 </em>was immaterial.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company granted 486,901 stock options during the <em style="font: inherit;">nine</em>-month ended <em style="font: inherit;"> September 30, 2022, </em>of which 398,314 shares were premium-priced options.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> September 30, 2022, </em>there was $8.7 million of unrecognized compensation cost related to unvested stock options. This expense is expected to be recognized over a weighted average period of 1.8 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The Company estimates the fair value of TSRs using Monte-Carlo simulation model where the expected volatility assumption is evaluated over 6.3 years. The actual number of TSR options that <em style="font: inherit;"> may </em>be earned ranges from 0% to 150% of the target number, depending on the total shareholder return of the Company relative to the peer group over the vesting period of 2.7 years. There were 104,638 TSRs as of <em style="font: inherit;"> September 30, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The assumptions used in the Black-Scholes pricing model for options granted during the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;">2021,</em> along with the weighted-average grant-date fair values, were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:21.3%;"> </td><td colspan="8" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:20.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Nine Months Ended September 30,</b></p> </td></tr> <tr><td style="vertical-align:bottom;width:21.3%;"> </td><td colspan="4" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td><td colspan="4" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk free interest rate</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893256">1.3%</span></p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893258">3.4%</span></p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893259">0.3%</span></p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893261">0.7%</span></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected volatility</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">53.8%</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55.5%</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">54.8%</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">56.1%</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected life (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.5</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.0</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected dividend yield</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893275">0.0%</span></p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893278">0.0%</span></p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fair value per option</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$11.26</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$14.55</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Restricted Stock Units</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">RSUs generally vest in equal annual installments over a <span style="-sec-ix-hidden:c90893180">three</span>-year period. The grant-date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of RSUs based on the closing price of its common stock on the date of grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">RSU activity for the <em style="font: inherit;">nine</em>-month period ended <em style="font: inherit;"> September 30, 2022 </em>was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Shares</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted Average Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">412,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">507,524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(159,871</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forfeited and cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(67,389</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">692,922</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The weighted-average grant-date fair value per share of RSUs granted was $25.14 for the <em style="font: inherit;">nine</em>-month period ended <em style="font: inherit;"> September 30, 2022. </em>The total fair value of RSUs vested was $5.8 million and $3.9 million for the <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> September 30, 2022, </em>there was $14.8 million of unrecognized compensation cost related to time-based RSUs, which was expected to be recognized over a weighted-average period of 2.0 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Performance Stock Units</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">PSU activity for the <em style="font: inherit;">nine</em>-month ended <em style="font: inherit;"> September 30, 2022 </em>was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Shares</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted Average Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">158,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Performance factor adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(19,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forfeited and cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">117,897</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34.98</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The total fair value of PSUs vested was $0.6 million and $0 for the <em style="font: inherit;">nine</em>-month period ended <em style="font: inherit;"> September 30, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. As of <em style="font: inherit;"> September 30, 2022, </em><em style="font: inherit;">none</em> of the milestones related to the outstanding PSUs were expected to be achieved.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 250000 4600000 4850000 2 1200000 125000 4883 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cost of revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">645</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">485</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research &amp; development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">360</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,267</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,003</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Selling, general &amp; administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,361</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,590</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,431</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,876</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,863</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,502</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 242000 142000 645000 485000 397000 360000 1267000 1003000 3237000 2361000 8590000 6431000 3876000 2863000 10502000 7919000 1.10 P10Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 18pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;text-indent:-9pt;"><b><b>Number of Options</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 18pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;text-indent:-5pt;"><b><b>Weighted Average Exercise Price</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;text-indent:-6pt;"><b><b>Weighted Average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;text-indent:-6pt;"><b><b>Remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;text-indent:-6pt;"><b><b>Contractual</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;text-indent:-6pt;"><b><b>Term (in years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 27pt;text-indent:-5pt;"><b><b>Aggregate Intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;text-indent:-14pt;"><b><b>Value</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 27pt;text-indent:-14pt;"><b><b>(in thousands)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,175,993</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39.56</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">486,901</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(437</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forfeited and canceled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(156,672</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">44.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,505,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vested, September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499,617</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vested or expected to vest, September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,505,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 1175993 39.56 486901 27.60 437 9.10 10000 156672 44.08 1505785 35.21 P8Y3M18D 78000 499617 40.00 P7Y3M18D 8000 1505785 35.21 P8Y3M18D 78000 486901 398314 8700000 P1Y9M18D P6Y3M18D 0 1.50 P2Y8M12D 104638 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:21.3%;"> </td><td colspan="8" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:20.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Nine Months Ended September 30,</b></p> </td></tr> <tr><td style="vertical-align:bottom;width:21.3%;"> </td><td colspan="4" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td><td colspan="4" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk free interest rate</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893256">1.3%</span></p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893258">3.4%</span></p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893259">0.3%</span></p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893261">0.7%</span></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected volatility</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">53.8%</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55.5%</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">54.8%</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-</p> </td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">56.1%</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected life (years)</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.5</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.0</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Expected dividend yield</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893275">0.0%</span></p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c90893278">0.0%</span></p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:21.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fair value per option</p> </td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$11.26</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:0.5%;"> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td><td style="vertical-align:bottom;width:3.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$14.55</p> </td><td style="vertical-align:bottom;width:3.7%;"><em style="font: inherit;"> </em></td></tr> </tbody></table> 0.538 0.555 0.548 0.561 P4Y6M P4Y 0.1126 0.1455 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Shares</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted Average Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">412,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">507,524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(159,871</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forfeited and cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(67,389</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">692,922</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 412658 36.33 507524 25.14 159871 36.48 67389 32.45 692922 28.48 25.14 5800000 3900000 14800000 P2Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Shares</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted Average Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">158,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Performance factor adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(19,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forfeited and cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outstanding as of September 30, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">117,897</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34.98</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 158297 37.44 2125 32.53 19125 32.53 23400 41.86 117897 34.98 600000 0 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em></b></p> </td><td style="vertical-align:top;width:183.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Income Taxes</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company recorded an income tax benefit of $1.2 million and $2.4 million for the <em style="font: inherit;">three</em>- and <em style="font: inherit;">nine</em>-month periods ended  <em style="font: inherit;"> September 30, 2022</em><i>,</i> resulting in effective tax rates of 22.1% and 19.5%, respectively. The Company recorded income tax expense of $0.7 million and $1.7 million for the <em style="font: inherit;">three</em>- and <em style="font: inherit;">nine</em>-month periods ended  <em style="font: inherit;"> September 30, 2021, </em>based on effective tax rates of 55.4% and 14.4%, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The decrease in the effective tax rate for the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> September 30, 2022, </em>as compared to the same period in <em style="font: inherit;">2021,</em> was primarily due to non-deductible stock-option activity during the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> September 30, 2021. </em>The increase in the effective tax rate for the <em style="font: inherit;">nine</em>-month period ended  <em style="font: inherit;"> September 30, 2022, </em>as compared to the same period in <em style="font: inherit;">2021,</em> was primarily due to the year-to-date net tax benefit in <em style="font: inherit;">2021</em> on the change in the fair value of contingent consideration, in the amount of $1.1 million, and a year-to-date discrete charge of $0.7 million in <em style="font: inherit;">2022</em> related to non-deductible stock compensation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate, which varies by jurisdiction.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In connection with the preparation of the financial statements, the Company assessed whether it is more likely than <em style="font: inherit;">not</em> that it will be able to utilize, in future periods, the Company’s deferred income tax assets to offset future taxable income and tax liabilities. The Company concluded that it is more likely than <em style="font: inherit;">not</em> that its deferred tax assets will be realized, after evaluation and consideration of both the positive and negative evidence. On <em style="font: inherit;"> December 31, 2021, </em>the Company released a valuation allowance that had been previously recorded related to its net deferred tax assets in Italy in the amount of $0.9 million. The Company did <span style="-sec-ix-hidden:c90893331">not</span> record a valuation allowance on its deferred tax balances as of <em style="font: inherit;"> September 30, 2022.</em></p> -1200000 -2400000 0.221 0.195 700000 1700000 0.554 0.144 1100000 700000 -900000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:6.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">14.</em></b></p> </td><td style="vertical-align:top;width:183.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Earnings Per Share (</b>“<b>EPS</b>”<b>)</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are <em style="font: inherit;">not</em> considered outstanding for purposes of calculating basic EPS. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding share-based awards using the treasury stock method</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table provides share information used in the calculation of the Company's basic and diluted earnings per share (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Month Period Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Shares used in the calculation of basic earnings per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,603</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,429</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,542</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,389</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Effect of dilutive securities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Share-based payment awards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diluted shares used in the calculation of earnings per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,603</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,647</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,542</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,588</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company had a net loss during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em>-months ended <em style="font: inherit;"> September 30, 2022, </em>and therefore all potential common shares would have been anti-dilutive and accordingly were excluded from the computation of diluted EPS. Stock options of 1.1 million shares were outstanding for the <em style="font: inherit;">nine</em>-month period ended <em style="font: inherit;"> September 30, 2021, </em>respectively, and were <em style="font: inherit;">not</em> included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding: 0px; width: 0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Month Period Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Shares used in the calculation of basic earnings per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,603</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,429</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,542</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,389</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Effect of dilutive securities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Share-based payment awards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diluted shares used in the calculation of earnings per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,603</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,647</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,542</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,588</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 14603000 14429000 14542000 14389000 0 218000 0 199000 14603000 14647000 14542000 14588000 1100000 EXCEL 68 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ࣈ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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 70 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 218 271 1 false 42 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited- Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited- Consolidated Statements of Operations and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited- Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited- Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Basis of Presentation Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation- Note 2 - Basis of Presentation Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Business Combinations Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations Note 3 - Business Combinations Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Inventories Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories Note 5 - Inventories Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Intangible Assets Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets- Note 6 - Intangible Assets Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Goodwill Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill Note 7 - Goodwill Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Leases Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases Note 8 - Leases Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities Note 9 - Accrued Expenses and Other Liabilities Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Commitments and Contingencies Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies Note 10 - Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Revenue and Geographic Information Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information Note 11 - Revenue and Geographic Information Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Equity Incentive Plan Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan Note 12 - Equity Incentive Plan Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Income Taxes Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes Note 13 - Income Taxes Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Earnings Per Share ("EPS") Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps Note 14 - Earnings Per Share ("EPS") Notes 20 false false R21.htm 020 - Disclosure - Note 3 - Business Combinations (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables Note 3 - Business Combinations (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations 21 false false R22.htm 021 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements 22 false false R23.htm 022 - Disclosure - Note 5 - Inventories (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables Note 5 - Inventories (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories 23 false false R24.htm 023 - Disclosure - Note 6 - Intangible Assets (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables Note 6 - Intangible Assets (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets- 24 false false R25.htm 024 - Disclosure - Note 7 - Goodwill (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables Note 7 - Goodwill (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill 25 false false R26.htm 025 - Disclosure - Note 8 - Leases (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables Note 8 - Leases (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases 26 false false R27.htm 026 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables Note 9 - Accrued Expenses and Other Liabilities (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities 27 false false R28.htm 027 - Disclosure - Note 11 - Revenue and Geographic Information (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables Note 11 - Revenue and Geographic Information (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information 28 false false R29.htm 028 - Disclosure - Note 12 - Equity Incentive Plan (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables Note 12 - Equity Incentive Plan (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan 29 false false R30.htm 029 - Disclosure - Note 14 - Earnings Per Share ("EPS") (Tables) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables Note 14 - Earnings Per Share ("EPS") (Tables) Tables http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps 30 false false R31.htm 030 - Disclosure - Note 3 - Business Combinations (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual Note 3 - Business Combinations (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables 31 false false R32.htm 031 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details Note 3 - Business Combinations - Consideration Transferred (Details) Details 32 false false R33.htm 032 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) Details 33 false false R34.htm 033 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details Note 3 - Business Combinations - Intangible Assets Acquired (Details) Details 34 false false R35.htm 034 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Details 35 false false R36.htm 035 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details Note 4 - Fair Value Measurements - Contingent Consideration (Details) Details 36 false false R37.htm 036 - Disclosure - Note 5 - Inventories (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual Note 5 - Inventories (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables 37 false false R38.htm 037 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details Note 5 - Inventories - Summary of Inventories (Details) Details 38 false false R39.htm 038 - Disclosure - Note 6 - Intangible Assets (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual Note 6 - Intangible Assets (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables 39 false false R40.htm 039 - Disclosure - Note 6 - Intangible Assets - Summary of Intangible Assets (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details Note 6 - Intangible Assets - Summary of Intangible Assets (Details) Details 40 false false R41.htm 040 - Disclosure - Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Details 41 false false R42.htm 041 - Disclosure - Note 8 - Leases (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual Note 8 - Leases (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables 42 false false R43.htm 042 - Disclosure - Note 8 - Leases - Future Minimum Rental Payments for Leases (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details Note 8 - Leases - Future Minimum Rental Payments for Leases (Details) Details 43 false false R44.htm 043 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) Details 44 false false R45.htm 044 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual Note 10 - Commitments and Contingencies (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies 45 false false R46.htm 045 - Disclosure - Note 11 - Revenue and Geographic Information (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual Note 11 - Revenue and Geographic Information (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables 46 false false R47.htm 046 - Disclosure - Note 11 - Revenue and Geographic Information - Revenues (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details Note 11 - Revenue and Geographic Information - Revenues (Details) Details http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables 47 false false R48.htm 047 - Disclosure - Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) Details 48 false false R49.htm 048 - Disclosure - Note 12 - Equity Incentive Plan (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual Note 12 - Equity Incentive Plan (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables 49 false false R50.htm 049 - Disclosure - Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Details 50 false false R51.htm 050 - Disclosure - Note 12 - Equity Incentive Plan - Stock Options (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details Note 12 - Equity Incentive Plan - Stock Options (Details) Details 51 false false R52.htm 051 - Disclosure - Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Details 52 false false R53.htm 052 - Disclosure - Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details) Details 53 false false R54.htm 053 - Disclosure - Note 12 - Equity Incentive Plan - Performance Stock Units (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details Note 12 - Equity Incentive Plan - Performance Stock Units (Details) Details 54 false false R55.htm 054 - Disclosure - Note 13 - Income Taxes (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual Note 13 - Income Taxes (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes 55 false false R56.htm 055 - Disclosure - Note 14 - Earnings Per Share ("EPS") (Details Textual) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual Note 14 - Earnings Per Share ("EPS") (Details Textual) Details http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables 56 false false R57.htm 056 - Disclosure - Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Sheet http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details Note 14 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Details http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables 57 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 32 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DeferredTaxAssetsValuationAllowance, us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProductWarrantyAccrual, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod - anik20220930_10q.htm 8, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 anik20220930_10q.htm anik-20220930.xsd anik-20220930_cal.xml anik-20220930_def.xml anik-20220930_lab.xml anik-20220930_pre.xml ex_440237.htm ex_440238.htm ex_440239.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "anik20220930_10q.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 218, "dts": { "calculationLink": { "local": [ "anik-20220930_cal.xml" ] }, "definitionLink": { "local": [ "anik-20220930_def.xml" ] }, "inline": { "local": [ "anik20220930_10q.htm" ] }, "labelLink": { "local": [ "anik-20220930_lab.xml" ] }, "presentationLink": { "local": [ "anik-20220930_pre.xml" ] }, "schema": { "local": [ "anik-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 399, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 33, "http://xbrl.sec.gov/dei/2022": 6, "total": 39 }, "keyCustom": 27, "keyStandard": 244, "memberCustom": 13, "memberStandard": 29, "nsprefix": "anik", "nsuri": "http://www.anikatherapeutics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Fair Value Measurements", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements", "shortName": "Note 4 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Inventories", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories", "shortName": "Note 5 - Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Intangible Assets", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-", "shortName": "Note 6 - Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Goodwill", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill", "shortName": "Note 7 - Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Leases", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases", "shortName": "Note 8 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities", "shortName": "Note 9 - Accrued Expenses and Other Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Commitments and Contingencies", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies", "shortName": "Note 10 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Revenue and Geographic Information", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information", "shortName": "Note 11 - Revenue and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Equity Incentive Plan", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "shortName": "Note 12 - Equity Incentive Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Income Taxes", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "shortName": "Note 13 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "shortName": "Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Earnings Per Share (\"EPS\")", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps", "shortName": "Note 14 - Earnings Per Share (\"EPS\")", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 3 - Business Combinations (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables", "shortName": "Note 3 - Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 4 - Fair Value Measurements (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables", "shortName": "Note 4 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 5 - Inventories (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables", "shortName": "Note 5 - Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 6 - Intangible Assets (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables", "shortName": "Note 6 - Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 7 - Goodwill (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables", "shortName": "Note 7 - Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "anik:LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 8 - Leases (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables", "shortName": "Note 8 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "anik:LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables", "shortName": "Note 9 - Accrued Expenses and Other Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 11 - Revenue and Geographic Information (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables", "shortName": "Note 11 - Revenue and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 12 - Equity Incentive Plan (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables", "shortName": "Note 12 - Equity Incentive Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 14 - Earnings Per Share (\"EPS\") (Tables)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables", "shortName": "Note 14 - Earnings Per Share (\"EPS\") (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 3 - Business Combinations (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "shortName": "Note 3 - Business Combinations (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2020-01-24_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-7", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2020-01-24_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "shortName": "Note 3 - Business Combinations - Consideration Transferred (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2020-01-24_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "shortName": "Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "shortName": "Note 3 - Business Combinations - Intangible Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "shortName": "Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "shortName": "Note 4 - Fair Value Measurements - Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 5 - Inventories (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual", "shortName": "Note 5 - Inventories (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details", "shortName": "Note 5 - Inventories - Summary of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 6 - Intangible Assets (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual", "shortName": "Note 6 - Intangible Assets (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 6 - Intangible Assets - Summary of Intangible Assets (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "shortName": "Note 6 - Intangible Assets - Summary of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details", "shortName": "Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": "-4", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 8 - Leases (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual", "shortName": "Note 8 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 8 - Leases - Future Minimum Rental Payments for Leases (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "shortName": "Note 8 - Leases - Future Minimum Rental Payments for Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "shortName": "Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual", "shortName": "Note 10 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "2", "first": true, "lang": null, "name": "anik:RevenuesFromAgreementsAsPercentOfTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 11 - Revenue and Geographic Information (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual", "shortName": "Note 11 - Revenue and Geographic Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "2", "first": true, "lang": null, "name": "anik:RevenuesFromAgreementsAsPercentOfTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 11 - Revenue and Geographic Information - Revenues (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details", "shortName": "Note 11 - Revenue and Geographic Information - Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30_ProductOrServiceAxis-OAPainManagementMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "shortName": "Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "0", "lang": null, "name": "anik:PercentageOfNetRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 12 - Equity Incentive Plan (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "shortName": "Note 12 - Equity Incentive Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30_AwardTypeAxis-PremiumPricedEmployeeStockOptionsMember", "decimals": "1", "lang": null, "name": "anik:SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details", "shortName": "Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 12 - Equity Incentive Plan - Stock Options (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details", "shortName": "Note 12 - Equity Incentive Plan - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "shortName": "Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": "4", "lang": null, "name": "anik:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details", "shortName": "Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-PerformanceSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 12 - Equity Incentive Plan - Performance Stock Units (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "shortName": "Note 12 - Equity Incentive Plan - Performance Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-PerformanceSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 13 - Income Taxes (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual", "shortName": "Note 13 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 14 - Earnings Per Share (\"EPS\") (Details Textual)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual", "shortName": "Note 14 - Earnings Per Share (\"EPS\") (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 14 - Earnings Per Share (\"EPS\") - Basic and Diluted Earnings Per Share (Details)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "shortName": "Note 14 - Earnings Per Share (\"EPS\") - Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-07-01_2022-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Nature of Business", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business", "shortName": "Note 1 - Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Basis of Presentation", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation-", "shortName": "Note 2 - Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Business Combinations", "role": "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "shortName": "Note 3 - Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20220930_10q.htm", "contextRef": "d_2022-01-01_2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "anik_APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition of cost (benefit) for award under share-based payment arrangement.", "label": "anik_APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit", "terseLabel": "Stock-based compensation expense" } } }, "localname": "APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "monetaryItemType" }, "anik_AccruedClinicalTrialCostsCurrent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents accrued clinical trial costs current.", "label": "anik_AccruedClinicalTrialCostsCurrent", "verboseLabel": "Clinical trial costs" } } }, "localname": "AccruedClinicalTrialCostsCurrent", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "anik_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to accrued expenses and other current liabilities.", "label": "Accrued Expenses and Other Current Liabilities [Member]" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "domainItemType" }, "anik_AccumulatedCurrencyTranslationAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of the accumulated currency translation adjustment.", "label": "anik_AccumulatedCurrencyTranslationAdjustment", "negatedLabel": "Accumulated Currency Translation Adjustment" } } }, "localname": "AccumulatedCurrencyTranslationAdjustment", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "anik_AmortizationOfAcquisitionRelatedIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expenses related to the acquisition related intangible assets.", "label": "Amortization of acquisition related intangible assets" } } }, "localname": "AmortizationOfAcquisitionRelatedIntangibleAssets", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "anik_AmortizationOfAcquisitionRelatedInventoryStepUp": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expenses related to the acquisition inventory step-up.", "label": "Amortization of acquisition related inventory step-up" } } }, "localname": "AmortizationOfAcquisitionRelatedInventoryStepUp", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "anik_ArthrosurfaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Arthrosurface.", "label": "Arthrosurface [Member]" } } }, "localname": "ArthrosurfaceMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "domainItemType" }, "anik_BusinessCombinationConsiderationTransferredDeferredConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred consideration by the acquirer as part of consideration transferred in a business combination.", "label": "Deferred consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredDeferredConsideration", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details" ], "xbrltype": "monetaryItemType" }, "anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease, right of use assets acquired at the acquisition date.", "label": "anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "verboseLabel": "Right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease right-of-use liabilities assumed at the acquisition date.", "label": "anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseLiabilities", "negatedLabel": "Lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseLiabilities", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "anik_CashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the fair value disclosure for cash equivalents as of the balance sheet date.", "label": "anik_CashEquivalentsFairValueDisclosure", "verboseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsFairValueDisclosure", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "anik_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the contingent consideration.", "label": "Contingent Consideration [Member]" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "domainItemType" }, "anik_IncomeTaxExpenseBenefitChangeInFairValueOfContingentConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to change in fair value of contingent consideration in continuing operations.", "label": "anik_IncomeTaxExpenseBenefitChangeInFairValueOfContingentConsideration", "terseLabel": "Income Tax Expense (Benefit), Change in Fair Value of Contingent Consideration" } } }, "localname": "IncomeTaxExpenseBenefitChangeInFairValueOfContingentConsideration", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "anik_IncreaseDecreaseInContingentConsideration": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability.", "label": "anik_IncreaseDecreaseInContingentConsideration", "terseLabel": "Contingent consideration" } } }, "localname": "IncreaseDecreaseInContingentConsideration", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "anik_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the lease liabilities.", "label": "anik_IncreaseDecreaseInLeaseLiabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of raw materials, work in process and finished goods.", "label": "anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal", "terseLabel": "Total" } } }, "localname": "InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "anik_JointPreservationAndRestorationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Joint Preservation and Restoration.", "label": "Joint Preservation and Restoration [Member]" } } }, "localname": "JointPreservationAndRestorationMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details" ], "xbrltype": "domainItemType" }, "anik_LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease and finance lease liability.", "label": "Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables" ], "xbrltype": "textBlockItemType" }, "anik_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "anik_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "terseLabel": "Thereafter, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "anik_LesseeOperatingLeasesAndFinanceLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases and finance leases of lessee.", "label": "Lessee, Operating Leases and Finance Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesAndFinanceLeasesTextBlock", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases" ], "xbrltype": "textBlockItemType" }, "anik_LiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to liabilities.", "label": "Liabilities [Member]" } } }, "localname": "LiabilitiesMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "domainItemType" }, "anik_NonorthopedicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents non-orthopedic.", "label": "Non-Orthopedic [Member]" } } }, "localname": "NonorthopedicMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details" ], "xbrltype": "domainItemType" }, "anik_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_NumberOfSharesAvailableForGrantReducedByEachShareAwardIssuedOtherThanOptionsOrSARs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares by which shares available for grant is reduced for each share award issued after a specified date other than options or stock appreciation rights.", "label": "anik_NumberOfSharesAvailableForGrantReducedByEachShareAwardIssuedOtherThanOptionsOrSARs", "terseLabel": "Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs (in shares)" } } }, "localname": "NumberOfSharesAvailableForGrantReducedByEachShareAwardIssuedOtherThanOptionsOrSARs", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "anik_OAPainManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents QA pain management.", "label": "OA Pain Management [member]" } } }, "localname": "OAPainManagementMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details" ], "xbrltype": "domainItemType" }, "anik_OtherLocationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents other location.", "label": "Other Location [Member]" } } }, "localname": "OtherLocationMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "domainItemType" }, "anik_ParcusMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Parcus Medical.", "label": "Parcus Medical [Member]" } } }, "localname": "ParcusMedicalMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details" ], "xbrltype": "domainItemType" }, "anik_PercentageOfNetRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net revenue.", "label": "Percentage of Revenue" } } }, "localname": "PercentageOfNetRevenue", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "percentItemType" }, "anik_PremiumPricedEmployeeStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to premium priced employee stock options.", "label": "Premium-Priced Employee Stock Options [Member]" } } }, "localname": "PremiumPricedEmployeeStockOptionsMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_ProvisionForDoubtfulAccountsNetOfRecoveries": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense credit loss on accounts receivable, net of recoveries.", "label": "Provision (recovery) for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccountsNetOfRecoveries", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "anik_RevenuesFromAgreementsAsPercentOfTotalRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of total revenue that revenue from agreements comprises.", "label": "anik_RevenuesFromAgreementsAsPercentOfTotalRevenue", "terseLabel": "Revenues From Agreements as Percent of Total Revenue" } } }, "localname": "RevenuesFromAgreementsAsPercentOfTotalRevenue", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual" ], "xbrltype": "percentItemType" }, "anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class.", "label": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]" } } }, "localname": "ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents schedule of revenue and operating income, by geographical areas.", "label": "Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]" } } }, "localname": "ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables" ], "xbrltype": "textBlockItemType" }, "anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents fair value per option related to share based compensation arrangement by share based payment award.", "label": "Fair value per option" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" ], "xbrltype": "pureItemType" }, "anik_SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date related to performance factor adjustment.", "label": "Performance factor adjustment (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details" ], "xbrltype": "perShareItemType" }, "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that are related to performance factor adjustment during the reporting period.", "label": "Performance factor adjustment (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceFactorAdjustmentInPeriod", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details" ], "xbrltype": "sharesItemType" }, "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfTargetNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of target market for actual number of shares that may be earned for share-based compensation.", "label": "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfTargetNumber", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfTargetNumber", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The exercise price of premium priced options granted during the reporting period represented as percentage of market price.", "label": "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Premium Priced Options, Exercise Price as Percentage of Market Price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_The2017PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Anika Therapeutics, Inc. Omnibus Incentive Plan (the \u201c2017 Plan\u201d).", "label": "The 2017 Plan [Member]" } } }, "localname": "The2017PlanMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_The2021InducementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2021 Inducement Plan.", "label": "The 2021 Inducement Plan [Member]" } } }, "localname": "The2021InducementPlanMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_TotalShareholderReturnTsrsOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to total shareholder return (\"TSRs\") options.", "label": "Total Shareholder Return (\"TSRs\") Options [Member]" } } }, "localname": "TotalShareholderReturnTsrsOptionsMember", "nsuri": "http://www.anikatherapeutics.com/20220930", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_statement-statement-note-11-revenue-and-geographic-information-revenues-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Revenue and Geographic Information - Revenues (Details)" } } }, "localname": "statement-statement-note-11-revenue-and-geographic-information-revenues-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-11-revenue-and-geographic-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Revenue and Geographic Information" } } }, "localname": "statement-statement-note-11-revenue-and-geographic-information-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)" } } }, "localname": "statement-statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)" } } }, "localname": "statement-statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-12-equity-incentive-plan-performance-stock-units-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Equity Incentive Plan - Performance Stock Units (Details)" } } }, "localname": "statement-statement-note-12-equity-incentive-plan-performance-stock-units-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-12-equity-incentive-plan-restricted-stock-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Equity Incentive Plan - Restricted Stock Activity (Details)" } } }, "localname": "statement-statement-note-12-equity-incentive-plan-restricted-stock-activity-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-12-equity-incentive-plan-stock-options-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Equity Incentive Plan - Stock Options (Details)" } } }, "localname": "statement-statement-note-12-equity-incentive-plan-stock-options-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-12-equity-incentive-plan-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Equity Incentive Plan" } } }, "localname": "statement-statement-note-12-equity-incentive-plan-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Earnings Per Share (\"EPS\") - Basic and Diluted Earnings Per Share (Details)" } } }, "localname": "statement-statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-14-earnings-per-share-eps-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Earnings Per Share (\"EPS\")" } } }, "localname": "statement-statement-note-14-earnings-per-share-eps-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-consideration-transferred-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations - Consideration Transferred (Details)" } } }, "localname": "statement-statement-note-3-business-combinations-consideration-transferred-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details)" } } }, "localname": "statement-statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-intangible-assets-acquired-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations - Intangible Assets Acquired (Details)" } } }, "localname": "statement-statement-note-3-business-combinations-intangible-assets-acquired-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations" } } }, "localname": "statement-statement-note-3-business-combinations-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-4-fair-value-measurements-contingent-consideration-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements - Contingent Consideration (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurements-contingent-consideration-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-4-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements" } } }, "localname": "statement-statement-note-4-fair-value-measurements-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-5-inventories-summary-of-inventories-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Inventories - Summary of Inventories (Details)" } } }, "localname": "statement-statement-note-5-inventories-summary-of-inventories-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-5-inventories-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Inventories" } } }, "localname": "statement-statement-note-5-inventories-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-6-intangible-assets-summary-of-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Intangible Assets - Summary of Intangible Assets (Details)" } } }, "localname": "statement-statement-note-6-intangible-assets-summary-of-intangible-assets-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-6-intangible-assets-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Intangible Assets" } } }, "localname": "statement-statement-note-6-intangible-assets-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details)" } } }, "localname": "statement-statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-7-goodwill-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Goodwill" } } }, "localname": "statement-statement-note-7-goodwill-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-8-leases-future-minimum-rental-payments-for-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Leases - Future Minimum Rental Payments for Leases (Details)" } } }, "localname": "statement-statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-8-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Leases" } } }, "localname": "statement-statement-note-8-leases-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "anik_statement-statement-note-9-accrued-expenses-and-other-liabilities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Accrued Expenses and Other Liabilities" } } }, "localname": "statement-statement-note-9-accrued-expenses-and-other-liabilities-tables", "nsuri": "http://www.anikatherapeutics.com/20220930", "xbrltype": "stringItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information", "http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation-", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information", "http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation-", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r183", "r184", "r185", "r186", "r201", "r206", "r236", "r238", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r454", "r457", "r481", "r482" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r183", "r184", "r185", "r186", "r201", "r206", "r236", "r238", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r454", "r457", "r481", "r482" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r130", "r184", "r185", "r220", "r223", "r422", "r453", "r455" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r130", "r184", "r185", "r220", "r223", "r422", "r453", "r455" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r178", "r183", "r184", "r185", "r186", "r201", "r206", "r226", "r236", "r238", "r267", "r268", "r269", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r454", "r457", "r481", "r482" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r178", "r183", "r184", "r185", "r186", "r201", "r206", "r226", "r236", "r238", "r267", "r268", "r269", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r454", "r457", "r481", "r482" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r131", "r132", "r220", "r224", "r456", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r131", "r132", "r220", "r224", "r456", "r470", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34", "r410" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedProfessionalFeesCurrent", "verboseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r43", "r44", "r45", "r442", "r465", "r469" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r42", "r45", "r52", "r53", "r54", "r85", "r86", "r87", "r339", "r407", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r85", "r86", "r87", "r279", "r280", "r281", "r352" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r88", "r89", "r90", "r91", "r100", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r279", "r280", "r281", "r295", "r296", "r297", "r298", "r320", "r321", "r322", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r385", "r386", "r388", "r389", "r390", "r391", "r402", "r403", "r404", "r405", "r406", "r407", "r424", "r425", "r426", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Retirement of common stock for minimum tax withholdings" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r25", "r134", "r145" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable, reserves" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r73", "r166", "r172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r16", "r80", "r120", "r123", "r128", "r138", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r336", "r340", "r368", "r408", "r410", "r430", "r441" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r33", "r80", "r138", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r336", "r340", "r368", "r408", "r410" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r263", "r264", "r266", "r267", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r235", "r237", "r315" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r235", "r237", "r310", "r311", "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r325", "r326", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Estimated total purchase consideration", "terseLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r323", "r325", "r326", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Estimated fair value of contingent consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r72", "r331" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r332" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r324", "r327" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Contingent consideration", "terseLabel": "Business Combination, Contingent Consideration, Liability, Current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r316", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "verboseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "negatedLabel": "Accounts payable, accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "negatedLabel": "Deferred tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "verboseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r312", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "verboseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r312", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "verboseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r312", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "verboseLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "negatedLabel": "Other long-term liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "verboseLabel": "Other long-term assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r312", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "verboseLabel": "Property and equipment, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "verboseLabel": "Estimated total purchase consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r84", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r76", "r77", "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r12", "r75" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r70", "r75", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r70", "r377" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r39", "r433", "r446" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 10)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r180", "r181", "r182", "r187", "r471" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r85", "r86", "r352" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r207" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r410" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.01 par value; 90,000 shares authorized, 14,607 and 14,441 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r48", "r50", "r51", "r59", "r437", "r449" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive (loss) income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r209", "r210", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r63", "r422" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r61" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r73", "r81", "r294", "r301", "r302", "r303" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r284", "r285" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r73", "r175" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r239", "r240", "r273", "r274", "r276", "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps", "http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation-", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities" ], "xbrltype": "stringItemType" }, "us-gaap_DistributionRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.", "label": "Distribution Rights [Member]" } } }, "localname": "DistributionRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r60", "r92", "r93", "r94", "r95", "r96", "r101", "r103", "r105", "r106", "r107", "r111", "r112", "r353", "r354", "r438", "r450" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "us-gaap_EarningsPerShareBasic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r60", "r92", "r93", "r94", "r95", "r96", "r103", "r105", "r106", "r107", "r111", "r112", "r353", "r354", "r438", "r450" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "us-gaap_EarningsPerShareDiluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r108", "r109", "r110", "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r377" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Exchange rate impact on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "verboseLabel": "Compensation and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r52", "r53", "r54", "r85", "r86", "r87", "r89", "r97", "r99", "r114", "r142", "r207", "r208", "r279", "r280", "r281", "r297", "r298", "r352", "r378", "r379", "r380", "r381", "r382", "r384", "r407", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r202", "r203", "r204", "r365" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r356", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r202", "r203", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r357", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r202", "r203", "r204", "r356", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r202", "r227", "r228", "r233", "r234", "r357", "r411" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r202", "r203", "r204", "r227", "r228", "r233", "r234", "r357", "r412" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r202", "r203", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r357", "r413" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r358", "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "negatedLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r202", "r203", "r204", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r393" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "us-gaap_FinanceLeaseLiabilityCurrent", "verboseLabel": "Financing lease liability \u2013 current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r395", "r396" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "us-gaap_FinanceLeasePrincipalPayments", "negatedLabel": "Payments made on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Useful life (Year)", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r14", "r171" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r167", "r168", "r171", "r173", "r423", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r167", "r170" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Loss on disposal of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r13", "r150", "r151", "r158", "r163", "r410", "r429" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r159", "r161", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r156" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillForeignCurrencyTranslationGainLoss", "terseLabel": "Effect of foreign currency adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r62", "r80", "r120", "r122", "r124", "r127", "r129", "r138", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r368" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r56", "r120", "r122", "r124", "r127", "r129", "r428", "r434", "r439", "r451" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "(Loss) income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r177", "r179" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r82", "r288", "r290", "r293", "r299", "r304", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r98", "r99", "r119", "r286", "r300", "r305", "r452" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "(Benefit from) provision for income taxes", "terseLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r287" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r72" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r72" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r72" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r72" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses, other current and long-term liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r72" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r72" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses, other current and long-term assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r13" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Gross value" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r165", "r169" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net", "terseLabel": "Net book value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest and other income (expense), net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r26", "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r32", "r410" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories, net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r15" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "us-gaap_InventoryNoncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r28", "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r32", "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r27", "r148" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r146" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Provision for inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2023, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2026, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2025, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2024, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2022 (Remainder of Year), operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Present value adjustment, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r80", "r138", "r368", "r410", "r431", "r444" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r10", "r37", "r80", "r138", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r337", "r340", "r341", "r368", "r408", "r409", "r410" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Accounts receivable, less allowance for credit losses of $1,566 and $1,442 at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Italy.", "label": "Ministry of Economic Affairs and Finance, Italy [Member]" } } }, "localname": "MinistryOfEconomicAffairsAndFinanceItalyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r70" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r70" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r70", "r71", "r74" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r46", "r49", "r54", "r57", "r74", "r80", "r88", "r92", "r93", "r94", "r95", "r98", "r99", "r104", "r120", "r122", "r124", "r127", "r129", "r138", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r354", "r368", "r435", "r447" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net (loss) income", "totalLabel": "Net (loss) income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r120", "r122", "r124", "r127", "r129" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "(Loss) income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "us-gaap_OperatingLeaseLiability", "verboseLabel": "Present value of lease payments, operating leases" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r393" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "us-gaap_OperatingLeaseLiabilityCurrent", "negatedLabel": "Less current portion included in Accrued expenses and other current liabilities, operating leases", "verboseLabel": "Operating lease liability \u2013 current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r393" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liabilities", "terseLabel": "Total lease liabilities, operating leases" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r392" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Non-cash operating lease cost" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r399", "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r398", "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r15" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r334", "r335", "r338" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r47", "r50", "r52", "r53", "r55", "r58", "r207", "r378", "r383", "r384", "r436", "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "us-gaap_OtherNoncashIncomeExpense", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities", "negatedLabel": "Contingent consideration payout", "terseLabel": "Payment for Contingent Consideration Liability, Financing Activities" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r68" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Cash paid for tax withheld on vested restricted stock awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r65", "r329" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r65" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "negatedLabel": "Acquisition of Parcus Medical and Arthrosurface, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r263", "r264", "r266", "r267", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r263", "r264", "r266", "r267", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member] [Default]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r205" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r205" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r410" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r67", "r278" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercises of equity awards" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r188", "r189", "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "us-gaap_ProductWarrantyAccrual", "terseLabel": "Standard and Extended Product Warranty Accrual, Ending Balance" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r176", "r410", "r440", "r445" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r283", "r421", "r483" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research & development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r208", "r410", "r443", "r464", "r469" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r85", "r86", "r87", "r89", "r97", "r99", "r142", "r279", "r280", "r281", "r297", "r298", "r352", "r460", "r462" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r117", "r118", "r121", "r125", "r126", "r130", "r131", "r133", "r219", "r220", "r422" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r222", "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r397", "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r29", "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r243", "r259", "r262" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general & administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited and cancelled, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Forfeited and cancelled, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted, weighted average grant date fair value (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Outstanding, weighted average grant date fair value (in dollars per share)", "periodStartLabel": "Outstanding, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested, shares (in shares)", "negatedTerseLabel": "Vested, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Exercised, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited and canceled, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Granted, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, Weighted Average Exercise (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r240", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r263", "r264", "r266", "r267", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited and canceled, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life (years) (Year)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Vested, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Vested, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Outstanding, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Vested, shares (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Vested, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation", "negatedLabel": "Retirement of common stock for minimum tax withholdings (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r41", "r52", "r53", "r54", "r85", "r86", "r87", "r89", "r97", "r99", "r114", "r142", "r207", "r208", "r279", "r280", "r281", "r297", "r298", "r352", "r378", "r379", "r380", "r381", "r382", "r384", "r407", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation-", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r85", "r86", "r87", "r114", "r422" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies", "http://www.anikatherapeutics.com/20220930/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-revenues-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-restricted-stock-activity-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes", "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-2-basis-of-presentation-", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-summary-of-inventories-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r17", "r18", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Issuance of ESPP shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r17", "r18", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r17", "r18", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Issuance of common stock for equity awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r207", "r208", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "negatedLabel": "Exercised, shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r17", "r18", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Issuance of ESPP shares" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r17", "r18", "r208", "r260" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Issuance of common stock for equity awards" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r80", "r135", "r138", "r368", "r410" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Balance", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-11-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-12-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-7-goodwill-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-8-leases-tables", "http://www.anikatherapeutics.com/20220930/role/statement-note-9-accrued-expenses-and-other-liabilities-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20220930/role/statement-note-6-intangible-assets-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r88", "r89", "r90", "r91", "r100", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r279", "r280", "r281", "r295", "r296", "r297", "r298", "r320", "r321", "r322", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r385", "r386", "r388", "r389", "r390", "r391", "r402", "r403", "r404", "r405", "r406", "r407", "r424", "r425", "r426", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-cash-flows-unaudited-" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-13-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r107" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "verboseLabel": "Share-based payment awards (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r102", "r107" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "totalLabel": "Diluted shares used in the calculation of earnings per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r101", "r107" ], "calculation": { "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)", "verboseLabel": "Shares used in the calculation of basic earnings per share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20220930/role/statement-consolidated-statements-of-operations-and-comprehensive-income-unaudited-", "http://www.anikatherapeutics.com/20220930/role/statement-note-14-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r484": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r485": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r486": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r487": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r488": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r489": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" } }, "version": "2.1" } ZIP 75 0001171843-22-007281-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-007281-xbrl.zip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end